Blastic Plasmacytoid Dendritic Cell Neoplasm

MONDO:0019467 Pathograph 63 Show in embeddings browser plasmacytoid dendritic cell neoplasm

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive haematologic malignancy arising from precursors of plasmacytoid dendritic cells (pDCs). It typically presents with disseminated violaceous or bluish-livid cutaneous plaques and nodules, followed by bone marrow, peripheral blood, lymph node and — often occultly — central nervous system involvement. Diagnosis rests on an immunophenotype combining CD123 (IL3RA) with pDC-lineage markers (TCF4, TCL1, CD303/BDCA2, CD304/BDCA4) and CD4 and/or CD56, in the absence of lineage-defining myeloid, B-cell and T-cell markers. BPDCN is a somatic clonal disease: recurrent loss-of-function lesions in epigenetic regulators (TET2, ASXL1), in the X-linked splicing factor ZRSR2, and in the pDC differentiation factor IKZF1 arise in a hematopoietic progenitor, frequently on a background of clonal hematopoiesis shared with a preceding or concurrent myeloid neoplasm. The transformed clone remains addicted to the normal pDC master transcription factor TCF4 acting through BRD4-bound super-enhancers, retains high surface CD123, and depends on BCL2 for survival — the three dependencies that underpin its current and investigational targeted therapies.

Ask OpenScientist

Ask a research question about Blastic Plasmacytoid Dendritic Cell Neoplasm. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🏷

Classifications

ICD-O Morphology

Harrison's Part

◈

Mechanistic Hypotheses

UV selection during a cutaneous route to BPDCN

UV_ASSOCIATED_TRANSFORMATION EMERGING

Evidence balance 1 support

Human phylogenies and ex vivo Tet2 experiments support UV selection in a subset of BPDCN. The intervening transformation steps and applicability to noncutaneous disease remain unresolved.

Pathograph links

UV-Selected Survival of TET2-Mutant pDC Precursors in Sun-Exposed Skin -> Cutaneous Infiltration by Malignant pDC Blasts INDIRECT KNOWN INTERMEDIATES Human phylogenies and ex vivo selection experiments support a proposed UV-associated route to skin tumors; further transforming events intervene.

Show evidence (1 reference)

PMID:37286599 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"A reconstruction of tumour phylogenies reveals that UV damage can precede the acquisition of alterations associated with malignant transformation"

Supports the ordering claim - UV damage before transformation - that makes this a selective step rather than a consequence of the tumour.

Adhesion-gene dysregulation contributes to skin homing

ADHESION_SKIN_TROPISM EMERGING

Evidence balance 1 support

IKZF1-associated expression changes may promote tissue retention or homing. Functional BPDCN migration and tissue-homing studies are needed.

Pathograph links

Aberrant Cell Adhesion Program -> Cutaneous Infiltration by Malignant pDC Blasts INDIRECT UNKNOWN INTERMEDIATES Proposed, not demonstrated. The adhesion program is an association in bulk tumour transcriptome; no experiment ties it to skin homing.

Show evidence (1 reference)

PMID:31846142 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"up-regulation of cellular processes responsible for cell-cell and cell-ECM interactions, which is a hallmark of IKZF1 deficiency, was prominent in BPDCN"

Reports the adhesion-program upregulation and attributes it to IKZF1 deficiency.

Accumulated blasts sustain interferon-associated T-cell exhaustion

CHRONIC_IFN_TCELL_EXHAUSTION EMERGING

Evidence balance 1 support

The small single-cell study supports expression and clonotype associations; tumor-derived chronic interferon as their cause requires direct perturbation.

Pathograph links

Clonal Expansion of pDC-Lineage Blasts -> T Cell Exhaustion in the Marrow Microenvironment INDIRECT UNKNOWN INTERMEDIATES The authors propose that accumulated pDC-lineage blasts sustain chronic interferon stimulation; the study measures expression signatures and clonotype associations rather than experimentally proving this causal chain.

Show evidence (1 reference)

PMID:35359938 SUPPORT INDIRECT Other

"We hypothesize that, despite the tumor cells exhibiting lower IFNA production at the individual cell level, abnormal accumulation of pDC-like tumor cells in BPDCN may lead to increased IFNA production and chronic T-cell activation, eventually leading to T-cell exhaustion and consequent TNFA..."

The authors propose this sequence; cytokine production and its causal contribution were not experimentally demonstrated.

Discussions and Knowledge Gaps

How do UV selection and adhesion-gene dysregulation contribute to cutaneous disease?

KNOWLEDGE GAP bpdcn_cutaneous_tropism_mechanism

Attached to

pathophysiology#UV-Selected Survival of TET2-Mutant pDC Precursors in Sun-Exposed Skin pathophysiology#Aberrant Cell Adhesion Program pathophysiology#Cutaneous Infiltration by Malignant pDC Blasts

Human phylogenies and Tet2-edited cultures support UV-associated selection during a cutaneous route in some BPDCN cases. IKZF1-associated adhesion signatures suggest a separate possible contribution to homing or retention. Neither establishes a universal explanation for skin involvement, and the two processes have not been directly tested together.

Which additional events convert a premalignant pDC-lineage clone into BPDCN?

HUMAN MODEL MISMATCH bpdcn_models_omit_founder_lesion

Attached to

pathophysiology#TET2 Loss in a Hematopoietic Precursor experimental_models#Tet2-edited HOXB8 dendritic differentiation culture animal_models#Zrsr2 and Tet2 edited marrow chimera

Tet2-edited HOXB8 cultures model UV survival before transformation, and Zrsr2/Tet2 marrow chimeras model pDC expansion and impaired activation without developing BPDCN in the reported experiment. Thus founder-lesion models exist, but a complete model connecting clonal hematopoiesis, tissue exposure, additional lesions and human BPDCN remains missing.

Does reduced TXNRD1 cause tagraxofusp resistance in patients?

KNOWLEDGE GAP bpdcn_txnrd1_resistance

Attached to

pathophysiology#Diphthamide Pathway Silencing

A 12-patient study found low TXNRD1 expression in residual tumor clusters and increased CAL1 viability after TXNRD1 inhibition. The proposed impairment of toxin processing or translocation was not directly measured; inhibitor-associated survival effects also occurred without tagraxofusp. TXNRD1 is a candidate biomarker and resistance mechanism requiring functional rescue and prospective validation.

Show evidence (2 references)

PMID:42410207 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Unlike that study, we found reduced expression of TXNRD1, a key enzyme in the cytosolic release of diphtheria toxin, in cluster 22."

The primary observation concerns expression in residual tumor cells; the proposed toxin-processing consequence remains to be tested.

PMID:42410207 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Here, we have identified TXNRD1 as a potential biomarker of response for further investigation."

The authors explicitly treat the marker as a candidate rather than a validated predictor.

Which resistance changes in pivekimab-exposed GEN2.2 cells operate in patients?

KNOWLEDGE GAP bpdcn_pivek_resistance

Attached to

pathophysiology#CD123 Overexpression on Malignant pDC Blasts treatments#Pivekimab Sunirine

Serial pivekimab exposure generated resistant GEN2.2 cells with reduced CD123 protein but preserved RNA levels and increased ABCB1 expression. The study did not establish a functional ABCB1 rescue or validate these routes in patients. These observations show why CD123 retention in earlier tagraxofusp models should not be generalized to every CD123-directed therapy.

Show evidence (1 reference)

PMID:41641634 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Our results showed an antigen loss (CD123) at protein levels but not RNA levels."

Protein and transcript findings diverged in the selected GEN2.2 resistance model.

Do neural-associated expression programs promote BPDCN dissemination?

KNOWLEDGE GAP bpdcn_neural_program

Attached to

pathophysiology#Central Nervous System Infiltration

miRNA/transcriptome analysis and immunohistochemistry found neural-associated gene expression in BPDCN cells, including DCX, UCHL1 and cholinergic machinery. The 15-biopsy validation set lacked tumor-associated nerve fibers or neural cells. Marker expression does not demonstrate neurotransmitter exchange, CNS migration or a clinically effective neural target; functional experiments are needed.

Show evidence (1 reference)

PMID:34572907 SUPPORT DIRECT Human Clinical

"Future studies are needed to assess their mechanistic role in BPDCN metastasis and evaluate their prognostic and or therapeutic relevance in the BPDCN clinical setting."

The authors identify mechanistic and clinical validation as future work, despite suggestive expression and staining results.

⚙

Pathophysiology

TET2 Loss in a Hematopoietic Precursor

Somatic TET2 alterations occur in premalignant marrow hematopoietic precursors that can give rise to BPDCN. Truncating loss-of-function variants are common, but not every reported missense allele has demonstrated functional loss. Multiple TET2 variants and high combined variant allele fractions suggest biallelic involvement in some series; these observations do not phase every pair of variants. TET2 and ASXL1 can occur in different orders within branching clones.

hematopoietic precursor cell CL:0008001

TET2 hgnc:25941

Genetic context TET2 hgnc:25941 variant_origin: SOMATIC functional_impact_category: LOSS_OF_FUNCTION

Downstream

Clonal Hematopoiesis of the Mutant Progenitor TET2 alterations mark expanded ancestral clones; the human reconstruction does not isolate their sufficiency for clonal expansion.

UV-Selected Survival of TET2-Mutant pDC Precursors in Sun-Exposed Skin Tet2 knockout selectively increases pDC survival after UV exposure in the ex vivo culture model.

Show evidence (2 references)

PMID:37286599 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Overall, founder clones contained recurrent alterations in TET2 (5 out of 5 cases, 4 out of 5 cases with ≥2 alterations), ASXL1 (3 out of 5 cases) and splicing-factors (3 out of 5 cases), including ZRSR2 (2 out of 5 cases), suggesting privileged roles in premalignant evolution in BPDCN (Fig. 1e (top))."

Human phylogenies support recurrent founder lesions, without a fixed TET2-before-ASXL1 mutation order.

PMID:36819168 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"The number of cases is small, but the variant allele fraction (VAF) sums of the TET2 mutations, as well as the persistence of TET2 mutations in a case of relapsed BPDCN, suggest an ancestral/founder nature of TET2 clones in the cases."

The five-patient series infers ancestral and biallelic involvement from VAF and persistence rather than direct phasing.

ASXL1 Truncating Mutation in a Hematopoietic Precursor

Somatic truncating ASXL1 variants affect chromatin regulation and can occur in ancestral marrow clones shared with BPDCN. The c.1934dupG allele occurred in all three ASXL1-mutant cases in a small institutional series; this does not define every ASXL1 alteration in BPDCN.

hematopoietic precursor cell CL:0008001

ASXL1 hgnc:18318

Genetic context ASXL1 hgnc:18318 variant_origin: SOMATIC

Downstream

Clonal Hematopoiesis of the Mutant Progenitor ASXL1-mutant ancestral clones can expand before overt BPDCN; cooperating lesions and mutation order vary.

Show evidence (2 references)

PMID:37286599 SUPPORT DIRECT PRIMARY RESULT Human Clinical

Human phylogenies support recurrent founder lesions, without a fixed TET2-before-ASXL1 mutation order.

PMID:36819168 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"All 3 ASXL1 mutations were the c.1934dupG (p.Gly646Trpfs*12) variant, with the VAFs ranging from 24% to 28%."

This specific frameshift recurred in the small series; the statement is cohort-bounded.

Clonal Hematopoiesis of the Mutant Progenitor

Premalignant hematopoietic clones in the marrow can retain multilineage differentiation and share founder mutations with BPDCN skin tumors or another myeloid neoplasm. Additional lineage-specific alterations accompany transformation. Shared variants establish ancestry but do not by themselves prove that an overt myeloid cancer directly converted into BPDCN.

hematopoietic precursor cell CL:0008001

Downstream

Clonal Expansion of pDC-Lineage Blasts A pDC-committed descendant may progress after additional lineage-specific alterations. This is a multistep route, not inevitable transformation of every founder clone or direct conversion of an overt myeloid cancer.

Show evidence (1 reference)

PMID:37286599 SUPPORT DIRECT PRIMARY RESULT Human Clinical

Human phylogenies support recurrent founder lesions, without a fixed TET2-before-ASXL1 mutation order.

CDKN2A and CDKN2B Deletion at 9p21.3

Recurrent copy-number loss at chromosome 9p21.3 removes CDKN2A/CDKN2B cell-cycle inhibitors. CDKN1B and RB1 can also be deleted in BPDCN, but they reside on chromosomes 12 and 13, respectively, and are separate lesions. Loss of CDKN2A can cooperate with MYB-driven cell-cycle deregulation.

CDKN2A hgnc:1787 CDKN2B hgnc:1788

Downstream

Clonal Expansion of pDC-Lineage Blasts Loss of the G1/S checkpoint can cooperate with MYB-mediated cell-cycle deregulation; this interaction is demonstrated in an engineered mouse model.

Show evidence (2 references)

PMID:30381297 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Whole-exome sequencing data were also used for cytogenetic CNV analysis, which highlighted extensive losses along the chromosome 9 and the associated deletion of the tumor suppressor CDKN2A gene in 8 out of 14 BPDCN samples (57%) (Online Supplementary Figure S2), as already reported in the..."

Primary copy-number analysis directly supports chromosome-9 CDKN2A loss; the other tumor suppressors are on different chromosomes.

PMID:34615655 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"These included loss of 7p (which harbors IKZF1), 9p (CDKN2A, CDKN2B), 12p (CDKN1B, ETV6), 13q (RB1), and 17p (TP53; Supplementary Fig. S2)."

Copy-number analysis of purified BPDCN cells places the recurrent losses on separate chromosomes.

MYC Rearrangement at 8q24

Rearrangement of the MYC locus, most often partnered with 6p21 (RUNX2) rather than an immunoglobulin locus, driving MYC overexpression. Reported frequencies differ substantially by cohort and ascertainment - 12% in one single-institution karyotype series, about a third in a cytogenetics review - and the rearranged cases are associated with an immunoblastoid cytomorphology.

MYC hgnc:7553

Downstream

Clonal Expansion of pDC-Lineage Blasts MYC overexpression amplifies proliferative and biosynthetic transcriptional programs.

Show evidence (2 references)

PMID:29407586 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We conclude that 8q24/MYC rearrangements occur in 10-15% of BPDCN, often partnered with non-immunoglobulin chromosomal loci, and may play a role in BPDCN pathogenesis."

The primary series behind this node, giving both the frequency and the non-immunoglobulin partner pattern.

PMID:32336417 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"One-third of cases of BPDCN harbor the 8q24 rearrangement, most frequently with 6p21 harboring RUNX2, which is associated with immunoblastoid cytomorphology and MYC expression."

A higher frequency estimate from a cytogenetics review, plus the RUNX2 partner and the cytomorphologic association. Curated alongside the 10-15% figure rather than in place of it, because the two disagree.

Glucocorticoid Resistance

Attenuated glucocorticoid-receptor function reduces glucocorticoid-induced responses in CAL1 perturbation experiments. This provides a potential resistance mechanism relevant to steroid-containing regimens, rather than a validated treatment-selection rule for all NR3C1-deleted patients.

Show evidence (1 reference)

PMID:27060168 SUPPORT DIRECT PRIMARY RESULT In Vitro

"functional analyses coupled with gene expression profiling identified corticoresistance and loss-of-EZH2 function as major downstream consequences of NR3C1 deletion in BPDCN"

Names corticoresistance as a demonstrated downstream consequence of the NR3C1 lesion, which is what this node records.

Lymphoid Organ Infiltration

BPDCN cells infiltrate lymph nodes and spleen. Lymph node enlargement and splenomegaly are clinical manifestations, while registry primary-site proportions describe a different measure of disease distribution.

lymph node UBERON:0000029

Downstream

Lymphadenopathy Expansion of infiltrated lymphoid organs can produce clinical enlargement; imaging alone does not establish the contribution of each cellular process.

Splenomegaly Expansion of infiltrated lymphoid organs can produce clinical enlargement; imaging alone does not establish the contribution of each cellular process.

Show evidence (2 references)

PMID:37407876 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Palpatorisch fiel eine Lymphadenopathie zervikal beidseits und axillär rechts auf."

Direct examination documented cervical and axillary lymphadenopathy.

PMID:41219867 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Positron emission tomography-computed tomography (PET-CT) scans showed lymphadenopathy at the base of the neck, mediastinum, axilla, and bilateral inguinal regions, splenomegaly, and mild pleural effusion (Fig. S1E)."

Direct imaging in the BPDCN index patient documents splenic enlargement.

ZRSR2 Loss-of-Function Splicing Defect

Loss of the X-linked splicing factor ZRSR2 causes intron retention with a strong U12-intron bias, while also affecting selected U2 introns. Mutations were found in 24 of 93 BPDCN cases, 23 in males and one in a female; truncating loss-of-function variants occurred only in males in that cohort. ZRSR2 contributes to the male predominance but does not explain all of it.

hematopoietic precursor cell CL:0008001

ZRSR2 hgnc:23019

Genetic context ZRSR2 hgnc:23019 variant_origin: SOMATIC functional_impact_category: LOSS_OF_FUNCTION

RNA splicing GO:0008380 ⚠ ABNORMAL

Downstream

IRF7 Intron Retention and Impaired Induction ZRSR2 dysfunction is associated with retention of IRF7 intron 4 and reduced inducibility; CAL1 rescue experiments support the causal chain.

Show evidence (1 reference)

PMID:34615655 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Loss-of-function mutations in ZRSR2, an X chromosome gene encoding a splicing factor, are enriched in BPDCN, and nearly all mutations occur in males."

Establishes both the recurrence of the lesion in BPDCN and its near-exclusive occurrence in males.

IKZF1 Structural Inactivation

Recurrent deletions and unbalanced rearrangements disrupt IKZF1. Structural alterations were detected in 13 of 25 patients across the sequencing and extension cohorts; this count includes one focal duplication whose functional effect was inferred. Reduced IKZF1 activity is implicated in altered pDC differentiation and adhesion-gene expression. Patient expression signatures and comparisons with experimental IKZF1-deficient systems support this interpretation, without direct demonstration of skin homing.

plasmacytoid dendritic cell CL:0000784

IKZF1 hgnc:13176

Downstream

Plasmacytoid Dendritic Cell Differentiation Block Patient expression signatures and comparison with IKZF1-deficient experimental systems support this relationship; it was not directly rescued in BPDCN cells.

Aberrant Cell Adhesion Program Patient expression signatures and comparison with IKZF1-deficient experimental systems support this relationship; it was not directly rescued in BPDCN cells.

Show evidence (1 reference)

PMID:31846142 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"revealed that IKZF1, a gene encoding a transcription factor required for the differentiation of plasmacytoid dendritic cell precursors, is focally inactivated through recurrent structural alterations in this neoplasm"

Direct whole-genome evidence for recurrent focal IKZF1 inactivation and its role in pDC precursor differentiation.

MYB Rearrangement

BPDCN-associated MYB rearrangements retain the N-terminal DNA-binding domain and remove or alter C-terminal regulation. MYB::PLEKHO1 produces a chimeric protein, whereas the out-of-frame MYB::ZFAT rearrangement produces truncated MYB without a ZFAT protein segment. Engineered models support enhanced G2/M-gene binding and leukemogenic potential, with partner-dependent requirements for cooperating lesions.

plasmacytoid dendritic cell CL:0000784

MYB hgnc:7545

Downstream

Plasmacytoid Dendritic Cell Differentiation Block

Aberrant G2/M Cell Cycle Gene Regulation CUT&RUN profiling shows the fusion switches MYB's binding from lineage genes to G2/M cell-cycle control genes.

Show evidence (1 reference)

PMID:39499902 SUPPORT DIRECT BACKGROUND Human Clinical

"Rearrangements of the hematopoietic transcription factor MYB are recurrently found in 20% of patients with blastic plasmacytoid DC neoplasm (BPDCN), a rare leukemia arising from cells of the plasmacytoid DC (pDC) lineage"

Quantifies the recurrence of MYB rearrangement in BPDCN.

Plasmacytoid Dendritic Cell Differentiation Block

Malignant cells retain a pDC-associated immunophenotype while showing abnormal differentiation and function. MYB perturbation models directly impair dendritic differentiation; IKZF1-related changes provide another proposed route. These findings do not establish a single developmental arrest point in every BPDCN.

plasmacytoid dendritic cell CL:0000784

plasmacytoid dendritic cell differentiation GO:0002273 ↓ DECREASED

Animal models

MYB fusion-driven myeloid-dendritic acute leukemia mouse Mouse partially recapitulates The model reproduces the differentiation block and transformation caused by a MYB fusion.

Show evidence (2 references)

PMID:39499902 SUPPORT DIRECT PRIMARY RESULT Model Organism

"expression of MYB fusions in vivo impaired DC differentiation and induced transformation to generate a mouse model of myeloid-dendritic acute leukemia."

In vivo demonstration that a BPDCN driver lesion produces a dendritic-cell differentiation block coupled to transformation.

PMID:30323983 SUPPORT DIRECT BACKGROUND Human Clinical

"characterized by neoplastic cells that are positive for CD123, CD4, BDCA2, and TCL1 and aberrant expression of CD56"

Human evidence for the retained pDC identity markers this node asserts, so the node does not rest on model-organism evidence alone.

TCF4-Dependent Super-Enhancer Network Addiction

TCF4 maintains a BPDCN-specific transcriptional program involving BRD4-associated super-enhancers. TCF4 or BRD4 depletion and BET inhibition reduce survival in CAL1 and GEN2.2 cells; rescue experiments support the specificity of TCF4 knockdown. This maintenance dependency is distinct from proving how an ancestral clone first transforms.

plasmacytoid dendritic cell CL:0000784

TCF4 hgnc:11634 BRD4 hgnc:13575

TCF4 transcription factor activity at BPDCN super-enhancers GO:0003700

Experimental models

CAL-1 and GEN2.2 BPDCN cell lines CELL LINE The lines reproduce the BPDCN-specific TCF4-driven transcriptional program and die when it is disrupted genetically or pharmacologically.

Downstream

CD123 Overexpression on Malignant pDC Blasts TCF4 depletion reduces CD123 surface expression in BPDCN cell lines.

Clonal Expansion of pDC-Lineage Blasts Disrupting the TCF4-BRD4 network kills BPDCN cells, so the network is required for maintenance of the expanded clone.

Show evidence (2 references)

PMID:27846392 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Using RNAi screening, we identified the E-box transcription factor TCF4 as a master regulator of the BPDCN oncogenic program."

Identifies TCF4 as the master regulator this node is built on.

PMID:27846392 SUPPORT DIRECT PRIMARY RESULT In Vitro

"High-throughput drug screening revealed that bromodomain and extra-terminal domain inhibitors (BETis) induced BPDCN apoptosis, which was attributable to disruption of a BPDCN-specific transcriptional network controlled by TCF4-dependent super-enhancers."

Establishes the BRD4/super-enhancer component of the network and its pharmacological tractability.

CD123 Overexpression on Malignant pDC Blasts

BPDCN blasts commonly express high levels of CD123, the IL3RA subunit. This provides the binding target for tagraxofusp, pivekimab and investigational CD123-directed cellular therapies. Tagraxofusp delivers a diphtheria toxin payload; receptor expression alone does not establish that IL-3 signaling drives BPDCN. Earlier RNAi screens suggest an IL3RA dependency, but other treatment targets include BCL2 and transcriptional regulators.

IL3RA hgnc:6012

Show evidence (1 reference)

PMID:31018069 SUPPORT DIRECT BACKGROUND Human Clinical

"Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive hematologic cancer that is caused by transformed plasmacytoid dendritic cells that overexpress interleukin-3 receptor subunit alpha (IL3RA or CD123)."

States CD123 overexpression on the transformed pDCs as the defining molecular feature of this node.

BCL2-Dependent Survival of Malignant pDCs

BH3 profiling demonstrated BCL2 dependence in the tested primary BPDCN samples, supported by venetoclax-induced apoptosis and responses in patient-derived xenografts. This functional dependence provides a therapeutic rationale but does not guarantee a durable clinical response in every patient. It is separate from the activation-coupled apoptosis defect associated with ZRSR2.

plasmacytoid dendritic cell CL:0000784

BCL2 hgnc:990

negative regulation of apoptotic process GO:0043066 ↑ INCREASED

Animal models

BPDCN patient-derived xenograft Mouse recapitulates Patient-derived xenografts retain the BCL2 dependence measured in primary cells and respond to venetoclax in vivo.

Downstream

Clonal Expansion of pDC-Lineage Blasts BCL2-mediated suppression of mitochondrial apoptosis supports blast survival.

Show evidence (1 reference)

PMID:27986708 SUPPORT DIRECT PRIMARY RESULT In Vitro

"We found that primary BPDCN cells were dependent on the antiapoptotic protein BCL2 and were uniformly sensitive to the BCL2 inhibitor venetoclax, as measured by direct cytotoxicity, apoptosis assays, and dynamic BH3 profiling."

Functional profiling establishes BCL2 dependence in the tested primary samples; it does not guarantee response in every patient.

Aberrant G2/M Cell Cycle Gene Regulation

MYB occupies and regulates G2/M cell-cycle genes in BPDCN with and without MYB fusions. Endogenous-locus MYB knock-ins in the K562 human leukemia line demonstrate stronger binding by truncated MYB and MYB::PLEKHO1 than by wild-type MYB. These experiments complement BPDCN-cell and xenograft chromatin profiles; K562 is not a BPDCN model.

G2/M transition of mitotic cell cycle GO:0000086 ↑ INCREASED

Downstream

Clonal Expansion of pDC-Lineage Blasts

Show evidence (1 reference)

PMID:39499902 SUPPORT DIRECT PRIMARY RESULT In Vitro

"MYB fusions found in patients with BPDCN increased the magnitude of DNA binding at these locations, and this was linked to BPDCN-associated gene expression changes."

Links the fusion's increased binding at G2/M loci to the expression changes this node names.

NR3C1 Haploinsufficiency

Monoallelic NR3C1 deletion was detected in 13 of 47 BPDCN cases and associated with reduced glucocorticoid-receptor expression and poorer survival in the index cohort. GCR knockdown and a separately identified NR3C1 fusion support impaired glucocorticoid responses and altered chromatin regulation. The deletion does not imply an identical 50% expression reduction or clinically proven steroid failure in every affected patient.

plasmacytoid dendritic cell CL:0000784

NR3C1 hgnc:7978

Downstream

Glucocorticoid Resistance Halved receptor dosage is the direct cause of the corticoresistant phenotype.

Reduced H3K27 Trimethylation after GCR Attenuation Reduced GCR function alters H3K27me3 in CAL1 perturbation experiments.

Show evidence (2 references)

PMID:27060168 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"we identify monoallelic deletion of NR3C1 (5q31), encoding the glucocorticoid receptor (GCR), in 13 of 47 (28%) BPDCN patients"

Quantifies the recurrence of the monoallelic NR3C1 deletion this node describes.

PMID:27060168 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Haploinsufficiency for NR3C1 defined a subset of BPDCN with lowered GCR expression and extremely poor overall survival (P = .0006)."

Establishes both the reduced receptor expression and the prognostic consequence.

UV-Selected Survival of TET2-Mutant pDC Precursors in Sun-Exposed Skin

Human tumor phylogenies identify a UV-associated route in which premalignant pDC-lineage cells acquire UV damage in skin before or during transformation. In an ex vivo mouse HOXB8 differentiation system, Tet2 knockout selectively protects pDCs from UV-induced death. Together these findings support selection in sun-exposed skin in some cases, without making UV exposure necessary for every BPDCN or demonstrating complete UV-driven transformation in vivo.

UV selection during a cutaneous route to BPDCN

plasmacytoid dendritic cell CL:0000784

TET2 hgnc:25941

Experimental models

Tet2-edited HOXB8 dendritic differentiation culture CELL LINE Tet2 knockout preferentially increases pDC survival after UV exposure.

Downstream

Cutaneous Infiltration by Malignant pDC Blasts Human phylogenies and ex vivo selection experiments support a proposed UV-associated route to skin tumors; further transforming events intervene.

Show evidence (2 references)

PMID:37286599 SUPPORT DIRECT PRIMARY RESULT In Vitro

"After UV exposure (100, 500 μJ cm−2), Tet2 knockout caused a further increase in the proportion of surviving pDCs, but had no protective effect on cDCs (Fig. 5e)."

Tet2 knockout was tested in differentiated mouse HOXB8 cultures ex vivo, not by inducing skin tumors with UV in living mice.

PMID:37286599 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"A reconstruction of tumour phylogenies reveals that UV damage can precede the acquisition of alterations associated with malignant transformation"

Supports the ordering claim - UV damage before transformation - that makes this a selective step rather than a consequence of the tumour.

Aberrant Cell Adhesion Program

Patient BPDCN transcriptomes show increased cell-cell and extracellular-matrix interaction programs. Comparisons with IKZF1-deficient experimental systems implicate IKZF1 dysfunction. A contribution to skin homing is plausible but has not been established by BPDCN migration or homing rescue experiments.

Adhesion-gene dysregulation contributes to skin homing

cell adhesion GO:0007155 ↑ INCREASED

Downstream

Cutaneous Infiltration by Malignant pDC Blasts Proposed, not demonstrated. The adhesion program is an association in bulk tumour transcriptome; no experiment ties it to skin homing.

Show evidence (1 reference)

PMID:31846142 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"up-regulation of cellular processes responsible for cell-cell and cell-ECM interactions, which is a hallmark of IKZF1 deficiency, was prominent in BPDCN"

Reports the adhesion-program upregulation and attributes it to IKZF1 deficiency.

Clonal Expansion of pDC-Lineage Blasts

The differentiation-arrested, apoptosis-resistant clone expands, and this expanded population is what subsequently distributes to skin, marrow, blood, lymph nodes and the leptomeninges.

Accumulated blasts sustain interferon-associated T-cell exhaustion

malignant plasmacytoid dendritic cell blast CL:0000784

cell population proliferation GO:0008283 ↑ INCREASED

Downstream

Cutaneous Infiltration by Malignant pDC Blasts

Bone Marrow and Leukemic Dissemination

Central Nervous System Infiltration

Lymphoid Organ Infiltration

T Cell Exhaustion in the Marrow Microenvironment The authors propose that accumulated pDC-lineage blasts sustain chronic interferon stimulation; the study measures expression signatures and clonotype associations rather than experimentally proving this causal chain.

Show evidence (1 reference)

PMID:27986708 SUPPORT DIRECT BACKGROUND Human Clinical

"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy that presents with skin nodules and tumors, lymph node and splenic enlargement, central nervous system involvement, circulating leukemia, and/or bone marrow infiltration"

Enumerates the compartments the expanded clone reaches, which are this node's downstream targets.

Cutaneous Infiltration by Malignant pDC Blasts

Blasts infiltrate the dermis and may extend into subcutaneous fat, producing erythematous to violaceous plaques or nodules. Skin disease may precede systemic involvement, coexist with it, or be absent at presentation.

skin UBERON:0002097

Downstream

Violaceous Cutaneous Plaques and Nodules Dermal and subcutaneous blast infiltrates underlie the clinically sampled plaques and nodules.

Show evidence (2 references)

PMID:37407876 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Direkt unterhalb der Epidermis und bis in die tiefe Subkutis hineinreichend zeigten sich relativ monomorphe klein- bis mittelgroßzellige Infiltrate mit erhöhter mitotischer Aktivität (Abb. 2)."

Direct BPDCN skin histology documents dermal-to-subcutaneous extension and monomorphic cells.

PMID:38132278 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The appearance of the disease in the skin biopsy consists of a typical monomorphic and diffuse infiltrate involving the dermis, with sparing of the epidermis and the presence of a visible Grenz zone."

The review describes the characteristic architecture, which is not sufficient alone for diagnosis.

Bone Marrow and Leukemic Dissemination

BPDCN cells may infiltrate marrow and circulate in blood. Marrow disease can occur at presentation or during progression and does not invariably follow cutaneous disease.

bone marrow UBERON:0002371

Downstream

Marrow Failure Cytopenias

Show evidence (1 reference)

PMID:38334635 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"BPDCN arises from plasmacytoid dendritic cells, manifesting primarily in the skin, bone marrow, and lymph nodes, occasionally involving the central nervous system (CNS)."

Names marrow as a primary compartment of involvement.

Marrow Failure Cytopenias

Marrow infiltration can impair normal hematopoiesis and contribute to cytopenias. Anemia, thrombocytopenia and neutropenia are reported manifestations, but an individual cytopenia requires assessment of other causes and treatment effects.

bone marrow UBERON:0002371

Downstream

Thrombocytopenia Impaired marrow hematopoiesis can reduce platelet counts; the cited case attributed severe pretreatment thrombocytopenia to infiltration as a likely explanation.

Show evidence (2 references)

PMID:38132278 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The most common findings in the peripheral blood are thrombocytopenia (78%), anemia (65%), and neutropenia (34%)."

The review records disease-associated cytopenias; it does not establish marrow replacement as the cause in every patient.

PMID:27986708 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"His platelets had been persistently below 10,000/μL despite transfusion, predating venetoclax treatment and likely related to bone marrow infiltration by BPDCN."

A BPDCN patient had severe thrombocytopenia before venetoclax; marrow infiltration was the authors' likely explanation.

Central Nervous System Infiltration

BPDCN blasts may infiltrate the leptomeningeal/CSF compartment while neurologic examination remains normal. CNS involvement is also a recognized relapse pattern. Sensitive CSF flow cytometry can detect occult disease; the small available cohorts do not define a uniform prevalence at diagnosis.

central nervous system UBERON:0001017

Downstream

Central Nervous System Involvement Accumulation of neoplastic pDCs in the CSF establishes compartment involvement, including clinically occult disease.

Show evidence (2 references)

PMID:38334635 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"This presents challenges in diagnosis and treatment, with CNS involvement often overlooked in standard diagnostic workups due to BPDCN's rarity and patients often being neurologically asymptomatic at diagnosis."

States that CNS involvement is present but clinically silent and therefore under-detected.

PMID:26840087 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"cerebrospinal fluid (CSF) samples positive for tumor plasmacytoid dendritic cells were found in 6/10 (60%) cases studied at diagnosis"

Flow cytometry detected occult CSF disease in six of ten newly diagnosed patients in a small prospective cohort; this is not a population prevalence.

Diphthamide Pathway Silencing

Acquired tagraxofusp resistance can involve reduced diphthamide-pathway activity, including methylation-associated DPH1 downregulation. DPH1 loss impairs the eEF2 substrate modification required for toxin-mediated ADP-ribosylation. CAL1 knockout/add-back and azacitidine experiments establish a reversible route; small patient and xenograft analyses support pathway impairment in vivo. CD123 was retained in this study, but this does not exclude other resistance mechanisms or antigen loss in other settings.

Show evidence (2 references)

url:https://www.jci.org/articles/view/128571 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Re-expression of full-length DPH1 also restored the cytotoxic activity of tagraxofusp in resistant cells"

DPH1 add-back directly reversed acquired resistance in CAL1 BPDCN cells.

PMID:31437130 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Expression of DPH1, encoding a diphthamide pathway enzyme, was reduced by DNA CpG methylation in resistant cells."

Primary study of acquired resistance; CAL1 and AML perturbation experiments establish methylation-associated downregulation.

T Cell Exhaustion in the Marrow Microenvironment

Single-cell profiling of five BPDCN marrows and five healthy controls found increased interferon-alpha response signatures, reduced TNF-alpha signaling signatures and higher CD8 memory T-cell exhaustion scores. TCR analysis in four evaluable patients linked larger clonotypes to higher exhaustion scores. These are transcriptional associations; chronic interferon secretion by accumulated tumor cells was proposed but not directly measured as the cause.

CD8-positive T cell CL:0000625

Show evidence (2 references)

PMID:35359938 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Integrating transcriptional data with T-cell receptor sequencing via shared barcodes reveals significant T-cell exhaustion in BPDCN that is positively correlated with T-cell clonotype expansion."

Direct single-cell evidence for the T-cell exhaustion this node asserts.

PMID:35359938 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"T-cells in BPDCN patients consistently upregulate interferon alpha (IFNA) response and downregulate tumor necrosis factor alpha (TNFA) pathways"

Supports the specific pathway directions described in this node.

IRF7 Intron Retention and Impaired Induction

ZRSR2-mutant BPDCN retains the weak fourth intron of IRF7 and fails to increase IRF7 protein normally after TLR stimulation. IRF7 is not a U12-intron-containing transcript. Missplicing in SRSF2- and SF3B1-mutant cases indicates that this defect is not restricted to ZRSR2.

plasmacytoid dendritic cell CL:0000784

Downstream

Blunted TLR-Induced pDC Activation Impaired IRF7 induction blunts the inflammatory activation program.

Show evidence (2 references)

PMID:34615655 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"IRF7 intron 4 was aberrantly retained in ZRSR2-mutant BPDCN (2 of 2), and the same intron–exon region was also misspliced in SRSF2-mutated (4 of 4) and SF3B1-mutated (1 of 1) cases but not in splicing factor wild-type BPDCN or in normal pDCs (Supplementary Table S4)."

IRF7 intron 4 is a weak, delayed-spliced U2-type intron; it is not a U12 intron.

PMID:34615655 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Wild-type intronless IRF7, which would not require ZRSR2 for splicing, restored LPS-induced growth arrest in ZRSR2-mutant cells, whereas inactive IRF7 did not (Supplementary Fig. S5D)."

Endogenous-locus intronless IRF7 rescue links the splicing defect to the impaired stimulated growth response.

Blunted TLR-Induced pDC Activation

After inflammatory TLR stimulation, ZRSR2-deficient pDC-lineage cells show reduced induction of IRF7, type I interferons and the proapoptotic mediator TRAIL. This is a selective impairment: other secreted mediators and downstream responses to exogenous TRAIL remain intact.

plasmacytoid dendritic cell CL:0000784

Animal models

Zrsr2 and Tet2 edited marrow chimera Mouse partially recapitulates Mutant pDCs show altered splicing and reduced activation after a TLR agonist.

Downstream

Resistance to Activation-Induced pDC Apoptosis Insufficient induction of proapoptotic TRAIL permits survival after TLR stimulation.

Show evidence (1 reference)

PMID:34615655 SUPPORT DIRECT PRIMARY RESULT In Vitro

"IRF7 and TRAIL induction by LPS were partially rescued in ZRSR2-mutant cells by overexpression of wild-type ZRSR2 (Fig. 6E)."

The CAL1 rescue experiment supports impaired IRF7-dependent activation and TRAIL induction downstream of ZRSR2 loss.

Resistance to Activation-Induced pDC Apoptosis

ZRSR2-deficient cells are relatively protected from growth arrest and apoptosis after TLR stimulation because activation and TRAIL induction are impaired. The advantage is stimulus-dependent; ZRSR2 loss did not increase baseline CAL1 growth, and exogenous TRAIL can still trigger apoptosis.

plasmacytoid dendritic cell CL:0000784

Downstream

Clonal Expansion of pDC-Lineage Blasts Escape from activation-induced growth arrest can support clone persistence in an inflammatory context.

Show evidence (3 references)

PMID:34615655 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Knockout of ZRSR2 conferred relative protection from LPS- or R848-induced apoptosis (Fig. 6B). The growth rate of CAL1 cells at steady state was not changed by ZRSR2 mutation."

CAL1 perturbation demonstrates a stimulation-dependent survival advantage.

PMID:34615655 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Treatment with exogenous TRAIL promoted apoptosis equivalently in control and ZRSR2-mutant CAL1 cells, as well as in normal pDCs and BPDCN, demonstrating that the cell death response downstream of TRAIL was intact (Fig. 6D; Supplementary Fig. S4B)."

The defect concerns activation-coupled apoptosis rather than an inability to execute cell death.

PMID:34615655 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Wild-type intronless IRF7, which would not require ZRSR2 for splicing, restored LPS-induced growth arrest in ZRSR2-mutant cells, whereas inactive IRF7 did not (Supplementary Fig. S5D)."

Endogenous-locus intronless IRF7 rescue links the splicing defect to the impaired stimulated growth response.

Reduced H3K27 Trimethylation after GCR Attenuation

In dexamethasone-treated CAL1 cells, GCR knockdown or expression of the NR3C1 fusion reduces global H3K27me3 and repressive marks at HOXA promoters. The associated expression program resembles loss of EZH2 activity. The molecular connection between GCR and PRC2 remains unresolved.

Show evidence (1 reference)

PMID:27060168 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Consistent with our GEP experiments, western blot analyses revealed global loss of H3K27me3 under attenuated GCR signaling (Figure 3D; supplemental Figure 3D)."

GCR knockdown or fusion expression in dexamethasone-treated CAL1 cells reduced H3K27me3; direct physical regulation of PRC2 remains unresolved.

lincRNA-3q-Dependent Cell-Cycle Program

The nuclear lincRNA-3q is aberrantly expressed in BPDCN samples. Its depletion in CAL1 reduces E2F-associated transcription, clonogenicity and G1/S progression without directly inducing cell death in the reported assay. This is a separate experimentally supported dependency; whether NR3C1 loss causes its activation is still proposed.

Downstream

Clonal Expansion of pDC-Lineage Blasts lincRNA-3q-dependent cell-cycle and clonogenic programs support leukemia growth in experimental models.

Show evidence (1 reference)

PMID:27060168 SUPPORT DIRECT PRIMARY RESULT In Vitro

"lincRNA-3q knockdown in CAL-1 and U937 cells induced a G1/S arrest (Figure 4Cand supplemental Figure 4C, respectively), without inducing cell death (supplemental Figure 4D)."

CAL1 knockdown impairs cell-cycle progression; U937 is a separate AML comparator.

✶

Histopathology

Blastic Dermal Infiltrate

Monomorphic small-to-medium blastoid cells can infiltrate the dermis and deep subcutis with relative epidermal sparing. Morphology requires an accompanying pDC immunophenotype to establish BPDCN.

Show evidence (2 references)

PMID:37407876 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Direkt unterhalb der Epidermis und bis in die tiefe Subkutis hineinreichend zeigten sich relativ monomorphe klein- bis mittelgroßzellige Infiltrate mit erhöhter mitotischer Aktivität (Abb. 2)."

Direct BPDCN skin histology documents dermal-to-subcutaneous extension and monomorphic cells.

PMID:38132278 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

The review describes the characteristic architecture, which is not sufficient alone for diagnosis.

CD123-Positive pDC Immunophenotype

WHO-5 criteria use CD123 plus another pDC marker with CD4 and/or CD56, or any three pDC markers with absent expected negative markers. TCF4, TCL1, CD303 and CD304 support pDC differentiation; CD3, CD14, CD34, lysozyme and MPO help exclude competing lineages. The CD4/CD56/CD123 triad alone can also occur in AML.

Show evidence (1 reference)

PMID:37946878 SUPPORT DIRECT BACKGROUND Other

"The suggested diagnosis criteria based on immunophenotyping requires expression of CD123 and one other pDC marker (e.g., TCF4, TCL1, CD303, or CD304) in addition to CD4 and/or CD56, or, expression of any three pDC markers and absent expression of all expected negative markers (e.g., CD3, CD14,..."

This is the discussion's summary of WHO-5 BPDCN criteria. The paper's index patient had AML and is not a BPDCN clinical observation.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Blood 3

Anemia HP:0001903

Show evidence (3 references)

PMID:37407876 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Das Differenzialblutbild zeigte bis auf eine leichte Erythrozytopenie und eine normozytäre, normochrome Anämie keine Auffälligkeiten."

Documents normocytic normochromic anaemia in a BPDCN patient. Quoted in the source language, as with the other findings from this German-language case report. A single case, not a frequency.

PMID:37407876 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Eine Knochenmarkbiopsie, Abdomensonographie und Röntgenaufnahme des Thorax waren unauffällig."

The initially normal marrow limits causal interpretation of the simultaneously observed anemia.

PMID:38132278 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The most common findings in the peripheral blood are thrombocytopenia (78%), anemia (65%), and neutropenia (34%)."

This narrative review summarizes pretreatment hematologic manifestations; the figures are literature-based and not a population-wide estimate.

Thrombocytopenia HP:0001873

Show evidence (2 references)

PMID:38132278 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The most common findings in the peripheral blood are thrombocytopenia (78%), anemia (65%), and neutropenia (34%)."

This narrative review summarizes pretreatment hematologic manifestations; the figures are literature-based and not a population-wide estimate.

PMID:27986708 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"His platelets had been persistently below 10,000/μL despite transfusion, predating venetoclax treatment and likely related to bone marrow infiltration by BPDCN."

A BPDCN patient had severe thrombocytopenia before venetoclax; marrow infiltration was the authors' likely explanation.

Neutropenia Decreased total neutrophil count HP:0001875

Show evidence (1 reference)

PMID:38132278 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The most common findings in the peripheral blood are thrombocytopenia (78%), anemia (65%), and neutropenia (34%)."

This narrative review summarizes pretreatment hematologic manifestations; the figures are literature-based and not a population-wide estimate.

Cardiovascular 2

Lymphadenopathy FREQUENT HP:0002716

Show evidence (2 references)

PMID:37407876 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Palpatorisch fiel eine Lymphadenopathie zervikal beidseits und axillär rechts auf."

Direct examination documented cervical and axillary lymphadenopathy.

PMID:38132278 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Lymphadenopathy is identified in 56% of cases, splenomegaly in 44%."

The review summarizes clinical lymphadenopathy frequency; this is distinct from SEER primary-site proportions.

Splenomegaly HP:0001744

Show evidence (1 reference)

PMID:41219867 SUPPORT DIRECT PRIMARY RESULT Human Clinical

Direct imaging in the BPDCN index patient documents splenic enlargement.

Integument 2

Violaceous Cutaneous Plaques and Nodules VERY_FREQUENT Skin nodule HP:0200036

Sequelae: Pruritus

Show evidence (2 references)

PMID:37407876 SUPPORT DIRECT BACKGROUND Human Clinical

"characterized by disseminated, erythematous or bluish-livid plaques or nodi"

Describes the lesion morphology and distribution this phenotype names.

PMID:34615655 SUPPORT DIRECT BACKGROUND Human Clinical

"tumor formation in the skin (in ∼90% of cases)"

Introductory literature summary estimates skin tumors in approximately 90% of cases; this is not a newly measured cohort proportion.

Pruritus HP:0000989

Show evidence (1 reference)

PMID:37407876 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Diese seien insbesondere am Rücken von einem moderaten Juckreiz (5/10 nach numerischer Analogskala (NAS)) begleitet."

The patient reported moderate itching over the cutaneous lesions; this is a single case.

Nervous System 1

Central Nervous System Involvement Abnormal cerebrospinal fluid morphology HP:0002921

Show evidence (2 references)

PMID:38334635 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"CNS involvement typically emerges during relapse, yet clinical trials often exclude such cases, limiting our understanding of its development and treatment."

Supports CNS disease as a recognized and under-studied relapse compartment.

PMID:26840087 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"cerebrospinal fluid (CSF) samples positive for tumor plasmacytoid dendritic cells were found in 6/10 (60%) cases studied at diagnosis"

Flow cytometry detected occult CSF disease in six of ten newly diagnosed patients in a small prospective cohort; this is not a population prevalence.

Constitutional 2

Night Sweats HP:0030166

Show evidence (1 reference)

PMID:37407876 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Weiterhin berichtete der Patient über eine allgemeine Abgeschlagenheit und Nachtschweiß."

A documented BPDCN patient reporting fatigue and night sweats. Quoted in the source language: this is a German-language case report whose English abstract does not enumerate the symptoms.

Fatigue HP:0012378

Show evidence (1 reference)

PMID:37407876 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Weiterhin berichtete der Patient über eine allgemeine Abgeschlagenheit und Nachtschweiß."

The patient reported fatigue and night sweats.

Growth 1

Weight Loss HP:0001824

Show evidence (1 reference)

PMID:37407876 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"allerdings wurde ein Gewichtsverlust von 3 kg in ca. 6 Wochen festgestellt"

Documents the weight loss in the same BPDCN patient, again quoted in the source language.

🧬

Genetic Associations

TET2

Gene: TET2 hgnc:25941 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (3 references)

PMID:36689729 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"In multivariate analysis, having at least 1 TET2 truncating mutation was the only risk factor significantly associated with overall survival"

Establishes the prognostic significance of the truncating mutation class.

PMID:36689729 SUPPORT DIRECT BACKGROUND Human Clinical

"The most recurrently mutated gene related to DNA methylation is TET2"

Establishes the recurrence claim, which the prognostic sentence above does not carry.

PMID:37286599 SUPPORT DIRECT PRIMARY RESULT Human Clinical

Human phylogenies support recurrent founder lesions, without a fixed TET2-before-ASXL1 mutation order.

ASXL1

Gene: ASXL1 hgnc:18318 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (2 references)

PMID:36819168 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"identified a high frequency of biallelic TET2 and canonical ASXL1 (c.1934dupG) mutations"

Names the recurrent ASXL1 allele and its co-occurrence with TET2.

PMID:37286599 SUPPORT DIRECT PRIMARY RESULT Human Clinical

Human phylogenies support recurrent founder lesions, without a fixed TET2-before-ASXL1 mutation order.

ZRSR2

Gene: ZRSR2 hgnc:23019 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (1 reference)

PMID:34615655 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Loss-of-function mutations in ZRSR2, an X chromosome gene encoding a splicing factor, are enriched in BPDCN, and nearly all mutations occur in males."

Establishes both enrichment and the sex distribution of the lesion.

IKZF1

Gene: IKZF1 hgnc:13176 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (1 reference)

PMID:31846142 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"IKZF1, a gene encoding a transcription factor required for the differentiation of plasmacytoid dendritic cell precursors, is focally inactivated through recurrent structural alterations in this neoplasm"

Whole-genome evidence for recurrent focal structural inactivation.

MYB

Gene: MYB hgnc:7545 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (1 reference)

PMID:39499902 SUPPORT DIRECT BACKGROUND Human Clinical

"Rearrangements of the hematopoietic transcription factor MYB are recurrently found in 20% of patients with blastic plasmacytoid DC neoplasm (BPDCN)"

Quantifies MYB rearrangement frequency in BPDCN.

NR3C1

Gene: NR3C1 hgnc:7978 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (2 references)

PMID:27060168 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"we identify monoallelic deletion of NR3C1 (5q31), encoding the glucocorticoid receptor (GCR), in 13 of 47 (28%) BPDCN patients"

Reports the deletion frequency in the defining cohort.

PMID:27060168 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Targeted deep sequencing in 36 BPDCN cases, including 10 with NR3C1 deletion, did not reveal NR3C1 point mutations or indels."

No sequence-level NR3C1 alterations were detected in this tested cohort; the negative finding does not exclude every possible NR3C1 lesion in BPDCN.

CDKN2A/CDKN2B

Gene: CDKN2A hgnc:1787 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (2 references)

PMID:30381297 SUPPORT DIRECT PRIMARY RESULT Human Clinical

Primary copy-number analysis directly supports chromosome-9 CDKN2A loss; the other tumor suppressors are on different chromosomes.

PMID:34615655 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"These included loss of 7p (which harbors IKZF1), 9p (CDKN2A, CDKN2B), 12p (CDKN1B, ETV6), 13q (RB1), and 17p (TP53; Supplementary Fig. S2)."

Copy-number analysis of purified BPDCN cells places the recurrent losses on separate chromosomes.

MYC

Gene: MYC hgnc:7553 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (2 references)

PMID:29407586 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Over an 8-year period in our hospital, 5 of 41 (12%) patients with BPDCN were shown 8q24/MYC rearrangements"

The single-institution denominator behind the lower frequency estimate.

PMID:32336417 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"One-third of cases of BPDCN harbor the 8q24 rearrangement, most frequently with 6p21 harboring RUNX2"

The higher review-level estimate and the characteristic partner locus.

💊

Medical Actions

Tagraxofusp

Action: Pharmacotherapy NCIT:C15986

Agent: tagraxofusp NCIT:C64769

Platform: Other

An approved CD123-directed cytotoxin consisting of human interleukin-3 fused to truncated diphtheria toxin. Receptor-mediated uptake delivers the toxin to inhibit protein synthesis. In the long-term trial analysis, 65 treatment-naive patients had a 75% overall response rate and 57% CR/CRc; median response duration was 24.9 months. Capillary leak syndrome, including fatal events, is an important toxicity. This fusion toxin is not protein replacement.

Mechanism Target:

CD123 Overexpression on Malignant pDC Blasts — The agent's IL-3 moiety uses the node's own overexpressed receptor as its address.

Show evidence (1 reference)

PMID:31018069 SUPPORT DIRECT BACKGROUND Other

"Tagraxofusp (SL-401) is a CD123-directed cytotoxin consisting of human interleukin-3 fused to truncated diphtheria toxin."

States the mechanism by which the drug engages the CD123 node.

Show evidence (2 references)

PMID:35820082 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"For treatment-naive patients, the overall response rate was 75%; 57% achieved CR + CRc."

Long-term efficacy result from the largest prospective BPDCN trial.

PMID:35820082 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Capillary leak syndrome occurred in 21% of patients (grade ≥ 3: 7%)."

Quantifies the characteristic toxicity this treatment's description warns about.

Venetoclax

Action: Pharmacotherapy NCIT:C15986

Agent: venetoclax CHEBI:133021

Platform: Small molecule

A BCL2 inhibitor used off-label and in investigational combinations for BPDCN. Functional profiling showed BCL2 dependence in the studied BPDCN samples, without proving universal clinical sensitivity. Two initially reported salvage patients had short-lived or compartment-specific responses; one had no appreciable marrow response at four weeks. Combination regimens now have prospective BPDCN data.

Mechanism Target:

BCL2-Dependent Survival of Malignant pDCs — BCL2 inhibition restores the apoptotic response this node blocks.

Show evidence (1 reference)

PMID:27986708 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Animals bearing BPDCN patient-derived xenografts had disease responses and improved survival after venetoclax treatment in vivo"

In vivo demonstration that inhibiting the node's effector produces disease response.

Show evidence (3 references)

PMID:27986708 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Finally, we report on 2 patients with relapsed/refractory BPDCN who received venetoclax off-label and experienced significant disease responses."

First human responses to BCL2 inhibition in BPDCN, from the same study establishing the dependency.

PMID:27986708 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"He had a decrease in the size of palpable cervical and preauricular lymph nodes, but did not have an appreciable response in his bone marrow at that time."

The first salvage patient had a discordant early compartment response.

PMID:27986708 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"He remained on venetoclax 400 mg daily for approximately 12 weeks, at which time he experienced disease progression."

The second salvage patient subsequently progressed; early responses do not establish durable monotherapy control.

Allogeneic Hematopoietic Cell Transplantation

Action: hematopoietic cell transplantation Ontology label: Hematopoietic Cell Transplantation NCIT:C15431

Platform: Cell therapy

The 2026 ASTCT guideline recommends allogeneic HCT for eligible patients in first or second complete remission. Myeloablative conditioning, preferably with total-body irradiation, is recommended for younger fit patients; reduced-intensity conditioning is recommended for older or frail patients. HCT is not recommended after primary induction failure or during active relapsed/refractory BPDCN. These recommendations should not be replaced by a causal interpretation of retrospective conditioning comparisons.

Mechanism Target:

Clonal Expansion of pDC-Lineage Blasts — Consolidation aims to control residual malignant hematopoiesis after remission induction; transplant outcomes do not isolate a single mechanistic component.

Clonal Hematopoiesis of the Mutant Progenitor — Unlike every pharmacological agent here, an allograft can remove the founder clone itself rather than only its malignant descendants.

Show evidence (3 references)

PMID:42612729 SUPPORT DIRECT REVIEW SYNTHESIS Other

"For BPDCN in first complete remission (CR1), the panelists recommended allogeneic HCT and suggested autologous HCT for patients who are unfit for allogeneic HCT but without BPDCN marrow involvement."

The 17-expert guideline defines the preferred consolidation and the narrower autologous option.

PMID:42612729 SUPPORT DIRECT REVIEW SYNTHESIS Other

"The panel recommended that conditioning intensity for younger fitter patients be myeloablative, preferentially containing total body irradiation, whereas reduced intensity conditioning was recommended for older and/or frail ones, in both CR1 or CR2."

Conditioning recommendations depend on fitness and age.

PMID:42612729 SUPPORT DIRECT REVIEW SYNTHESIS Other

"Conversely, the panelists did not recommend allogeneic or autologous HCT in BPDCN after primary induction failure or with active relapsed-refractory disease."

The guideline limits transplantation in uncontrolled disease.

Intrathecal CNS-Directed Chemotherapy

Action: Pharmacotherapy NCIT:C15986

Agent: methotrexate CHEBI:44185 cytarabine CHEBI:28680

Platform: Small molecule

Intrathecal methotrexate and/or cytarabine are used for prophylaxis and treatment of CSF disease alongside systemic therapy. In a small prospective series, all six CSF-positive patients assessed at diagnosis cleared CSF tumor cells after intrathecal treatment; nonrandomized survival comparisons cannot isolate its effect. The 2026 ASTCT guideline also recommends post-HCT intrathecal chemotherapy regardless of prior CNS involvement.

Mechanism Target:

Central Nervous System Infiltration — Intrathecal delivery treats or prevents disease in the CSF compartment alongside systemic therapy.

Show evidence (4 references)

PMID:38334635 SUPPORT DIRECT REVIEW SYNTHESIS Other

"Treatment options for CNS involvement include intrathecal (IT) chemotherapies like methotrexate and cytarabine, often in combination with systemic agents."

Names the agents and route this treatment describes.

PMID:38334635 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Tagraxofusp and traditional regimens for acute myeloid leukemia show limited success at preventing CNS relapse"

The negative result that makes a dedicated CNS-directed arm necessary rather than redundant.

PMID:26840087 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"follow-up CSF samples obtained after triple intrathecal therapy (TIT) showed absence of tumor cells in 6/6 CSF+ cases studied at diagnosis"

Direct CSF response in a small cohort; not randomized survival evidence.

+ 1 more reference

Intensive Induction Chemotherapy

Action: Chemotherapy NCIT:C15632

Platform: Small molecule

ALL-type (hyper-CVAD) and AML- or lymphoma-type multi-agent regimens. These are the backbone against which tagraxofusp is positioned, and remain an accepted upfront option rather than a historical one.

Mechanism Target:

Clonal Expansion of pDC-Lineage Blasts — Cytotoxic induction acts on the proliferating blast population rather than on any BPDCN-specific dependency.

Show evidence (3 references)

PMID:40525728 SUPPORT DIRECT REVIEW SYNTHESIS Other

"Either chemotherapy-based regimens or tagraxofusp, a CD123-directed interleukin 3 conjugated with diphtheria toxin, may be used for upfront therapy."

Places chemotherapy alongside tagraxofusp as an upfront option.

PMID:38334635 SUPPORT DIRECT REVIEW SYNTHESIS Other

"prompting exploration of combined therapies like hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HyperCVAD) with venetoclax and adding IT chemotherapy to other backbones."

Names the hyper-CVAD regimen and the venetoclax and intrathecal additions built onto it.

PMID:38132278 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"the main therapeutic schemes used were based on chemotherapy regimens already used in the treatment of lymphomas, acute lymphoblastic leukemia (ALL) and/or acute myeloid leukemia (AML)"

Explains why the regimens here are borrowed ones - there was no BPDCN-specific consensus before tagraxofusp.

Hypomethylating Agent Therapy

Action: Pharmacotherapy NCIT:C15986

Agent: azacitidine NCIT:C288

Platform: Small molecule

Azacitidine and decitabine have preclinical activity in BPDCN, and azacitidine is used in clinical combination regimens. In acquired-resistance CAL1 models, azacitidine restores DPH1 expression and tagraxofusp sensitivity. This specific rescue mechanism is not established as the explanation for every clinical response to a hypomethylating agent.

Mechanism Target:

Diphthamide Pathway Silencing — Azacitidine can reverse methylation-associated DPH1 silencing and restore toxin-mediated ADP-ribosylation in resistant cell models.

Show evidence (1 reference)

url:https://www.jci.org/articles/view/128571 SUPPORT DIRECT PRIMARY RESULT In Vitro

"In agreement with those results, azacitidine treatment also re-sensitized resistant AML and BPDCN cells to the cytotoxic activity of tagraxofusp"

Azacitidine restored drug sensitivity in acquired-resistance cell models; clinical benefit is evaluated separately.

Show evidence (2 references)

url:https://www.jci.org/articles/view/128571 SUPPORT DIRECT PRIMARY RESULT In Vitro

"In agreement with those results, azacitidine treatment also re-sensitized resistant AML and BPDCN cells to the cytotoxic activity of tagraxofusp"

Azacitidine restored drug sensitivity in acquired-resistance cell models; clinical benefit is evaluated separately.

PMID:30381297 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Our experiments revealed that the treatment with 5’-azacytidine in combination with decitabine significantly inhibits disease progression and extends survival (P<0.01) in a preclinical mouse model."

The dual-hypomethylating-agent combination was tested in a CAL1 xenograft, not a clinical trial.

All-Trans Retinoic Acid

Action: Pharmacotherapy NCIT:C15986

Agent: all-trans retinoic acid CHEBI:15367

Platform: Small molecule

Preclinical ATRA treatment causes MYB protein loss, differentiation, cell-cycle arrest and apoptosis in BPDCN models. Activity is not restricted to MYB-rearranged disease: CAL1 and primary xenograft-derived samples with or without MYB fusions showed sensitivity, and treatment reduced disease burden in mice. Clinical efficacy in BPDCN remains unestablished.

Mechanism Target:

Aberrant G2/M Cell Cycle Gene Regulation — Loss of MYB can disrupt its cell-cycle program whether or not a MYB fusion is present.

Show evidence (1 reference)

PMID:39499902 SUPPORT DIRECT PRIMARY RESULT In Vitro

"These data provide evidence that BPDCN cells, with or without MYB fusions, may show sensitivity to ATRA treatment via loss of MYB, as in ACC."

The primary results expressly include BPDCN without MYB fusions.

Show evidence (2 references)

PMID:39499902 SUPPORT DIRECT PRIMARY RESULT In Vitro

"These data provide evidence that BPDCN cells, with or without MYB fusions, may show sensitivity to ATRA treatment via loss of MYB, as in ACC."

The primary results expressly include BPDCN without MYB fusions.

PMID:39499902 SUPPORT DIRECT PRIMARY RESULT Model Organism

"We also found that ATRA treatment in vivo reduced the leukemic burden in NSG mice transplanted with a human BPDCN primary PDX (Figure 6C)."

ATRA activity extends to a primary BPDCN xenograft experiment.

BET Inhibition

Action: Pharmacotherapy NCIT:C15986

Platform: Small molecule

Investigational. BET inhibitors disrupt the TCF4-dependent super-enhancer network and kill BPDCN cells in vitro and in xenografts. No approved agent exists for this indication.

Mechanism Target:

TCF4-Dependent Super-Enhancer Network Addiction — BET inhibition dismantles the BRD4-bound super-enhancers the node depends on.

Show evidence (1 reference)

PMID:27846392 SUPPORT DIRECT PRIMARY RESULT In Vitro

Attributes the killing directly to disruption of the targeted network.

lincRNA-3q-Dependent Cell-Cycle Program — BET inhibition reduces the lincRNA-3q program in CAL1 experiments.

Show evidence (1 reference)

PMID:27060168 SUPPORT DIRECT PRIMARY RESULT In Vitro

"In keeping with this, treatment with one such BET inhibitor (JQ1) led to suppression of lincRNA-3q levels in a time-dependent manner in MUTZ-3, U937, and CAL-1 BPDCN cells, but not in K562 cells (Figure 5D)."

JQ1 suppresses lincRNA-3q in CAL1 as well as selected AML models; this is not a clinically validated drug effect.

Show evidence (2 references)

PMID:27846392 SUPPORT DIRECT PRIMARY RESULT Model Organism

"BETis retarded the growth of BPDCN xenografts, supporting their clinical evaluation in this recalcitrant malignancy."

In vivo efficacy supporting the investigational status of this approach.

PMID:27060168 SUPPORT DIRECT PRIMARY RESULT In Vitro

"identifies BET inhibition, acting at least partially via lncRNA blockade, as a novel treatment option in BPDCN"

An independent route to the same conclusion - BET inhibition reached through NR3C1-deletion biology and lincRNA-3q blockade rather than through the TCF4 super-enhancer screen.

CD123-Directed CAR-T and CAR-NK Cell Therapy

Action: CD123-directed chimeric antigen receptor cell therapy Ontology label: Cellular Therapy NCIT:C70601

Platform: Cell therapy

CD123-directed CAR-T and CAR-NK products remain investigational. In the phase 1 CAR-T study, two BPDCN patients received autologous cells: one achieved CR, but both progressed by days 100 and 29; both subsequently underwent allogeneic transplantation. Neither developed CRS and both had grade 1 neurotoxicity. Separate reports describe severe toxicity, including a death after allogeneic UCART123 with no definitive cause established. A combined ASCT/CAR-T/venetoclax case achieved a 13-month remission but cannot isolate the benefit of each component. CAR-NK trial enrollment does not itself establish efficacy.

Mechanism Target:

CD123 Overexpression on Malignant pDC Blasts — The engineered receptor addresses the same overexpressed antigen as tagraxofusp.

Show evidence (4 references)

PMID:42681647 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Of the 2 patients treated on Arm 2, 1 patient achieved CR with complete resolution of an extramedullary mass (Fig. 2A). Both patients had disease progression on day 100 and day 29 post infusion, respectively, proceeded to an alloHCT at 154 and 99 days post infusion, and received additional treatment."

These are the BPDCN-specific outcomes; the AML response denominator is not imported.

PMID:42681647 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Neither patient with BPDCN developed CRS but both experienced grade 1 neurotoxicity."

Safety results in the two treated BPDCN patients.

PMID:35963025 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"No definitive cause of death was determined, but we hypothesized that the patient may have succumbed to CAR-T-mediated cardiopulmonary toxicity."

The fatal UCART123 report includes refractory clinical CRS but does not prove a definitive cause of death.

+ 1 more reference

Pivekimab Sunirine

Action: CD123-directed antibody-based immunotherapy Ontology label: Immunotherapy NCIT:C15262

Agent: pivekimab sunirine (IMGN632) NCIT:C184834

Platform: Monoclonal antibody

Pivekimab sunirine-pvzy (Decnupaz) is a CD123-directed antibody conjugated to an alkylating payload, FDA-approved for adults with BPDCN on May 27, 2026. In the FDA CADENZA analysis, CR/CRc occurred in 23/33 treatment-naive patients (69.7%) and 8/51 relapsed/refractory patients (15.7%), with median response durations of 9.7 and 9.2 months. Active CNS disease was excluded. The label carries a boxed warning for hepatotoxicity including hepatic veno-occlusive disease; other risks include infusion reactions, edema, sulfite allergy and embryo-fetal toxicity. The single-arm study does not establish superiority over another treatment.

Mechanism Target:

CD123 Overexpression on Malignant pDC Blasts — The antibody binds CD123 and delivers an alkylating payload to the malignant cells.

Show evidence (5 references)

url:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pivekimab-sunirine-pvzy-blastic-plasmacytoid-dendritic-cell-neoplasm-ultra-rare SUPPORT DIRECT Other

"On May 27, 2026, the Food and Drug Administration approved pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN)."

The FDA approval supersedes the former investigational-only description.

url:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pivekimab-sunirine-pvzy-blastic-plasmacytoid-dendritic-cell-neoplasm-ultra-rare SUPPORT DIRECT Human Clinical

"In patients with treatment-naïve BPDCN (N = 33), 23 patients (69.7%; 95% CI: 51.3, 84.4) achieved a CR/CRc with a median follow-up of 21.5 months."

The regulatory efficacy analysis uses the entire treatment-naive cohort.

url:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pivekimab-sunirine-pvzy-blastic-plasmacytoid-dendritic-cell-neoplasm-ultra-rare SUPPORT DIRECT Human Clinical

"In patients with relapsed or refractory BPDCN (N = 51), 8 patients (15.7%; 95% CI: 7.0, 28.6) achieved a CR/CRc with a median follow-up of 24.1 months."

FDA efficacy result for the relapsed/refractory cohort.

+ 2 more references

Autologous Hematopoietic Cell Transplantation

Action: hematopoietic cell transplantation Ontology label: Hematopoietic Cell Transplantation NCIT:C15431

Platform: Cell therapy

The 2026 ASTCT guideline suggests autologous HCT for selected patients in CR1 or CR2 who are unfit for allogeneic HCT and have no BPDCN marrow involvement. A separate investigational CAR-T/ASCT case with residual marrow disease does not establish the safety or efficacy of broader autologous transplantation.

Show evidence (1 reference)

PMID:42612729 SUPPORT DIRECT REVIEW SYNTHESIS Other

The 17-expert guideline defines the preferred consolidation and the narrower autologous option.

CD123-Directed Bispecific Antibodies

Action: Immunotherapy NCIT:C15262

Platform: Monoclonal antibody

Investigational CD123-directed bispecific antibodies recruit T cells to malignant blasts. They are distinct from the approved CD123 antibody-drug conjugate pivekimab and from engineered CAR cell products.

Mechanism Target:

CD123 Overexpression on Malignant pDC Blasts — Bispecific binding brings effector T cells into contact with CD123-expressing tumor cells.

Show evidence (1 reference)

PMID:38338733 SUPPORT DIRECT REVIEW SYNTHESIS Other

"Ongoing developments with SL-401, IMGN632, CD123 chimeric antigen receptor (CAR) T-cells, and bispecific antibodies (BsAb) show promising advancements."

The review identifies bispecific-antibody development; it predates the pivekimab approval.

Tagraxofusp, Azacitidine and Venetoclax Combination

Action: Chemotherapy NCIT:C15632

Platform: Other

A 2026 single-arm phase 2 report included 27 BPDCN patients: 16 previously untreated and 11 relapsed/refractory. Composite CR/CRi/CRc rates were 88% and 64%, respectively; capillary leak occurred in 15%, mostly grade 2. Many patients subsequently underwent allogeneic HCT. The endpoint includes incomplete count recovery and should not be equated with CADENZA CR/CRc or interpreted as a randomized comparison.

Show evidence (2 references)

PMID:42413008 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Twenty-seven patients were enrolled (16 1L, 11 R/R), with median age of 70 years (range 21-81). Composite complete remission (CR/CRi/CRc) rates were 88% in 1L and 64% in R/R cohorts."

Prospective BPDCN-specific combination efficacy with explicit denominators and endpoint.

PMID:42413008 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"CLS occurred in 15% of patients; most were grade 2."

Capillary leak remains a safety issue with the combination.

🌍

Environmental Factors

Cutaneous ultraviolet radiation exposure

UV-associated mutational signatures in BPDCN skin tumors and human clonal reconstructions implicate exposure during a cutaneous route to disease. Tet2-edited cultures support lineage-specific survival selection. These data do not estimate population-level risk per UV dose or establish UV as necessary for every BPDCN.

Show evidence (1 reference)

PMID:37286599 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"BPDCN skin tumours first develop at sun-exposed anatomical sites and are distinguished by clonally expanded mutations induced by ultraviolet (UV) radiation"

Establishes the exposure's fingerprint in the tumours themselves rather than by epidemiologic inference.

Mechanism Target:

PREDISPOSES UV-Selected Survival of TET2-Mutant pDC Precursors in Sun-Exposed Skin — UV exposure imposes the selective pressure under which Tet2-deficient pDCs preferentially survive in the ex vivo differentiation assay.

Show evidence (1 reference)

PMID:37286599 SUPPORT DIRECT PRIMARY RESULT In Vitro

"After UV exposure (100, 500 μJ cm−2), Tet2 knockout caused a further increase in the proportion of surviving pDCs, but had no protective effect on cDCs (Fig. 5e)."

Tet2 knockout was tested in differentiated mouse HOXB8 cultures ex vivo, not by inducing skin tumors with UV in living mice.

🔬

Biochemical Markers

PLD4 expression in BPDCN tissue

Show evidence (2 references)

PMID:41219867 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"The specificity was 77.08% (37/48) for CD123 and 83.33% (40/48) for PLD4."

The measured specificity is limited to this study's control panel, despite broader specificity language in the abstract.

PMID:41219867 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"To further assess the diagnostic accuracy, we performed IHC analysis on skin biopsies from the second validation cohort of six BPDCN patients, and the results showed that PLD4 was positive in the dermis of all patients (Fig. S3A)."

Independent small-cohort immunostaining supports further biomarker evaluation.

🔬

Diagnosis

Immunophenotyping by Flow Cytometry or Immunohistochemistry

Diagnosis integrates tissue morphology with flow cytometry or immunohistochemistry. A pDC marker panel and exclusion of competing lineages distinguish BPDCN from AML mimics; expression of the CD4/CD56/CD123 triad alone is insufficient.

Show evidence (1 reference)

PMID:37946878 SUPPORT DIRECT BACKGROUND Other

This is the discussion's summary of WHO-5 BPDCN criteria. The paper's index patient had AML and is not a BPDCN clinical observation.

Cerebrospinal Fluid Examination

Deliberate CSF examination at diagnosis, because CNS involvement is frequently present while the patient is neurologically asymptomatic.

Show evidence (2 references)

PMID:38334635 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"with CNS involvement often overlooked in standard diagnostic workups due to BPDCN's rarity and patients often being neurologically asymptomatic at diagnosis"

Justifies CSF examination as a deliberate rather than symptom-triggered step.

PMID:26840087 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"cerebrospinal fluid (CSF) samples positive for tumor plasmacytoid dendritic cells were found in 6/10 (60%) cases studied at diagnosis"

Flow cytometry detected occult CSF disease in six of ten newly diagnosed patients in a small prospective cohort; this is not a population prevalence.

Myeloid Next-Generation Sequencing Panel

Targeted sequencing characterizes the clone and identifies prognostically relevant lesions, notably TET2 truncating mutations.

Show evidence (1 reference)

PMID:36689729 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"In multivariate analysis, having at least 1 TET2 truncating mutation was the only risk factor significantly associated with overall survival"

Identifies the specific sequencing result that carries prognostic weight.

Assessment of disease distribution

Skin examination, marrow evaluation and imaging establish cutaneous, marrow, nodal and other extramedullary involvement. CSF assessment is considered separately because imaging and neurologic examination may miss occult disease.

Show evidence (1 reference)

PMID:38132278 SUPPORT DIRECT REVIEW SYNTHESIS Other

"A Positron Emission Tomography (PET)/CT or CT scan should then be performed to study the lymph nodes and extramedullary sites, which may or may not indicate the execution of a lymph node biopsy."

The review summarizes the diagnostic staging approach.

📈

Progression

Chemotherapy-Era Outcome

Aggressive and rapid. Median overall survival is reported in the range of 12 to 24 months from diagnosis, with relapse typical after an initial chemotherapy response. These are outcomes under conventional chemotherapy, not untreated natural history - both sources describe patients who responded and then relapsed.

Show evidence (2 references)

PMID:34615655 SUPPORT DIRECT BACKGROUND Human Clinical

"Outcomes for patients with BPDCN are poor, with a median survival of 12 to 24 months from diagnosis"

The survival figure this phase records.

PMID:31846142 SUPPORT DIRECT BACKGROUND Human Clinical

"The median overall survival of patients with BPDCN ranges from 12 to 14 months as the disease typically relapses after initial response to chemotherapy."

Independent survival estimate and the relapse pattern after initial chemotherapy response.

Population-Based Long-Term Survival

SEER data on 340 first/only-primary BPDCN cases diagnosed during 2001-2019, restricted to ages 20-89 and excluding zero/unknown survival, report 1-, 3-, 5- and 10-year OS of 68.7%, 49.8%, 43.9% and 39.2%. The mean age was 53.7 years. Selection, historical coding, missing regimen details and treatment-era differences limit comparison with institutional series. Associations with radiotherapy or subsequent malignancies are observational and do not establish a treatment effect.

Show evidence (2 references)

PMID:37251924 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"For all the patients, the 1-year, 3-year, 5-year, and 10-year overall survival (OS) were 68.7%, 49.8%, 43.9%, and 39.2%, respectively"

The population-based survival figures this phase records.

PMID:37251924 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"multivariate AFT analysis indicated that older age was independently associated with worse survival, while second primary malignancies (SPMs) and radiation therapy were independently associated with extended survival."

The full multivariate result. Three factors survived adjustment, not one: age adversely, and second primary malignancies and radiotherapy favourably. The latter two are hard to read causally in a registry series and are recorded as the source reports them.

📊

Prevalence

Worldwide

Unknown Ultra Rare

Reported as accounting for less than 0.5% of all haematologic malignancies. That is a proportional-burden figure, not a rate, so it does not by itself fix a numeric band - hence measure_type UNKNOWN and a qualitative tier rather than a rate_per_100000. No dedicated registry prevalence estimate was found.

Show evidence (1 reference)

PMID:38334635 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"the incidence of BPDCN accounting for less than 0.5% of all hematologic malignancies"

The proportional-burden figure this record records as a qualitative rarity tier.

🌍

Epidemiology

Male Predominance

BPDCN occurs at least three times more often in men than in women. The ZRSR2 finding — X-linked loss-of-function mutations occurring almost exclusively in males — is the first mechanistic account of this bias.

Show evidence (2 references)

PMID:34615655 SUPPORT DIRECT BACKGROUND Human Clinical

"BPDCN occurs at least three times more frequently in men than in women, but the reasons for this sex bias are unknown."

Quantifies the male predominance this record describes.

PMID:37251924 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"A total of 340 primary BPDCN patients were included in this study. The average age was 53.7 ± 19.4 years, with 71.5% being male."

Independent population-based confirmation of the sex ratio.

Age Distribution

The dominant burden falls in older adults, with the median age at diagnosis in the seventh decade; a smaller paediatric and young-adult group also occurs.

Show evidence (2 references)

PMID:35788129 SUPPORT DIRECT BACKGROUND Human Clinical

"Median age at diagnosis lies within the seventh decennium and a male predominance is observed"

States the median age this record describes.

PMID:38334635 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"BPDCN has also been seen in younger populations, including children in a bimodal distribution pattern."

Supports the paediatric and young-adult half of this record, which the seventh-decade sentence above does not carry.

Antecedent or Concurrent Myeloid Neoplasm

A substantial minority of cases occur alongside or after another myeloid neoplasm — CMML, AML or MDS — reflecting a shared clonal-hematopoiesis origin rather than coincidence.

Show evidence (2 references)

PMID:35788129 SUPPORT DIRECT BACKGROUND Human Clinical

"Syn- and metachronous myeloid neoplasms (CMML, AML and MDS) have been reported in up to 20% of cases"

Quantifies the association this record describes.

PMID:30323983 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"The case demonstrates that minimal transformative disease of BPDCN may be detectable in patients with MDS well before fulminant progression."

Serial flow cytometry detected an aberrant pDC population before overt BPDCN in a patient with MDS; this case alone does not prove the genetic ancestry of the two neoplasms.

🔀

Differential Diagnoses

Conditions with similar clinical presentations that must be differentiated from Blastic Plasmacytoid Dendritic Cell Neoplasm:

Acute Myeloid Leukemia with Monocytic Differentiation

Overlapping Features Acute monocytic leukaemia can express CD4, CD56 and CD123 and share the blastic morphology. Myeloperoxidase and lysozyme expression, and the absence of the full pDC marker set, resolve it.

Show evidence (1 reference)

PMID:37946878 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Tandem flow cytometry showed an atypical population of dim CD45 events with expression of CD4, CD56, CD117, CD123, and monocytic markers such as CD64."

A worked case in which AML reproduced the BPDCN marker profile, which is what makes this the key differential.

Mature Plasmacytoid Dendritic Cell Proliferation Associated with Myeloid Neoplasm

Overlapping Features Mature plasmacytoid dendritic cell proliferation associated with a myeloid neoplasm shares the pDC lineage with BPDCN but consists of mature pDCs rather than blasts. Morphology and the associated myeloid neoplasm are important alongside immunophenotyping.

Show evidence (1 reference)

PMID:38334635 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"While both conditions have origins with proliferation of pDCs, MPDC is characterized by findings of normal morphologic and mature pDC proliferation, while BPDCN differs with regard to proliferation of the immature pDCs or blasts."

Review-level comparison of the two pDC neoplasm categories.

Leukemia Cutis and Myeloid Sarcoma

Overlapping Features Cutaneous involvement by acute myeloid leukemia. Shares the site and the blastic morphology; separated by myeloperoxidase and lysozyme expression and the absence of the pDC marker set.

Show evidence (1 reference)

PMID:40525728 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Diagnosis is based on biopsy of an involved site and is typically based on the identification of blastoid cells displaying the classical immunophenotypes CD123, CD4, and CD56 in addition to specific pDC markers."

States the marker requirement - specific pDC markers on top of the CD123/CD4/CD56 triad - that separates BPDCN from myeloid infiltrates sharing that triad.

📊

Related Datasets

Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin geo:GSE227690

Single-cell transcriptomics with genotyping plus tumour phylogenomics on BPDCN patient material, the primary data behind the UV-selection and marrow-origin findings curated in this entry.

human SINGLE CELL RNA SEQ

PMID:37286599

Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis [PDX] geo:GSE278318

RNA-seq of BPDCN patient-derived xenografts from the study linking X-linked ZRSR2 loss to the disease's male predominance.

human BULK RNA SEQ

PMID:34615655

BPDCN MYB Fusions Regulate Cell Cycle Genes, Impair Differentiation and Induce Myeloid-Dendritic Cell Leukemia [BPDCNCutRun] geo:GSE261534

CUT&RUN chromatin profiling in BPDCN cells showing MYB fusion binding redirected onto G2/M cell-cycle loci.

human CHIP SEQ

PMID:39499902

CUT&RUN data are represented under the closest available chromatin-profiling data type. The companion series GSE261411 profiles K562 rather than BPDCN material.

Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target geo:GSE164939

RNA sequencing associated with the original epigenetic-regulation study: five discovery BPDCN samples, four extension BPDCN samples and four normal pDC controls. The dataset was subsequently reused in the neural-program study PMID:34572907.

human BULK RNA SEQ

PMID:30381297

The broader publication also includes whole-exome and histone-mark profiling; these modalities should not all be inferred from the BULK_RNA_SEQ label.

🔬

Clinical Trials

NCT02113982 PHASE_II COMPLETED

Pivotal dose-escalation and expansion study of tagraxofusp, including untreated and relapsed/refractory BPDCN.

Show evidence (1 reference)

clinicaltrials:NCT02113982 SUPPORT DIRECT Other

"This is a 4-stage, non-randomized, open-label, dose escalation and expansion, multicenter study."

Registry description establishes the intervention and study scope; phase and recruitment status are registry metadata.

NCT03386513 PHASE_II ACTIVE_NOT_RECRUITING

Pivekimab sunirine monotherapy study including the CADENZA BPDCN cohorts that supported FDA approval.

Show evidence (1 reference)

clinicaltrials:NCT03386513 SUPPORT DIRECT Other

"This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease."

Registry description establishes the intervention and study scope; phase and recruitment status are registry metadata.

NCT07007052 PHASE_II RECRUITING

Phase 2 tagraxofusp plus venetoclax study in previously untreated adult BPDCN.

Show evidence (1 reference)

clinicaltrials:NCT07007052 SUPPORT DIRECT Other

"The goal of this clinical trial is to study the efficacy of the tagraxofusp + venetoclax combination in treatment-naive blastic plasmacytoid dendritic cell neoplasm adult patients."

Registry description establishes the intervention and study scope; phase and recruitment status are registry metadata.

NCT03113643 PHASE_I RECRUITING

Tagraxofusp with azacitidine, with or without venetoclax, in AML, high-risk MDS and BPDCN.

Show evidence (3 references)

clinicaltrials:NCT03113643 SUPPORT DIRECT Other

"This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS."

Registry description establishes the intervention and study scope; phase and recruitment status are registry metadata.

PMID:42413008 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Twenty-seven patients were enrolled (16 1L, 11 R/R), with median age of 70 years (range 21-81). Composite complete remission (CR/CRi/CRc) rates were 88% in 1L and 64% in R/R cohorts."

Prospective BPDCN-specific combination efficacy with explicit denominators and endpoint.

PMID:42413008 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"CLS occurred in 15% of patients; most were grade 2."

Capillary leak remains a safety issue with the combination.

NCT03485547 PHASE_I COMPLETED

Phase 1 venetoclax study specifically enrolling BPDCN.

Show evidence (1 reference)

clinicaltrials:NCT03485547 SUPPORT DIRECT Other

"This research study is studying a drug as a possible treatment for BPDCN."

Registry description establishes the intervention and study scope; phase and recruitment status are registry metadata.

NCT02159495 PHASE_I ACTIVE_NOT_RECRUITING

Phase 1 CD123-directed CAR-T study with separate AML and BPDCN arms.

Show evidence (1 reference)

clinicaltrials:NCT02159495 SUPPORT DIRECT Other

"This phase I trial studies the side effects and the best dose of genetically modified T-cells after lymphodepleting chemotherapy in treating patients with acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm that has returned after a period of improvement or has not responded..."

Registry description establishes the intervention and study scope; phase and recruitment status are registry metadata.

NCT06006403 PHASE_II COMPLETED

Phase 1/2 CD123-directed CAR-NK study in relapsed/refractory AML or BPDCN.

Show evidence (1 reference)

clinicaltrials:NCT06006403 SUPPORT DIRECT Other

"This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of targeting CD123 CAR-NK cell preparations in Relapsed/refractory acute myeloid leukemia (AML) or blastocytic plasmacytoid dendritic cell neoplasm (BPDCN)."

Registry description establishes the intervention and study scope; phase and recruitment status are registry metadata.

NCT06690827 PHASE_I RECRUITING

Phase 1 CD123-directed CAR-NK study in relapsed/refractory AML or BPDCN.

Show evidence (1 reference)

clinicaltrials:NCT06690827 SUPPORT DIRECT Other

"This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD123 CAR-NK in the treatment of patients with relapsed/refractory acute myeloid leukemia or blastic plasma cell like dendritic cell tumors."

Registry description establishes the intervention and study scope; phase and recruitment status are registry metadata.

🧫

Experimental Models

CAL-1 and GEN2.2 BPDCN cell lines CELL_LINE

The two established human BPDCN cell lines used across the mechanistic literature. They were the platform for the RNAi and drug screens that identified the TCF4-BRD4 dependency.

Organism

human NCBITaxon:9606

Publication

PMID:27846392

Pathograph links

TCF4-Dependent Super-Enhancer Network Addiction recapitulates fidelity: moderate observes: molecular The lines reproduce the BPDCN-specific TCF4-driven transcriptional program and die when it is disrupted genetically or pharmacologically.

Limitations: Established lines carry the transcriptional dependency but not the clonal-evolution history (founder TET2/ASXL1 lesions, transformation from an antecedent myeloid neoplasm) or the immune microenvironment, so they cannot report on the initiating steps of the chain.

Show evidence (1 reference)

PMID:27846392 SUPPORT DIRECT PRIMARY RESULT In Vitro

"its downregulation caused the loss of the BPDCN-specific gene expression program and apoptosis"

Establishes the lines as informative for the TCF4 dependency node.

Tet2-edited HOXB8 dendritic differentiation culture CELL_LINE

Mouse marrow progenitors immortalized with estrogen-responsive HOXB8 are gene-edited and differentiated into pDCs and cDCs after estrogen withdrawal. UV exposure is applied ex vivo during differentiation.

Organism

Mus musculus NCBITaxon:10090

Publication

PMID:37286599

Pathograph links

UV-Selected Survival of TET2-Mutant pDC Precursors in Sun-Exposed Skin partially recapitulates fidelity: moderate observes: cellular Tet2 knockout preferentially increases pDC survival after UV exposure.

Limitations: The experiment tests lineage-specific UV survival in culture. It does not reproduce skin homing, complete malignant transformation or systemic dissemination.

Show evidence (1 reference)

PMID:37286599 SUPPORT DIRECT PRIMARY RESULT In Vitro

"After UV exposure (100, 500 μJ cm−2), Tet2 knockout caused a further increase in the proportion of surviving pDCs, but had no protective effect on cDCs (Fig. 5e)."

Tet2 knockout was tested in differentiated mouse HOXB8 cultures ex vivo, not by inducing skin tumors with UV in living mice.

🐁

Animal Models

BPDCN patient-derived xenograft

Xenografts of primary patient BPDCN cells in immunodeficient mice, used to test BCL2 inhibition in vivo before the first off-label human use.

Species

Mouse

Genotype

Immunodeficient host engrafted with primary patient BPDCN cells

Publication

PMID:27986708

Pathograph links

BCL2-Dependent Survival of Malignant pDCs recapitulates fidelity: moderate observes: cellular Patient-derived xenografts retain the BCL2 dependence measured in primary cells and respond to venetoclax in vivo.

Limitations: Immunodeficient hosts cannot reproduce the T-cell exhaustion and interferon-skewed microenvironment described in patient marrow, so the model is silent on the immune component of the disease.

Show evidence (1 reference)

PMID:27986708 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Animals bearing BPDCN patient-derived xenografts had disease responses and improved survival after venetoclax treatment in vivo"

Establishes the xenograft as informative for the BCL2-dependent survival node.

MYB fusion-driven myeloid-dendritic acute leukemia mouse

Transplanted Hoxb8-FL-derived cells expressing MYB::PLEKHO1 induced myeloid-dendritic leukemia with intact or deleted Cdkn2a. Truncated MYB required Cdkn2a knockout in this system.

Species

Mouse

Genotype

MYB::PLEKHO1 or truncated MYB in Hoxb8-FL hematopoietic progenitors, with genotype-specific Cdkn2a status

Publication

PMID:39499902

Pathograph links

Plasmacytoid Dendritic Cell Differentiation Block partially recapitulates fidelity: moderate observes: organism The model reproduces the differentiation block and transformation caused by a MYB fusion.

Limitations: The leukemia is myeloid-dendritic rather than a complete phenocopy of human BPDCN. Hoxb8 immortalization creates a nonphysiological progenitor state, and the cooperating-lesion requirement differs between MYB constructs.

Show evidence (2 references)

PMID:39499902 SUPPORT DIRECT PRIMARY RESULT Model Organism

"expression of MYB fusions in vivo impaired DC differentiation and induced transformation to generate a mouse model of myeloid-dendritic acute leukemia."

Establishes the model and the differentiation-block phenotype it reproduces.

+ 1 more reference

Zrsr2 and Tet2 edited marrow chimera

Eight-week marrow-chimera experiments test the effects of BPDCN-associated founder lesions on hematopoiesis, pDC abundance, RNA splicing and activation.

Species

Mouse

Genotype

Cas9 marrow progenitors edited for Zrsr2, Tet2 or both, transplanted into irradiated wild-type recipients

Publication

PMID:34615655

Pathograph links

Blunted TLR-Induced pDC Activation partially recapitulates fidelity: moderate observes: cellular Mutant pDCs show altered splicing and reduced activation after a TLR agonist.

Limitations: No BPDCN or overt clonal evolution was observed in these short-term experiments. The model supports premalignant phenotypes, not sufficiency for malignant transformation.

Show evidence (1 reference)

PMID:34615655 SUPPORT DIRECT PRIMARY RESULT Model Organism

"In vivo, Zrsr2/Tet2-mutant pDCs had impaired activation after systemic exposure to R848 (Fig. 7F)."

Edited marrow chimeras reproduce reduced pDC activation in vivo.

{ }

Source YAML

click to show

name: Blastic Plasmacytoid Dendritic Cell Neoplasm
creation_date: '2026-09-06T00:00:00Z'
description: >-
  Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive
  haematologic malignancy arising from precursors of plasmacytoid dendritic
  cells (pDCs). It typically presents with disseminated violaceous or
  bluish-livid cutaneous plaques and nodules, followed by bone marrow,
  peripheral blood, lymph node and — often occultly — central nervous system
  involvement. Diagnosis rests on an immunophenotype combining CD123 (IL3RA)
  with pDC-lineage markers (TCF4, TCL1, CD303/BDCA2, CD304/BDCA4) and CD4
  and/or CD56, in the absence of lineage-defining myeloid, B-cell and T-cell
  markers. BPDCN is a somatic clonal disease: recurrent loss-of-function
  lesions in epigenetic regulators (TET2, ASXL1), in the X-linked splicing
  factor ZRSR2, and in the pDC differentiation factor IKZF1 arise in a
  hematopoietic progenitor, frequently on a background of clonal
  hematopoiesis shared with a preceding or concurrent myeloid neoplasm. The
  transformed clone remains addicted to the normal pDC master transcription
  factor TCF4 acting through BRD4-bound super-enhancers, retains high surface
  CD123, and depends on BCL2 for survival — the three dependencies that
  underpin its current and investigational targeted therapies.
categories:
- Hematologic Malignancy
- Dendritic Cell Neoplasm
- Acute Leukemia
parents:
- plasmacytoid dendritic cell neoplasm
disease_term:
  preferred_term: blastic plasmacytoid dendritic cell neoplasm
  term:
    id: MONDO:0019467
    label: CD4+/CD56+ hematodermic neoplasm
synonyms:
- BPDCN
- blastic plasmacytoid dendritic cell neoplasm
- CD4+/CD56+ hematodermic neoplasm
- blastic NK-cell lymphoma
- agranular CD4+ natural killer cell leukemia
- plasmacytoid dendritic cell leukemia
classifications:
  icdo_morphology:
    classification_value: Leukemia
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
pathophysiology:
- name: TET2 Loss in a Hematopoietic Precursor
  description: >-
    Somatic TET2 alterations occur in premalignant marrow hematopoietic precursors that can give rise to BPDCN.
    Truncating loss-of-function variants are common, but not every reported missense allele has demonstrated
    functional loss. Multiple TET2 variants and high combined variant allele fractions suggest biallelic involvement
    in some series; these observations do not phase every pair of variants. TET2 and ASXL1 can occur in different
    orders within branching clones.
  biological_scale: MOLECULAR
  genes:
  - preferred_term: TET2
    term:
      id: hgnc:25941
      label: TET2
  downstream:
  - target: Clonal Hematopoiesis of the Mutant Progenitor
    description: >-
      TET2 alterations mark expanded ancestral clones; the human reconstruction does not isolate their sufficiency
      for clonal expansion.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:37286599
      reference_title: Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        Overall, founder clones contained recurrent alterations in TET2 (5 out of 5 cases, 4 out of 5 cases
        with ≥2 alterations), ASXL1 (3 out of 5 cases) and splicing-factors (3 out of 5 cases), including ZRSR2
        (2 out of 5 cases), suggesting privileged roles in premalignant evolution in BPDCN (Fig. 1e (top)).
      explanation: >-
        Human phylogenies support recurrent founder lesions, without a fixed TET2-before-ASXL1 mutation order.
      quote_role: PRIMARY_RESULT
  - target: UV-Selected Survival of TET2-Mutant pDC Precursors in Sun-Exposed Skin
    description: >-
      Tet2 knockout selectively increases pDC survival after UV exposure in the ex vivo culture model.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37286599
      reference_title: Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin.
      supports: SUPPORT
      evidence_source: IN_VITRO
      directness: DIRECT
      snippet: >-
        After UV exposure (100, 500 μJ cm−2), Tet2 knockout caused a further increase in the proportion of
        surviving pDCs, but had no protective effect on cDCs (Fig. 5e).
      explanation: >-
        Tet2 knockout was tested in differentiated mouse HOXB8 cultures ex vivo, not by inducing skin tumors
        with UV in living mice.
      quote_role: PRIMARY_RESULT
  evidence:
  - reference: PMID:37286599
    reference_title: Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Overall, founder clones contained recurrent alterations in TET2 (5 out of 5 cases, 4 out of 5 cases with
      ≥2 alterations), ASXL1 (3 out of 5 cases) and splicing-factors (3 out of 5 cases), including ZRSR2 (2
      out of 5 cases), suggesting privileged roles in premalignant evolution in BPDCN (Fig. 1e (top)).
    explanation: >-
      Human phylogenies support recurrent founder lesions, without a fixed TET2-before-ASXL1 mutation order.
    quote_role: PRIMARY_RESULT
  - reference: PMID:36819168
    reference_title: 'Biallelic TET2 mutations and canonical ASXL1 mutations are frequent and cooccur in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): An institutional experience and review of literature.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      The number of cases is small, but the variant allele fraction (VAF) sums of the TET2 mutations, as well
      as the persistence of TET2 mutations in a case of relapsed BPDCN, suggest an ancestral/founder nature
      of TET2 clones in the cases.
    explanation: >-
      The five-patient series infers ancestral and biallelic involvement from VAF and persistence rather than
      direct phasing.
    quote_role: PRIMARY_RESULT
  genetic_context:
    gene:
      preferred_term: TET2
      term:
        id: hgnc:25941
        label: TET2
    variant_origin: SOMATIC
    functional_impact_category: LOSS_OF_FUNCTION
  cell_types:
  - preferred_term: hematopoietic precursor cell
    term:
      id: CL:0008001
      label: hematopoietic precursor cell
- name: ASXL1 Truncating Mutation in a Hematopoietic Precursor
  description: >-
    Somatic truncating ASXL1 variants affect chromatin regulation and can occur in ancestral marrow clones
    shared with BPDCN. The c.1934dupG allele occurred in all three ASXL1-mutant cases in a small institutional
    series; this does not define every ASXL1 alteration in BPDCN.
  biological_scale: MOLECULAR
  evidence:
  - reference: PMID:37286599
    reference_title: Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Overall, founder clones contained recurrent alterations in TET2 (5 out of 5 cases, 4 out of 5 cases with
      ≥2 alterations), ASXL1 (3 out of 5 cases) and splicing-factors (3 out of 5 cases), including ZRSR2 (2
      out of 5 cases), suggesting privileged roles in premalignant evolution in BPDCN (Fig. 1e (top)).
    explanation: >-
      Human phylogenies support recurrent founder lesions, without a fixed TET2-before-ASXL1 mutation order.
    quote_role: PRIMARY_RESULT
  - reference: PMID:36819168
    reference_title: 'Biallelic TET2 mutations and canonical ASXL1 mutations are frequent and cooccur in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): An institutional experience and review of literature.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      All 3 ASXL1 mutations were the c.1934dupG (p.Gly646Trpfs*12) variant, with the VAFs ranging from 24%
      to 28%.
    explanation: >-
      This specific frameshift recurred in the small series; the statement is cohort-bounded.
    quote_role: PRIMARY_RESULT
  downstream:
  - target: Clonal Hematopoiesis of the Mutant Progenitor
    description: >-
      ASXL1-mutant ancestral clones can expand before overt BPDCN; cooperating lesions and mutation order vary.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:37286599
      reference_title: Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        Overall, founder clones contained recurrent alterations in TET2 (5 out of 5 cases, 4 out of 5 cases
        with ≥2 alterations), ASXL1 (3 out of 5 cases) and splicing-factors (3 out of 5 cases), including ZRSR2
        (2 out of 5 cases), suggesting privileged roles in premalignant evolution in BPDCN (Fig. 1e (top)).
      explanation: >-
        Human phylogenies support recurrent founder lesions, without a fixed TET2-before-ASXL1 mutation order.
      quote_role: PRIMARY_RESULT
  genetic_context:
    gene:
      preferred_term: ASXL1
      term:
        id: hgnc:18318
        label: ASXL1
    variant_origin: SOMATIC
  cell_types:
  - preferred_term: hematopoietic precursor cell
    term:
      id: CL:0008001
      label: hematopoietic precursor cell
  genes:
  - preferred_term: ASXL1
    term:
      id: hgnc:18318
      label: ASXL1
- name: Clonal Hematopoiesis of the Mutant Progenitor
  description: >-
    Premalignant hematopoietic clones in the marrow can retain multilineage differentiation and share founder
    mutations with BPDCN skin tumors or another myeloid neoplasm. Additional lineage-specific alterations accompany
    transformation. Shared variants establish ancestry but do not by themselves prove that an overt myeloid
    cancer directly converted into BPDCN.
  biological_scale: CELLULAR
  downstream:
  - target: Clonal Expansion of pDC-Lineage Blasts
    description: >-
      A pDC-committed descendant may progress after additional lineage-specific alterations. This is a multistep
      route, not inevitable transformation of every founder clone or direct conversion of an overt myeloid
      cancer.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:37286599
      reference_title: Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        These pDC-committed cells then acquire additional mutations during malignant transformation to BPDCN.
      explanation: >-
        The phylogenomic study supports progression of a pDC-committed descendant of the founder clone after
        additional alterations; clonal hematopoiesis alone is not sufficient.
      quote_role: PRIMARY_RESULT
  evidence:
  - reference: PMID:37286599
    reference_title: Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Overall, founder clones contained recurrent alterations in TET2 (5 out of 5 cases, 4 out of 5 cases with
      ≥2 alterations), ASXL1 (3 out of 5 cases) and splicing-factors (3 out of 5 cases), including ZRSR2 (2
      out of 5 cases), suggesting privileged roles in premalignant evolution in BPDCN (Fig. 1e (top)).
    explanation: >-
      Human phylogenies support recurrent founder lesions, without a fixed TET2-before-ASXL1 mutation order.
    quote_role: PRIMARY_RESULT
  cell_types:
  - preferred_term: hematopoietic precursor cell
    term:
      id: CL:0008001
      label: hematopoietic precursor cell
- name: CDKN2A and CDKN2B Deletion at 9p21.3
  description: >-
    Recurrent copy-number loss at chromosome 9p21.3 removes CDKN2A/CDKN2B cell-cycle inhibitors. CDKN1B and
    RB1 can also be deleted in BPDCN, but they reside on chromosomes 12 and 13, respectively, and are separate
    lesions. Loss of CDKN2A can cooperate with MYB-driven cell-cycle deregulation.
  biological_scale: MOLECULAR
  genes:
  - preferred_term: CDKN2A
    term:
      id: hgnc:1787
      label: CDKN2A
  - preferred_term: CDKN2B
    term:
      id: hgnc:1788
      label: CDKN2B
  downstream:
  - target: Clonal Expansion of pDC-Lineage Blasts
    description: >-
      Loss of the G1/S checkpoint can cooperate with MYB-mediated cell-cycle deregulation; this interaction
      is demonstrated in an engineered mouse model.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39499902
      reference_title: BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      directness: INDIRECT
      snippet: >-
        Interestingly, we found that, in the case of MYB-TR (which models the MYB::ZFAT fusion recurrent in
        BPDCN) (2), overriding the G1/S checkpoint by Cdkn2a KO was also required for leukemic transformation.
      explanation: >-
        Cdkn2a loss cooperated specifically with truncated MYB in the Hoxb8-derived mouse transplantation model.
      quote_role: PRIMARY_RESULT
  evidence:
  - reference: PMID:30381297
    reference_title: 'Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Whole-exome sequencing data were also used for cytogenetic CNV analysis, which highlighted extensive
      losses along the chromosome 9 and the associated deletion of the tumor suppressor CDKN2A gene in 8 out
      of 14 BPDCN samples (57%) (Online Supplementary Figure S2), as already reported in the literature.12,15,20
    explanation: >-
      Primary copy-number analysis directly supports chromosome-9 CDKN2A loss; the other tumor suppressors
      are on different chromosomes.
    quote_role: PRIMARY_RESULT
  - reference: PMID:34615655
    reference_title: Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      These included loss of 7p (which harbors IKZF1), 9p (CDKN2A, CDKN2B), 12p (CDKN1B, ETV6), 13q (RB1),
      and 17p (TP53; Supplementary Fig. S2).
    explanation: >-
      Copy-number analysis of purified BPDCN cells places the recurrent losses on separate chromosomes.
    quote_role: PRIMARY_RESULT
- name: MYC Rearrangement at 8q24
  description: >-
    Rearrangement of the MYC locus, most often partnered with 6p21 (RUNX2)
    rather than an immunoglobulin locus, driving MYC overexpression. Reported
    frequencies differ substantially by cohort and ascertainment - 12% in one
    single-institution karyotype series, about a third in a cytogenetics
    review - and the rearranged cases are associated with an immunoblastoid
    cytomorphology.
  biological_scale: MOLECULAR
  genes:
  - preferred_term: MYC
    term:
      id: hgnc:7553
      label: MYC
  downstream:
  - target: Clonal Expansion of pDC-Lineage Blasts
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      MYC overexpression amplifies proliferative and biosynthetic
      transcriptional programs.
    evidence:
    - reference: PMID:29407586
      reference_title: "8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We conclude that 8q24/MYC rearrangements occur in 10-15% of BPDCN, often partnered with non-immunoglobulin chromosomal loci, and may play a role in BPDCN pathogenesis."
      explanation: >-
        The primary series behind this node, giving both the frequency and the
        non-immunoglobulin partner pattern.
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
  evidence:
  - reference: PMID:29407586
    reference_title: "8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We conclude that 8q24/MYC rearrangements occur in 10-15% of BPDCN, often partnered with non-immunoglobulin chromosomal loci, and may play a role in BPDCN pathogenesis."
    explanation: >-
      The primary series behind this node, giving both the frequency and the
      non-immunoglobulin partner pattern.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:32336417
    reference_title: "Cytogenetics of Blastic Plasmacytoid Dendritic Cell Neoplasm: Chromosomal Rearrangements and DNA Copy-Number Alterations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "One-third of cases of BPDCN harbor the 8q24 rearrangement, most frequently with 6p21 harboring RUNX2, which is associated with immunoblastoid cytomorphology and MYC expression."
    explanation: >-
      A higher frequency estimate from a cytogenetics review, plus the RUNX2
      partner and the cytomorphologic association. Curated alongside the 10-15%
      figure rather than in place of it, because the two disagree.

    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
- name: Glucocorticoid Resistance
  description: >-
    Attenuated glucocorticoid-receptor function reduces glucocorticoid-induced responses in CAL1 perturbation
    experiments. This provides a potential resistance mechanism relevant to steroid-containing regimens, rather
    than a validated treatment-selection rule for all NR3C1-deleted patients.
  biological_scale: CELLULAR
  evidence:
  - reference: PMID:27060168
    reference_title: "Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "functional analyses coupled with gene expression profiling identified corticoresistance and loss-of-EZH2 function as major downstream consequences of NR3C1 deletion in BPDCN"
    explanation: >-
      Names corticoresistance as a demonstrated downstream consequence of the
      NR3C1 lesion, which is what this node records.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
- name: Lymphoid Organ Infiltration
  description: >-
    BPDCN cells infiltrate lymph nodes and spleen. Lymph node enlargement and splenomegaly are clinical manifestations,
    while registry primary-site proportions describe a different measure of disease distribution.
  biological_scale: TISSUE
  locations:
  - preferred_term: lymph node
    term:
      id: UBERON:0000029
      label: lymph node
  evidence:
  - reference: PMID:37407876
    reference_title: '[Blastic plasmacytoid dendritic cell neoplasm (BPDCN) : A rare hematologic neoplasm with frequent cutaneous involvement].'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: "Palpatorisch fiel eine Lymphadenopathie zervikal beidseits und axillär rechts auf."  # codespell:ignore-line
    explanation: >-
      Direct examination documented cervical and axillary lymphadenopathy.
    quote_role: PRIMARY_RESULT
  - reference: PMID:41219867
    reference_title: Multi-organ single-cell analysis reveals PLD4 as a biomarker and potential therapeutic target of blastic plasmacytoid dendritic cell neoplasm.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Positron emission tomography-computed tomography (PET-CT) scans showed lymphadenopathy at the base of
      the neck, mediastinum, axilla, and bilateral inguinal regions, splenomegaly, and mild pleural effusion
      (Fig. S1E).
    explanation: >-
      Direct imaging in the BPDCN index patient documents splenic enlargement.
    quote_role: PRIMARY_RESULT
  downstream:
  - target: Lymphadenopathy
    description: >-
      Expansion of infiltrated lymphoid organs can produce clinical enlargement; imaging alone does not establish
      the contribution of each cellular process.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:41219867
      reference_title: Multi-organ single-cell analysis reveals PLD4 as a biomarker and potential therapeutic target of blastic plasmacytoid dendritic cell neoplasm.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        Positron emission tomography-computed tomography (PET-CT) scans showed lymphadenopathy at the base
        of
        the neck, mediastinum, axilla, and bilateral inguinal regions, splenomegaly, and mild pleural effusion
        (Fig. S1E).
      explanation: >-
        Direct imaging in the BPDCN index patient documents splenic enlargement.
      quote_role: PRIMARY_RESULT
  - target: Splenomegaly
    description: >-
      Expansion of infiltrated lymphoid organs can produce clinical enlargement; imaging alone does not establish
      the contribution of each cellular process.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:41219867
      reference_title: Multi-organ single-cell analysis reveals PLD4 as a biomarker and potential therapeutic target of blastic plasmacytoid dendritic cell neoplasm.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        Positron emission tomography-computed tomography (PET-CT) scans showed lymphadenopathy at the base
        of
        the neck, mediastinum, axilla, and bilateral inguinal regions, splenomegaly, and mild pleural effusion
        (Fig. S1E).
      explanation: >-
        Direct imaging in the BPDCN index patient documents splenic enlargement.
      quote_role: PRIMARY_RESULT
- name: ZRSR2 Loss-of-Function Splicing Defect
  description: >-
    Loss of the X-linked splicing factor ZRSR2 causes intron retention with a strong U12-intron bias, while
    also affecting selected U2 introns. Mutations were found in 24 of 93 BPDCN cases, 23 in males and one in
    a female; truncating loss-of-function variants occurred only in males in that cohort. ZRSR2 contributes
    to the male predominance but does not explain all of it.
  biological_scale: MOLECULAR
  genes:
  - preferred_term: ZRSR2
    term:
      id: hgnc:23019
      label: ZRSR2
  biological_processes:
  - preferred_term: RNA splicing
    modifier: ABNORMAL
    term:
      id: GO:0008380
      label: RNA splicing
  downstream:
  - target: IRF7 Intron Retention and Impaired Induction
    description: >-
      ZRSR2 dysfunction is associated with retention of IRF7 intron 4 and reduced inducibility; CAL1 rescue
      experiments support the causal chain.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:34615655
      reference_title: Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: DIRECT
      snippet: >-
        IRF7 intron 4 was aberrantly retained in ZRSR2-mutant BPDCN (2 of 2), and the same intron–exon region
        was also misspliced in SRSF2-mutated (4 of 4) and SF3B1-mutated (1 of 1) cases but not in splicing
        factor wild-type BPDCN or in normal pDCs (Supplementary Table S4).
      explanation: >-
        IRF7 intron 4 is a weak, delayed-spliced U2-type intron; it is not a U12 intron.
      quote_role: PRIMARY_RESULT
  evidence:
  - reference: PMID:34615655
    reference_title: "Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Loss-of-function mutations in ZRSR2, an X chromosome gene encoding a splicing factor, are enriched in BPDCN, and nearly all mutations occur in males."
    explanation: Establishes both the recurrence of the lesion in BPDCN and its near-exclusive occurrence in males.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
  genetic_context:
    gene:
      preferred_term: ZRSR2
      term:
        id: hgnc:23019
        label: ZRSR2
    variant_origin: SOMATIC
    functional_impact_category: LOSS_OF_FUNCTION
  cell_types:
  - preferred_term: hematopoietic precursor cell
    term:
      id: CL:0008001
      label: hematopoietic precursor cell
- name: IKZF1 Structural Inactivation
  description: >-
    Recurrent deletions and unbalanced rearrangements disrupt IKZF1. Structural alterations were detected in
    13 of 25 patients across the sequencing and extension cohorts; this count includes one focal duplication
    whose functional effect was inferred. Reduced IKZF1 activity is implicated in altered pDC differentiation
    and adhesion-gene expression. Patient expression signatures and comparisons with experimental IKZF1-deficient
    systems support this interpretation, without direct demonstration of skin homing.
  biological_scale: MOLECULAR
  genes:
  - preferred_term: IKZF1
    term:
      id: hgnc:13176
      label: IKZF1
  downstream:
  - target: Plasmacytoid Dendritic Cell Differentiation Block
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Patient expression signatures and comparison with IKZF1-deficient experimental systems support this relationship;
      it was not directly rescued in BPDCN cells.
    evidence:
    - reference: PMID:31846142
      reference_title: "Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "revealed that IKZF1, a gene encoding a transcription factor required for the differentiation of plasmacytoid dendritic cell precursors, is focally inactivated through recurrent structural alterations in this neoplasm"
      explanation: Direct whole-genome evidence for recurrent focal IKZF1 inactivation and its role in pDC precursor differentiation.

      quote_role: PRIMARY_RESULT
      directness: INDIRECT
  - target: Aberrant Cell Adhesion Program
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Patient expression signatures and comparison with IKZF1-deficient experimental systems support this relationship;
      it was not directly rescued in BPDCN cells.
    evidence:
    - reference: PMID:31846142
      reference_title: "Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "revealed that IKZF1, a gene encoding a transcription factor required for the differentiation of plasmacytoid dendritic cell precursors, is focally inactivated through recurrent structural alterations in this neoplasm"
      explanation: Direct whole-genome evidence for recurrent focal IKZF1 inactivation and its role in pDC precursor differentiation.

      quote_role: PRIMARY_RESULT
      directness: INDIRECT
  evidence:
  - reference: PMID:31846142
    reference_title: "Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "revealed that IKZF1, a gene encoding a transcription factor required for the differentiation of plasmacytoid dendritic cell precursors, is focally inactivated through recurrent structural alterations in this neoplasm"
    explanation: Direct whole-genome evidence for recurrent focal IKZF1 inactivation and its role in pDC precursor differentiation.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
  cell_types:
  - preferred_term: plasmacytoid dendritic cell
    term:
      id: CL:0000784
      label: plasmacytoid dendritic cell
- name: MYB Rearrangement
  description: >-
    BPDCN-associated MYB rearrangements retain the N-terminal DNA-binding domain and remove or alter C-terminal
    regulation. MYB::PLEKHO1 produces a chimeric protein, whereas the out-of-frame MYB::ZFAT rearrangement
    produces truncated MYB without a ZFAT protein segment. Engineered models support enhanced G2/M-gene binding
    and leukemogenic potential, with partner-dependent requirements for cooperating lesions.
  biological_scale: MOLECULAR
  genes:
  - preferred_term: MYB
    term:
      id: hgnc:7545
      label: MYB
  downstream:
  - target: Plasmacytoid Dendritic Cell Differentiation Block
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39499902
      reference_title: "BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "expression of MYB fusions in vivo impaired DC differentiation and induced transformation to generate a mouse model of myeloid-dendritic acute leukemia."
      explanation: >-
        In vivo demonstration that a BPDCN driver lesion produces a
        dendritic-cell differentiation block coupled to transformation.
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
  - target: Aberrant G2/M Cell Cycle Gene Regulation
    causal_link_type: DIRECT
    description: >-
      CUT&RUN profiling shows the fusion switches MYB's binding from lineage
      genes to G2/M cell-cycle control genes.
    evidence:
    - reference: PMID:39499902
      reference_title: "BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "we found that, in BPDCN leukemogenesis, MYB switches from being a regulator of DC lineage genes to aberrantly regulating G2/M cell cycle control genes."
      explanation: States the redirection of MYB binding onto cell-cycle genes, which is precisely this edge.
      quote_role: PRIMARY_RESULT
      directness: DIRECT
  evidence:
  - reference: PMID:39499902
    reference_title: "BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Rearrangements of the hematopoietic transcription factor MYB are recurrently found in 20% of patients with blastic plasmacytoid DC neoplasm (BPDCN), a rare leukemia arising from cells of the plasmacytoid DC (pDC) lineage"
    explanation: Quantifies the recurrence of MYB rearrangement in BPDCN.

    quote_role: BACKGROUND
    directness: DIRECT
  cell_types:
  - preferred_term: plasmacytoid dendritic cell
    term:
      id: CL:0000784
      label: plasmacytoid dendritic cell
- name: Plasmacytoid Dendritic Cell Differentiation Block
  description: >-
    Malignant cells retain a pDC-associated immunophenotype while showing abnormal differentiation and function.
    MYB perturbation models directly impair dendritic differentiation; IKZF1-related changes provide another
    proposed route. These findings do not establish a single developmental arrest point in every BPDCN.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: plasmacytoid dendritic cell
    term:
      id: CL:0000784
      label: plasmacytoid dendritic cell
  biological_processes:
  - preferred_term: plasmacytoid dendritic cell differentiation
    modifier: DECREASED
    term:
      id: GO:0002273
      label: plasmacytoid dendritic cell differentiation
  downstream: []
  evidence:
  - reference: PMID:39499902
    reference_title: "BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "expression of MYB fusions in vivo impaired DC differentiation and induced transformation to generate a mouse model of myeloid-dendritic acute leukemia."
    explanation: >-
      In vivo demonstration that a BPDCN driver lesion produces a
      dendritic-cell differentiation block coupled to transformation.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:30323983
    reference_title: "Early detection of transformation to BPDCN in a patient with MDS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "characterized by neoplastic cells that are positive for CD123, CD4, BDCA2, and TCL1 and aberrant expression of CD56"
    explanation: >-
      Human evidence for the retained pDC identity markers this node asserts,
      so the node does not rest on model-organism evidence alone.

    quote_role: BACKGROUND
    directness: DIRECT
- name: TCF4-Dependent Super-Enhancer Network Addiction
  description: >-
    TCF4 maintains a BPDCN-specific transcriptional program involving BRD4-associated super-enhancers. TCF4
    or BRD4 depletion and BET inhibition reduce survival in CAL1 and GEN2.2 cells; rescue experiments support
    the specificity of TCF4 knockdown. This maintenance dependency is distinct from proving how an ancestral
    clone first transforms.
  biological_scale: MOLECULAR
  genes:
  - preferred_term: TCF4
    term:
      id: hgnc:11634
      label: TCF4
  - preferred_term: BRD4
    term:
      id: hgnc:13575
      label: BRD4
  molecular_functions:
  - preferred_term: TCF4 transcription factor activity at BPDCN super-enhancers
    term:
      id: GO:0003700
      label: DNA-binding transcription factor activity
  downstream:
  - target: CD123 Overexpression on Malignant pDC Blasts
    description: >-
      TCF4 depletion reduces CD123 surface expression in BPDCN cell lines.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:27846392
      reference_title: A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm.
      supports: SUPPORT
      evidence_source: IN_VITRO
      directness: DIRECT
      snippet: >-
        Notably, knockdown of TCF4, but not MYC, decreased surface expression of CD123 and CD56, which are
        diagnostic hallmarks of BPDCN (Figure 3E, S3E).
      explanation: >-
        Direct perturbation in BPDCN cell lines supports TCF4-dependent maintenance of CD123 expression.
      quote_role: PRIMARY_RESULT
  - target: Clonal Expansion of pDC-Lineage Blasts
    causal_link_type: DIRECT
    description: >-
      Disrupting the TCF4-BRD4 network kills BPDCN cells, so the network is
      required for maintenance of the expanded clone.
    evidence:
    - reference: PMID:27846392
      reference_title: "A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "its downregulation caused the loss of the BPDCN-specific gene expression program and apoptosis"
      explanation: >-
        Loss-of-function of the node kills the expanded clone, which is this
        edge's causal claim. Quoted from the knockdown clause only: the
        sentence's first clause is a human-tissue immunostaining result and
        belongs to a different evidence source.
      quote_role: PRIMARY_RESULT
      directness: DIRECT
  evidence:
  - reference: PMID:27846392
    reference_title: "A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Using RNAi screening, we identified the E-box transcription factor TCF4 as a master regulator of the BPDCN oncogenic program."
    explanation: Identifies TCF4 as the master regulator this node is built on.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:27846392
    reference_title: "A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "High-throughput drug screening revealed that bromodomain and extra-terminal domain inhibitors (BETis) induced BPDCN apoptosis, which was attributable to disruption of a BPDCN-specific transcriptional network controlled by TCF4-dependent super-enhancers."
    explanation: Establishes the BRD4/super-enhancer component of the network and its pharmacological tractability.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
  cell_types:
  - preferred_term: plasmacytoid dendritic cell
    term:
      id: CL:0000784
      label: plasmacytoid dendritic cell
- name: CD123 Overexpression on Malignant pDC Blasts
  description: >-
    BPDCN blasts commonly express high levels of CD123, the IL3RA subunit. This provides the binding target
    for tagraxofusp, pivekimab and investigational CD123-directed cellular therapies. Tagraxofusp delivers
    a diphtheria toxin payload; receptor expression alone does not establish that IL-3 signaling drives BPDCN.
    Earlier RNAi screens suggest an IL3RA dependency, but other treatment targets include BCL2 and transcriptional
    regulators.
  biological_scale: CELLULAR
  genes:
  - preferred_term: IL3RA
    term:
      id: hgnc:6012
      label: IL3RA
  gene_products:
  - preferred_term: interleukin-3 receptor alpha chain (CD123)
    term:
      id: NCIT:C39275
      label: Interleukin-3 Receptor Subunit Alpha
  downstream: []
  evidence:
  - reference: PMID:31018069
    reference_title: "Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive hematologic cancer that is caused by transformed plasmacytoid dendritic cells that overexpress interleukin-3 receptor subunit alpha (IL3RA or CD123)."
    explanation: States CD123 overexpression on the transformed pDCs as the defining molecular feature of this node.

    quote_role: BACKGROUND
    directness: DIRECT
- name: BCL2-Dependent Survival of Malignant pDCs
  description: >-
    BH3 profiling demonstrated BCL2 dependence in the tested primary BPDCN samples, supported by venetoclax-induced
    apoptosis and responses in patient-derived xenografts. This functional dependence provides a therapeutic
    rationale but does not guarantee a durable clinical response in every patient. It is separate from the
    activation-coupled apoptosis defect associated with ZRSR2.
  biological_scale: CELLULAR
  genes:
  - preferred_term: BCL2
    term:
      id: hgnc:990
      label: BCL2
  biological_processes:
  - preferred_term: negative regulation of apoptotic process
    modifier: INCREASED
    term:
      id: GO:0043066
      label: negative regulation of apoptotic process
  downstream:
  - target: Clonal Expansion of pDC-Lineage Blasts
    description: >-
      BCL2-mediated suppression of mitochondrial apoptosis supports blast survival.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:27986708
      reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "We found that primary BPDCN cells were dependent on the antiapoptotic protein BCL2 and were uniformly sensitive to the BCL2 inhibitor venetoclax, as measured by direct cytotoxicity, apoptosis assays, and dynamic BH3 profiling."
      explanation: >-
        Functional profiling establishes BCL2 dependence in the tested primary samples; it does not guarantee
        response in every patient.
      directness: DIRECT
      quote_role: PRIMARY_RESULT
  evidence:
  - reference: PMID:27986708
    reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We found that primary BPDCN cells were dependent on the antiapoptotic protein BCL2 and were uniformly sensitive to the BCL2 inhibitor venetoclax, as measured by direct cytotoxicity, apoptosis assays, and dynamic BH3 profiling."
    explanation: >-
      Functional profiling establishes BCL2 dependence in the tested primary samples; it does not guarantee
      response in every patient.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  cell_types:
  - preferred_term: plasmacytoid dendritic cell
    term:
      id: CL:0000784
      label: plasmacytoid dendritic cell
- name: Aberrant G2/M Cell Cycle Gene Regulation
  description: >-
    MYB occupies and regulates G2/M cell-cycle genes in BPDCN with and without MYB fusions. Endogenous-locus
    MYB knock-ins in the K562 human leukemia line demonstrate stronger binding by truncated MYB and MYB::PLEKHO1
    than by wild-type MYB. These experiments complement BPDCN-cell and xenograft chromatin profiles; K562 is
    not a BPDCN model.
  biological_scale: MOLECULAR
  biological_processes:
  - preferred_term: G2/M transition of mitotic cell cycle
    modifier: INCREASED
    term:
      id: GO:0000086
      label: G2/M transition of mitotic cell cycle
  downstream:
  - target: Clonal Expansion of pDC-Lineage Blasts
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39499902
      reference_title: "BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "MYB fusions found in patients with BPDCN increased the magnitude of DNA binding at these locations, and this was linked to BPDCN-associated gene expression changes."
      explanation: Links the fusion's increased binding at G2/M loci to the expression changes this node names.
      directness: INDIRECT
      quote_role: PRIMARY_RESULT
  evidence:
  - reference: PMID:39499902
    reference_title: "BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "MYB fusions found in patients with BPDCN increased the magnitude of DNA binding at these locations, and this was linked to BPDCN-associated gene expression changes."
    explanation: Links the fusion's increased binding at G2/M loci to the expression changes this node names.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
- name: NR3C1 Haploinsufficiency
  description: >-
    Monoallelic NR3C1 deletion was detected in 13 of 47 BPDCN cases and associated with reduced glucocorticoid-receptor
    expression and poorer survival in the index cohort. GCR knockdown and a separately identified NR3C1 fusion
    support impaired glucocorticoid responses and altered chromatin regulation. The deletion does not imply
    an identical 50% expression reduction or clinically proven steroid failure in every affected patient.
  biological_scale: MOLECULAR
  genes:
  - preferred_term: NR3C1
    term:
      id: hgnc:7978
      label: NR3C1
  downstream:
  - target: Glucocorticoid Resistance
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Halved receptor dosage is the direct cause of the corticoresistant
      phenotype.
    evidence:
    - reference: PMID:27060168
      reference_title: "Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "functional analyses coupled with gene expression profiling identified corticoresistance and loss-of-EZH2 function as major downstream consequences of NR3C1 deletion in BPDCN"
      explanation: >-
        Names corticoresistance as a demonstrated downstream consequence of the
        NR3C1 lesion, which is what this node records.

      quote_role: PRIMARY_RESULT
      directness: INDIRECT
  - target: Reduced H3K27 Trimethylation after GCR Attenuation
    description: >-
      Reduced GCR function alters H3K27me3 in CAL1 perturbation experiments.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:27060168
      reference_title: Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms.
      supports: SUPPORT
      evidence_source: IN_VITRO
      directness: DIRECT
      snippet: >-
        Consistent with our GEP experiments, western blot analyses revealed global loss of H3K27me3 under attenuated
        GCR signaling (Figure 3D; supplemental Figure 3D).
      explanation: >-
        GCR knockdown or fusion expression in dexamethasone-treated CAL1 cells reduced H3K27me3; direct physical
        regulation of PRC2 remains unresolved.
      quote_role: PRIMARY_RESULT
  evidence:
  - reference: PMID:27060168
    reference_title: "Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we identify monoallelic deletion of NR3C1 (5q31), encoding the glucocorticoid receptor (GCR), in 13 of 47 (28%) BPDCN patients"
    explanation: Quantifies the recurrence of the monoallelic NR3C1 deletion this node describes.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:27060168
    reference_title: "Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Haploinsufficiency for NR3C1 defined a subset of BPDCN with lowered GCR expression and extremely poor overall survival (P = .0006)."
    explanation: Establishes both the reduced receptor expression and the prognostic consequence.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
  cell_types:
  - preferred_term: plasmacytoid dendritic cell
    term:
      id: CL:0000784
      label: plasmacytoid dendritic cell
- name: UV-Selected Survival of TET2-Mutant pDC Precursors in Sun-Exposed Skin
  description: >-
    Human tumor phylogenies identify a UV-associated route in which premalignant pDC-lineage cells acquire
    UV damage in skin before or during transformation. In an ex vivo mouse HOXB8 differentiation system, Tet2
    knockout selectively protects pDCs from UV-induced death. Together these findings support selection in
    sun-exposed skin in some cases, without making UV exposure necessary for every BPDCN or demonstrating complete
    UV-driven transformation in vivo.
  biological_scale: CELLULAR
  genes:
  - preferred_term: TET2
    term:
      id: hgnc:25941
      label: TET2
  triggers:
  - preferred_term: exposure to ultraviolet radiation
    term:
      id: ECTO:0000006
      label: exposure to ultraviolet radiation
  downstream:
  - target: Cutaneous Infiltration by Malignant pDC Blasts
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Human phylogenies and ex vivo selection experiments support a proposed UV-associated route to skin tumors;
      further transforming events intervene.
    evidence:
    - reference: PMID:37286599
      reference_title: "Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We observe that BPDCN skin tumours first develop at sun-exposed anatomical sites and are distinguished by clonally expanded mutations induced by ultraviolet (UV) radiation."
      explanation: >-
        Ties the anatomical distribution of the tumours to UV exposure, which
        is the causal claim this edge makes.
      quote_role: PRIMARY_RESULT
      directness: DIRECT
    hypothesis_groups:
    - UV_ASSOCIATED_TRANSFORMATION
  evidence:
  - reference: PMID:37286599
    reference_title: Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin.
    supports: SUPPORT
    evidence_source: IN_VITRO
    directness: DIRECT
    snippet: >-
      After UV exposure (100, 500 μJ cm−2), Tet2 knockout caused a further increase in the proportion of surviving
      pDCs, but had no protective effect on cDCs (Fig. 5e).
    explanation: >-
      Tet2 knockout was tested in differentiated mouse HOXB8 cultures ex vivo, not by inducing skin tumors
      with UV in living mice.
    quote_role: PRIMARY_RESULT
  - reference: PMID:37286599
    reference_title: "Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A reconstruction of tumour phylogenies reveals that UV damage can precede the acquisition of alterations associated with malignant transformation"
    explanation: >-
      Supports the ordering claim - UV damage before transformation - that
      makes this a selective step rather than a consequence of the tumour.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
  cell_types:
  - preferred_term: plasmacytoid dendritic cell
    term:
      id: CL:0000784
      label: plasmacytoid dendritic cell
- name: Aberrant Cell Adhesion Program
  description: >-
    Patient BPDCN transcriptomes show increased cell-cell and extracellular-matrix interaction programs. Comparisons
    with IKZF1-deficient experimental systems implicate IKZF1 dysfunction. A contribution to skin homing is
    plausible but has not been established by BPDCN migration or homing rescue experiments.
  biological_scale: CELLULAR
  biological_processes:
  - preferred_term: cell adhesion
    modifier: INCREASED
    term:
      id: GO:0007155
      label: cell adhesion
  downstream:
  - target: Cutaneous Infiltration by Malignant pDC Blasts
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Proposed, not demonstrated. The adhesion program is an association in
      bulk tumour transcriptome; no experiment ties it to skin homing.
    hypothesis_groups:
    - ADHESION_SKIN_TROPISM
    evidence:
    - reference: PMID:31846142
      reference_title: "Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "up-regulation of cellular processes responsible for cell-cell and cell-ECM interactions, which is a hallmark of IKZF1 deficiency, was prominent in BPDCN"
      explanation: Reports the adhesion-program upregulation and attributes it to IKZF1 deficiency.

      quote_role: PRIMARY_RESULT
      directness: INDIRECT
  evidence:
  - reference: PMID:31846142
    reference_title: "Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "up-regulation of cellular processes responsible for cell-cell and cell-ECM interactions, which is a hallmark of IKZF1 deficiency, was prominent in BPDCN"
    explanation: Reports the adhesion-program upregulation and attributes it to IKZF1 deficiency.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
- name: Clonal Expansion of pDC-Lineage Blasts
  description: >-
    The differentiation-arrested, apoptosis-resistant clone expands, and this
    expanded population is what subsequently distributes to skin, marrow,
    blood, lymph nodes and the leptomeninges.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: malignant plasmacytoid dendritic cell blast
    term:
      id: CL:0000784
      label: plasmacytoid dendritic cell
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  downstream:
  - target: Cutaneous Infiltration by Malignant pDC Blasts
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27986708
      reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy that presents with skin nodules and tumors, lymph node and splenic enlargement, central nervous system involvement, circulating leukemia, and/or bone marrow infiltration"
      explanation: Enumerates the compartments the expanded clone reaches, which are this node's downstream targets.

      quote_role: BACKGROUND
      directness: INDIRECT
  - target: Bone Marrow and Leukemic Dissemination
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27986708
      reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy that presents with skin nodules and tumors, lymph node and splenic enlargement, central nervous system involvement, circulating leukemia, and/or bone marrow infiltration"
      explanation: Enumerates the compartments the expanded clone reaches, which are this node's downstream targets.

      quote_role: BACKGROUND
      directness: INDIRECT
  - target: Central Nervous System Infiltration
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27986708
      reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy that presents with skin nodules and tumors, lymph node and splenic enlargement, central nervous system involvement, circulating leukemia, and/or bone marrow infiltration"
      explanation: Enumerates the compartments the expanded clone reaches, which are this node's downstream targets.

      quote_role: BACKGROUND
      directness: INDIRECT
  - target: Lymphoid Organ Infiltration
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27986708
      reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy that presents with skin nodules and tumors, lymph node and splenic enlargement, central nervous system involvement, circulating leukemia, and/or bone marrow infiltration"
      explanation: Enumerates the compartments the expanded clone reaches, which are this node's downstream targets.

      quote_role: BACKGROUND
      directness: INDIRECT
  - target: T Cell Exhaustion in the Marrow Microenvironment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The authors propose that accumulated pDC-lineage blasts sustain chronic interferon stimulation; the study
      measures expression signatures and clonotype associations rather than experimentally proving this causal
      chain.
    hypothesis_groups:
    - CHRONIC_IFN_TCELL_EXHAUSTION
    evidence:
    - reference: PMID:35359938
      reference_title: Single-Cell Multiomics Reveals Clonal T-Cell Expansions and Exhaustion in Blastic Plasmacytoid Dendritic Cell Neoplasm.
      supports: SUPPORT
      evidence_source: OTHER
      directness: INDIRECT
      snippet: >-
        We hypothesize that, despite the tumor cells exhibiting lower IFNA production at the individual cell
        level, abnormal accumulation of pDC-like tumor cells in BPDCN may lead to increased IFNA production
        and chronic T-cell activation, eventually leading to T-cell exhaustion and consequent TNFA downregulation.
      explanation: >-
        The authors propose this sequence; cytokine production and its causal contribution were not experimentally
        demonstrated.
  evidence:
  - reference: PMID:27986708
    reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy that presents with skin nodules and tumors, lymph node and splenic enlargement, central nervous system involvement, circulating leukemia, and/or bone marrow infiltration"
    explanation: Enumerates the compartments the expanded clone reaches, which are this node's downstream targets.

    quote_role: BACKGROUND
    directness: DIRECT
- name: Cutaneous Infiltration by Malignant pDC Blasts
  description: >-
    Blasts infiltrate the dermis and may extend into subcutaneous fat, producing erythematous to violaceous
    plaques or nodules. Skin disease may precede systemic involvement, coexist with it, or be absent at presentation.
  biological_scale: TISSUE
  locations:
  - preferred_term: skin
    term:
      id: UBERON:0002097
      label: skin of body
  evidence:
  - reference: PMID:37407876
    reference_title: '[Blastic plasmacytoid dendritic cell neoplasm (BPDCN) : A rare hematologic neoplasm with frequent cutaneous involvement].'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: "Direkt unterhalb der Epidermis und bis in die tiefe Subkutis hineinreichend zeigten sich relativ monomorphe klein- bis mittelgroßzellige Infiltrate mit erhöhter mitotischer Aktivität (Abb. 2)."  # codespell:ignore-line
    explanation: >-
      Direct BPDCN skin histology documents dermal-to-subcutaneous extension and monomorphic cells.
    quote_role: PRIMARY_RESULT
  - reference: PMID:38132278
    reference_title: 'Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      The appearance of the disease in the skin biopsy consists of a typical monomorphic and diffuse infiltrate
      involving the dermis, with sparing of the epidermis and the presence of a visible Grenz zone.
    explanation: >-
      The review describes the characteristic architecture, which is not sufficient alone for diagnosis.
    quote_role: REVIEW_SYNTHESIS
  downstream:
  - target: Violaceous Cutaneous Plaques and Nodules
    description: >-
      Dermal and subcutaneous blast infiltrates underlie the clinically sampled plaques and nodules.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:37407876
      reference_title: '[Blastic plasmacytoid dendritic cell neoplasm (BPDCN) : A rare hematologic neoplasm with frequent cutaneous involvement].'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: "Direkt unterhalb der Epidermis und bis in die tiefe Subkutis hineinreichend zeigten sich relativ monomorphe klein- bis mittelgroßzellige Infiltrate mit erhöhter mitotischer Aktivität (Abb. 2)." # codespell:ignore-line
      explanation: >-
        Direct BPDCN skin histology documents dermal-to-subcutaneous extension and monomorphic cells.
      quote_role: PRIMARY_RESULT
- name: Bone Marrow and Leukemic Dissemination
  description: >-
    BPDCN cells may infiltrate marrow and circulate in blood. Marrow disease can occur at presentation or during
    progression and does not invariably follow cutaneous disease.
  biological_scale: TISSUE
  locations:
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  downstream:
  - target: Marrow Failure Cytopenias
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:38334635
      reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review of the Disease, Central Nervous System Presentations, and Treatment Strategies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "BPDCN arises from plasmacytoid dendritic cells, manifesting primarily in the skin, bone marrow, and lymph nodes, occasionally involving the central nervous system (CNS)."
      explanation: Names marrow as a primary compartment of involvement.

      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
  evidence:
  - reference: PMID:38334635
    reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review of the Disease, Central Nervous System Presentations, and Treatment Strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BPDCN arises from plasmacytoid dendritic cells, manifesting primarily in the skin, bone marrow, and lymph nodes, occasionally involving the central nervous system (CNS)."
    explanation: Names marrow as a primary compartment of involvement.

    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
- name: Marrow Failure Cytopenias
  description: >-
    Marrow infiltration can impair normal hematopoiesis and contribute to cytopenias. Anemia, thrombocytopenia
    and neutropenia are reported manifestations, but an individual cytopenia requires assessment of other causes
    and treatment effects.
  biological_scale: ORGANISM
  locations:
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  evidence:
  - reference: PMID:38132278
    reference_title: 'Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      The most common findings in the peripheral blood are thrombocytopenia (78%), anemia (65%), and neutropenia
      (34%).
    explanation: >-
      The review records disease-associated cytopenias; it does not establish marrow replacement as the cause
      in every patient.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:27986708
    reference_title: Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      His platelets had been persistently below 10,000/μL despite transfusion, predating venetoclax treatment
      and likely related to bone marrow infiltration by BPDCN.
    explanation: >-
      A BPDCN patient had severe thrombocytopenia before venetoclax; marrow infiltration was the authors' likely
      explanation.
    quote_role: PRIMARY_RESULT
  downstream:
  - target: Thrombocytopenia
    description: >-
      Impaired marrow hematopoiesis can reduce platelet counts; the cited case attributed severe pretreatment
      thrombocytopenia to infiltration as a likely explanation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27986708
      reference_title: Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        His platelets had been persistently below 10,000/μL despite transfusion, predating venetoclax treatment
        and likely related to bone marrow infiltration by BPDCN.
      explanation: >-
        A BPDCN patient had severe thrombocytopenia before venetoclax; marrow infiltration was the authors'
        likely
        explanation.
      quote_role: PRIMARY_RESULT
- name: Central Nervous System Infiltration
  description: >-
    BPDCN blasts may infiltrate the leptomeningeal/CSF compartment while neurologic examination remains normal.
    CNS involvement is also a recognized relapse pattern. Sensitive CSF flow cytometry can detect occult disease;
    the small available cohorts do not define a uniform prevalence at diagnosis.
  biological_scale: TISSUE
  locations:
  - preferred_term: central nervous system
    term:
      id: UBERON:0001017
      label: central nervous system
  evidence:
  - reference: PMID:38334635
    reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review of the Disease, Central Nervous System Presentations, and Treatment Strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This presents challenges in diagnosis and treatment, with CNS involvement often overlooked in standard diagnostic workups due to BPDCN's rarity and patients often being neurologically asymptomatic at diagnosis."
    explanation: States that CNS involvement is present but clinically silent and therefore under-detected.

    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
  - reference: PMID:26840087
    reference_title: Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      cerebrospinal fluid (CSF) samples positive for tumor plasmacytoid dendritic cells were found in 6/10
      (60%) cases studied at diagnosis
    explanation: >-
      Flow cytometry detected occult CSF disease in six of ten newly diagnosed patients in a small prospective
      cohort; this is not a population prevalence.
    quote_role: PRIMARY_RESULT
  downstream:
  - target: Central Nervous System Involvement
    description: >-
      Accumulation of neoplastic pDCs in the CSF establishes compartment involvement, including clinically
      occult disease.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26840087
      reference_title: Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        cerebrospinal fluid (CSF) samples positive for tumor plasmacytoid dendritic cells were found in 6/10
        (60%) cases studied at diagnosis
      explanation: >-
        Flow cytometry detected occult CSF disease in six of ten newly diagnosed patients in a small prospective
        cohort; this is not a population prevalence.
      quote_role: PRIMARY_RESULT
- name: Diphthamide Pathway Silencing
  description: >-
    Acquired tagraxofusp resistance can involve reduced diphthamide-pathway activity, including methylation-associated
    DPH1 downregulation. DPH1 loss impairs the eEF2 substrate modification required for toxin-mediated ADP-ribosylation.
    CAL1 knockout/add-back and azacitidine experiments establish a reversible route; small patient and xenograft
    analyses support pathway impairment in vivo. CD123 was retained in this study, but this does not exclude
    other resistance mechanisms or antigen loss in other settings.
  biological_scale: MOLECULAR
  evidence:
  - reference: url:https://www.jci.org/articles/view/128571
    reference_title: "JCI -\nDNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance"
    supports: SUPPORT
    evidence_source: IN_VITRO
    directness: DIRECT
    snippet: >-
      Re-expression of full-length DPH1 also restored the cytotoxic activity of tagraxofusp in resistant cells
    explanation: >-
      DPH1 add-back directly reversed acquired resistance in CAL1 BPDCN cells.
    quote_role: PRIMARY_RESULT
  - reference: PMID:31437130
    reference_title: DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.
    supports: SUPPORT
    evidence_source: IN_VITRO
    directness: DIRECT
    snippet: >-
      Expression of DPH1, encoding a diphthamide pathway enzyme, was reduced by DNA CpG methylation in resistant
      cells.
    explanation: >-
      Primary study of acquired resistance; CAL1 and AML perturbation experiments establish methylation-associated
      downregulation.
    quote_role: PRIMARY_RESULT
- name: T Cell Exhaustion in the Marrow Microenvironment
  description: >-
    Single-cell profiling of five BPDCN marrows and five healthy controls found increased interferon-alpha
    response signatures, reduced TNF-alpha signaling signatures and higher CD8 memory T-cell exhaustion scores.
    TCR analysis in four evaluable patients linked larger clonotypes to higher exhaustion scores. These are
    transcriptional associations; chronic interferon secretion by accumulated tumor cells was proposed but
    not directly measured as the cause.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: CD8-positive T cell
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  evidence:
  - reference: PMID:35359938
    reference_title: "Single-Cell Multiomics Reveals Clonal T-Cell Expansions and Exhaustion in Blastic Plasmacytoid Dendritic Cell Neoplasm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Integrating transcriptional data with T-cell receptor sequencing via shared barcodes reveals significant T-cell exhaustion in BPDCN that is positively correlated with T-cell clonotype expansion."
    explanation: Direct single-cell evidence for the T-cell exhaustion this node asserts.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:35359938
    reference_title: "Single-Cell Multiomics Reveals Clonal T-Cell Expansions and Exhaustion in Blastic Plasmacytoid Dendritic Cell Neoplasm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "T-cells in BPDCN patients consistently upregulate interferon alpha (IFNA) response and downregulate tumor necrosis factor alpha (TNFA) pathways"
    explanation: Supports the specific pathway directions described in this node.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
- name: IRF7 Intron Retention and Impaired Induction
  description: >-
    ZRSR2-mutant BPDCN retains the weak fourth intron of IRF7 and fails to increase IRF7 protein normally after
    TLR stimulation. IRF7 is not a U12-intron-containing transcript. Missplicing in SRSF2- and SF3B1-mutant
    cases indicates that this defect is not restricted to ZRSR2.
  biological_scale: MOLECULAR
  evidence:
  - reference: PMID:34615655
    reference_title: Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      IRF7 intron 4 was aberrantly retained in ZRSR2-mutant BPDCN (2 of 2), and the same intron–exon region
      was also misspliced in SRSF2-mutated (4 of 4) and SF3B1-mutated (1 of 1) cases but not in splicing factor
      wild-type BPDCN or in normal pDCs (Supplementary Table S4).
    explanation: >-
      IRF7 intron 4 is a weak, delayed-spliced U2-type intron; it is not a U12 intron.
    quote_role: PRIMARY_RESULT
  - reference: PMID:34615655
    reference_title: Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    directness: DIRECT
    snippet: >-
      Wild-type intronless IRF7, which would not require ZRSR2 for splicing, restored LPS-induced growth arrest
      in ZRSR2-mutant cells, whereas inactive IRF7 did not (Supplementary Fig. S5D).
    explanation: >-
      Endogenous-locus intronless IRF7 rescue links the splicing defect to the impaired stimulated growth response.
    quote_role: PRIMARY_RESULT
  downstream:
  - target: Blunted TLR-Induced pDC Activation
    description: >-
      Impaired IRF7 induction blunts the inflammatory activation program.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:34615655
      reference_title: Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.
      supports: SUPPORT
      evidence_source: IN_VITRO
      directness: DIRECT
      snippet: >-
        IRF7 and TRAIL induction by LPS were partially rescued in ZRSR2-mutant cells by overexpression of wild-type
        ZRSR2 (Fig. 6E).
      explanation: >-
        The CAL1 rescue experiment supports impaired IRF7-dependent activation and TRAIL induction downstream
        of ZRSR2 loss.
      quote_role: PRIMARY_RESULT
  cell_types:
  - preferred_term: plasmacytoid dendritic cell
    term:
      id: CL:0000784
      label: plasmacytoid dendritic cell
- name: Blunted TLR-Induced pDC Activation
  description: >-
    After inflammatory TLR stimulation, ZRSR2-deficient pDC-lineage cells show reduced induction of IRF7, type
    I interferons and the proapoptotic mediator TRAIL. This is a selective impairment: other secreted mediators
    and downstream responses to exogenous TRAIL remain intact.
  biological_scale: CELLULAR
  evidence:
  - reference: PMID:34615655
    reference_title: Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    directness: DIRECT
    snippet: >-
      IRF7 and TRAIL induction by LPS were partially rescued in ZRSR2-mutant cells by overexpression of wild-type
      ZRSR2 (Fig. 6E).
    explanation: >-
      The CAL1 rescue experiment supports impaired IRF7-dependent activation and TRAIL induction downstream
      of ZRSR2 loss.
    quote_role: PRIMARY_RESULT
  downstream:
  - target: Resistance to Activation-Induced pDC Apoptosis
    description: >-
      Insufficient induction of proapoptotic TRAIL permits survival after TLR stimulation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:34615655
      reference_title: Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.
      supports: SUPPORT
      evidence_source: IN_VITRO
      directness: DIRECT
      snippet: >-
        Knockout of ZRSR2 conferred relative protection from LPS- or R848-induced apoptosis (Fig. 6B). The
        growth rate of CAL1 cells at steady state was not changed by ZRSR2 mutation.
      explanation: >-
        CAL1 perturbation demonstrates a stimulation-dependent survival advantage.
      quote_role: PRIMARY_RESULT
  cell_types:
  - preferred_term: plasmacytoid dendritic cell
    term:
      id: CL:0000784
      label: plasmacytoid dendritic cell
- name: Resistance to Activation-Induced pDC Apoptosis
  description: >-
    ZRSR2-deficient cells are relatively protected from growth arrest and apoptosis after TLR stimulation because
    activation and TRAIL induction are impaired. The advantage is stimulus-dependent; ZRSR2 loss did not increase
    baseline CAL1 growth, and exogenous TRAIL can still trigger apoptosis.
  biological_scale: CELLULAR
  evidence:
  - reference: PMID:34615655
    reference_title: Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    directness: DIRECT
    snippet: >-
      Knockout of ZRSR2 conferred relative protection from LPS- or R848-induced apoptosis (Fig. 6B). The growth
      rate of CAL1 cells at steady state was not changed by ZRSR2 mutation.
    explanation: >-
      CAL1 perturbation demonstrates a stimulation-dependent survival advantage.
    quote_role: PRIMARY_RESULT
  - reference: PMID:34615655
    reference_title: Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    directness: DIRECT
    snippet: >-
      Treatment with exogenous TRAIL promoted apoptosis equivalently in control and ZRSR2-mutant CAL1 cells,
      as well as in normal pDCs and BPDCN, demonstrating that the cell death response downstream of TRAIL was
      intact (Fig. 6D; Supplementary Fig. S4B).
    explanation: >-
      The defect concerns activation-coupled apoptosis rather than an inability to execute cell death.
    quote_role: PRIMARY_RESULT
  - reference: PMID:34615655
    reference_title: Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    directness: DIRECT
    snippet: >-
      Wild-type intronless IRF7, which would not require ZRSR2 for splicing, restored LPS-induced growth arrest
      in ZRSR2-mutant cells, whereas inactive IRF7 did not (Supplementary Fig. S5D).
    explanation: >-
      Endogenous-locus intronless IRF7 rescue links the splicing defect to the impaired stimulated growth response.
    quote_role: PRIMARY_RESULT
  downstream:
  - target: Clonal Expansion of pDC-Lineage Blasts
    description: >-
      Escape from activation-induced growth arrest can support clone persistence in an inflammatory context.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:34615655
      reference_title: Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.
      supports: SUPPORT
      evidence_source: IN_VITRO
      directness: INDIRECT
      snippet: >-
        Wild-type intronless IRF7, which would not require ZRSR2 for splicing, restored LPS-induced growth
        arrest in ZRSR2-mutant cells, whereas inactive IRF7 did not (Supplementary Fig. S5D).
      explanation: >-
        Endogenous-locus intronless IRF7 rescue links the splicing defect to the impaired stimulated growth
        response.
      quote_role: PRIMARY_RESULT
  cell_types:
  - preferred_term: plasmacytoid dendritic cell
    term:
      id: CL:0000784
      label: plasmacytoid dendritic cell
- name: Reduced H3K27 Trimethylation after GCR Attenuation
  description: >-
    In dexamethasone-treated CAL1 cells, GCR knockdown or expression of the NR3C1 fusion reduces global H3K27me3
    and repressive marks at HOXA promoters. The associated expression program resembles loss of EZH2 activity.
    The molecular connection between GCR and PRC2 remains unresolved.
  biological_scale: MOLECULAR
  evidence:
  - reference: PMID:27060168
    reference_title: Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms.
    supports: SUPPORT
    evidence_source: IN_VITRO
    directness: DIRECT
    snippet: >-
      Consistent with our GEP experiments, western blot analyses revealed global loss of H3K27me3 under attenuated
      GCR signaling (Figure 3D; supplemental Figure 3D).
    explanation: >-
      GCR knockdown or fusion expression in dexamethasone-treated CAL1 cells reduced H3K27me3; direct physical
      regulation of PRC2 remains unresolved.
    quote_role: PRIMARY_RESULT
  downstream: []
- name: lincRNA-3q-Dependent Cell-Cycle Program
  description: >-
    The nuclear lincRNA-3q is aberrantly expressed in BPDCN samples. Its depletion in CAL1 reduces E2F-associated
    transcription, clonogenicity and G1/S progression without directly inducing cell death in the reported
    assay. This is a separate experimentally supported dependency; whether NR3C1 loss causes its activation
    is still proposed.
  biological_scale: MOLECULAR
  evidence:
  - reference: PMID:27060168
    reference_title: Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms.
    supports: SUPPORT
    evidence_source: IN_VITRO
    directness: DIRECT
    snippet: >-
      lincRNA-3q knockdown in CAL-1 and U937 cells induced a G1/S arrest (Figure 4Cand supplemental Figure
      4C, respectively), without inducing cell death (supplemental Figure 4D).
    explanation: >-
      CAL1 knockdown impairs cell-cycle progression; U937 is a separate AML comparator.
    quote_role: PRIMARY_RESULT
  downstream:
  - target: Clonal Expansion of pDC-Lineage Blasts
    description: >-
      lincRNA-3q-dependent cell-cycle and clonogenic programs support leukemia growth in experimental models.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27060168
      reference_title: Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      directness: INDIRECT
      snippet: >-
        Concordant with this, lincRNA-3q knockdown markedly impaired CAL-1 leukemia growth in an in vivo xenotransplantation
        assay (Figure 5A; supplemental Figure 4F).
      explanation: >-
        Knockdown of the RNA reduces growth of CAL1 xenografts.
      quote_role: PRIMARY_RESULT
phenotypes:
- category: Cutaneous
  name: Violaceous Cutaneous Plaques and Nodules
  description: >-
    Disseminated erythematous to bluish-livid, often bruise-like plaques and
    nodules, the presenting feature in the large majority of patients.
  phenotype_term:
    preferred_term: violaceous cutaneous plaques and nodules
    term:
      id: HP:0200036
      label: Skin nodule
  frequency: VERY_FREQUENT
  diagnostic: true
  reports_on:
  - target: Cutaneous Infiltration by Malignant pDC Blasts
    relationship: READOUT_OF
  sequelae:
  - target: Pruritus
  evidence:
  - reference: PMID:37407876
    reference_title: "[Blastic plasmacytoid dendritic cell neoplasm (BPDCN) : A rare hematologic neoplasm with frequent cutaneous involvement]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "characterized by disseminated, erythematous or bluish-livid plaques or nodi"
    explanation: Describes the lesion morphology and distribution this phenotype names.
    quote_role: BACKGROUND
    directness: DIRECT
  - reference: PMID:34615655
    reference_title: "Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "tumor formation in the skin (in ∼90% of cases)"
    explanation: >-
      Introductory literature summary estimates skin tumors in approximately 90% of cases; this is not a newly
      measured cohort proportion.

    quote_role: BACKGROUND
    directness: DIRECT
- category: Cutaneous
  name: Pruritus
  description: Itch accompanying the cutaneous infiltrates.
  phenotype_term:
    preferred_term: Pruritus
    term:
      id: HP:0000989
      label: Pruritus

  evidence:
  - reference: PMID:37407876
    reference_title: '[Blastic plasmacytoid dendritic cell neoplasm (BPDCN) : A rare hematologic neoplasm with frequent cutaneous involvement].'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Diese seien insbesondere am Rücken von einem moderaten Juckreiz (5/10 nach numerischer Analogskala (NAS))
      begleitet.
    explanation: >-
      The patient reported moderate itching over the cutaneous lesions; this is a single case.
    quote_role: PRIMARY_RESULT
- category: Hematologic
  name: Anemia
  description: >-
    Anemia may accompany BPDCN. The 2023 patient had mild normocytic, normochromic anemia despite an initially
    unremarkable marrow biopsy, so anemia in that case cannot be attributed to marrow replacement.
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  reports_on:
  - target: Marrow Failure Cytopenias
    relationship: READOUT_OF
    description: >-
      Anemia can report impaired marrow hematopoiesis, but the cited case had an initially unremarkable marrow
      and does not establish this cause.
  evidence:
  - reference: PMID:37407876
    reference_title: "[Blastic plasmacytoid dendritic cell neoplasm (BPDCN) : A rare hematologic neoplasm with frequent cutaneous involvement]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Das Differenzialblutbild zeigte bis auf eine leichte Erythrozytopenie und eine normozytäre, normochrome Anämie keine Auffälligkeiten."
    explanation: >-
      Documents normocytic normochromic anaemia in a BPDCN patient. Quoted in
      the source language, as with the other findings from this
      German-language case report. A single case, not a frequency.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:37407876
    reference_title: '[Blastic plasmacytoid dendritic cell neoplasm (BPDCN) : A rare hematologic neoplasm with frequent cutaneous involvement].'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Eine Knochenmarkbiopsie, Abdomensonographie und Röntgenaufnahme des Thorax waren unauffällig.
    explanation: >-
      The initially normal marrow limits causal interpretation of the simultaneously observed anemia.
    quote_role: PRIMARY_RESULT
  - reference: PMID:38132278
    reference_title: 'Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      The most common findings in the peripheral blood are thrombocytopenia (78%), anemia (65%), and neutropenia
      (34%).
    explanation: >-
      This narrative review summarizes pretreatment hematologic manifestations; the figures are literature-based
      and not a population-wide estimate.
    quote_role: REVIEW_SYNTHESIS
- category: Hematologic
  name: Thrombocytopenia
  description: >-
    Reduced platelet count is common and may reflect marrow infiltration; severe thrombocytopenia carries bleeding
    risk.
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
  reports_on:
  - target: Marrow Failure Cytopenias
    relationship: READOUT_OF

  evidence:
  - reference: PMID:38132278
    reference_title: 'Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      The most common findings in the peripheral blood are thrombocytopenia (78%), anemia (65%), and neutropenia
      (34%).
    explanation: >-
      This narrative review summarizes pretreatment hematologic manifestations; the figures are literature-based
      and not a population-wide estimate.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:27986708
    reference_title: Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      His platelets had been persistently below 10,000/μL despite transfusion, predating venetoclax treatment
      and likely related to bone marrow infiltration by BPDCN.
    explanation: >-
      A BPDCN patient had severe thrombocytopenia before venetoclax; marrow infiltration was the authors' likely
      explanation.
    quote_role: PRIMARY_RESULT
- category: Hematologic
  name: Neutropenia
  description: >-
    Reduced neutrophil count is reported in BPDCN and may accompany marrow disease; treatment and other causes
    also affect the count.
  phenotype_term:
    preferred_term: Decreased total neutrophil count
    term:
      id: HP:0001875
      label: Decreased total neutrophil count
  reports_on:
  - target: Marrow Failure Cytopenias
    relationship: READOUT_OF

  evidence:
  - reference: PMID:38132278
    reference_title: 'Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      The most common findings in the peripheral blood are thrombocytopenia (78%), anemia (65%), and neutropenia
      (34%).
    explanation: >-
      This narrative review summarizes pretreatment hematologic manifestations; the figures are literature-based
      and not a population-wide estimate.
    quote_role: REVIEW_SYNTHESIS
- category: Lymphoreticular
  name: Lymphadenopathy
  description: >-
    Lymph node enlargement is a common manifestation. Primary-site coding in a cancer registry does not measure
    the frequency of clinical lymphadenopathy.
  phenotype_term:
    preferred_term: Lymphadenopathy
    term:
      id: HP:0002716
      label: Lymphadenopathy
  frequency: FREQUENT
  reports_on:
  - target: Lymphoid Organ Infiltration
    relationship: READOUT_OF
  evidence:
  - reference: PMID:37407876
    reference_title: '[Blastic plasmacytoid dendritic cell neoplasm (BPDCN) : A rare hematologic neoplasm with frequent cutaneous involvement].'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: "Palpatorisch fiel eine Lymphadenopathie zervikal beidseits und axillär rechts auf."  # codespell:ignore-line
    explanation: >-
      Direct examination documented cervical and axillary lymphadenopathy.
    quote_role: PRIMARY_RESULT
  - reference: PMID:38132278
    reference_title: 'Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Lymphadenopathy is identified in 56% of cases, splenomegaly in 44%.
    explanation: >-
      The review summarizes clinical lymphadenopathy frequency; this is distinct from SEER primary-site proportions.
    quote_role: REVIEW_SYNTHESIS
- category: Lymphoreticular
  name: Splenomegaly
  description: Splenic enlargement from infiltration.
  phenotype_term:
    preferred_term: Splenomegaly
    term:
      id: HP:0001744
      label: Splenomegaly
  reports_on:
  - target: Lymphoid Organ Infiltration
    relationship: READOUT_OF
  evidence:
  - reference: PMID:41219867
    reference_title: Multi-organ single-cell analysis reveals PLD4 as a biomarker and potential therapeutic target of blastic plasmacytoid dendritic cell neoplasm.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Positron emission tomography-computed tomography (PET-CT) scans showed lymphadenopathy at the base of
      the neck, mediastinum, axilla, and bilateral inguinal regions, splenomegaly, and mild pleural effusion
      (Fig. S1E).
    explanation: >-
      Direct imaging in the BPDCN index patient documents splenic enlargement.
    quote_role: PRIMARY_RESULT
- category: Constitutional
  name: Night Sweats
  description: >-
    Night sweats were reported at presentation in a documented BPDCN case.
  phenotype_term:
    preferred_term: Night sweats
    term:
      id: HP:0030166
      label: Night sweats
  evidence:
  - reference: PMID:37407876
    reference_title: "[Blastic plasmacytoid dendritic cell neoplasm (BPDCN) : A rare hematologic neoplasm with frequent cutaneous involvement]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Weiterhin berichtete der Patient über eine allgemeine Abgeschlagenheit und Nachtschweiß."
    explanation: >-
      A documented BPDCN patient reporting fatigue and night sweats. Quoted in
      the source language: this is a German-language case report whose English
      abstract does not enumerate the symptoms.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
- category: Constitutional
  name: Weight Loss
  description: >-
    Unintentional weight loss can occur at presentation; the reported patient lost 3 kg over approximately
    six weeks.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
  evidence:
  - reference: PMID:37407876
    reference_title: "[Blastic plasmacytoid dendritic cell neoplasm (BPDCN) : A rare hematologic neoplasm with frequent cutaneous involvement]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "allerdings wurde ein Gewichtsverlust von 3 kg in ca. 6 Wochen festgestellt"
    explanation: >-
      Documents the weight loss in the same BPDCN patient, again quoted in the
      source language.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
- category: Neurologic
  name: Central Nervous System Involvement
  description: >-
    Tumor pDCs can be detected in CSF without neurologic symptoms. A small prospective study found occult involvement
    in 6/10 patients assessed at diagnosis, and three additional patients examined at relapse had CNS disease.
    The broad HPO binding records the abnormal CSF finding; the malignant-cell identity is specified here.
  phenotype_term:
    preferred_term: Tumor plasmacytoid dendritic cells in cerebrospinal fluid
    term:
      id: HP:0002921
      label: Abnormal cerebrospinal fluid morphology
  reports_on:
  - target: Central Nervous System Infiltration
    relationship: READOUT_OF
  evidence:
  - reference: PMID:38334635
    reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review of the Disease, Central Nervous System Presentations, and Treatment Strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CNS involvement typically emerges during relapse, yet clinical trials often exclude such cases, limiting our understanding of its development and treatment."
    explanation: Supports CNS disease as a recognized and under-studied relapse compartment.

    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
  - reference: PMID:26840087
    reference_title: Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      cerebrospinal fluid (CSF) samples positive for tumor plasmacytoid dendritic cells were found in 6/10
      (60%) cases studied at diagnosis
    explanation: >-
      Flow cytometry detected occult CSF disease in six of ten newly diagnosed patients in a small prospective
      cohort; this is not a population prevalence.
    quote_role: PRIMARY_RESULT
- name: Fatigue
  description: >-
    Generalized fatigue was reported at presentation in the 2023 case; no population frequency is assigned.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
  evidence:
  - reference: PMID:37407876
    reference_title: '[Blastic plasmacytoid dendritic cell neoplasm (BPDCN) : A rare hematologic neoplasm with frequent cutaneous involvement].'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Weiterhin berichtete der Patient über eine allgemeine Abgeschlagenheit und Nachtschweiß.
    explanation: >-
      The patient reported fatigue and night sweats.
    quote_role: PRIMARY_RESULT
  category: Constitutional
histopathology:
- name: Blastic Dermal Infiltrate
  description: >-
    Monomorphic small-to-medium blastoid cells can infiltrate the dermis and deep subcutis with relative epidermal
    sparing. Morphology requires an accompanying pDC immunophenotype to establish BPDCN.
  finding_term:
    preferred_term: Monomorphic blastic dermal and subcutaneous infiltrate
    term:
      id: NCIT:C38666
      label: Monomorphic Cellular Infiltrate
  diagnostic: false
  evidence:
  - reference: PMID:37407876
    reference_title: '[Blastic plasmacytoid dendritic cell neoplasm (BPDCN) : A rare hematologic neoplasm with frequent cutaneous involvement].'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: "Direkt unterhalb der Epidermis und bis in die tiefe Subkutis hineinreichend zeigten sich relativ monomorphe klein- bis mittelgroßzellige Infiltrate mit erhöhter mitotischer Aktivität (Abb. 2)."  # codespell:ignore-line
    explanation: >-
      Direct BPDCN skin histology documents dermal-to-subcutaneous extension and monomorphic cells.
    quote_role: PRIMARY_RESULT
  - reference: PMID:38132278
    reference_title: 'Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      The appearance of the disease in the skin biopsy consists of a typical monomorphic and diffuse infiltrate
      involving the dermis, with sparing of the epidermis and the presence of a visible Grenz zone.
    explanation: >-
      The review describes the characteristic architecture, which is not sufficient alone for diagnosis.
    quote_role: REVIEW_SYNTHESIS
- name: CD123-Positive pDC Immunophenotype
  description: >-
    WHO-5 criteria use CD123 plus another pDC marker with CD4 and/or CD56, or any three pDC markers with absent
    expected negative markers. TCF4, TCL1, CD303 and CD304 support pDC differentiation; CD3, CD14, CD34, lysozyme
    and MPO help exclude competing lineages. The CD4/CD56/CD123 triad alone can also occur in AML.
  finding_term:
    preferred_term: CD123-positive plasmacytoid dendritic cell immunophenotype
  diagnostic: true
  evidence:
  - reference: PMID:37946878
    reference_title: 'A Case of Acute Myeloid Leukemia Mimicking Blastic Plasmacytoid Dendritic Cell Neoplasm: Utility of the Proposed Upcoming WHO-5 Diagnostic Criteria.'
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      The suggested diagnosis criteria based on immunophenotyping requires expression of CD123 and one other
      pDC marker (e.g., TCF4, TCL1, CD303, or CD304) in addition to CD4 and/or CD56, or, expression of any
      three pDC markers and absent expression of all expected negative markers (e.g., CD3, CD14, CD34, lysozyme,
      and MPO).
    explanation: >-
      This is the discussion's summary of WHO-5 BPDCN criteria. The paper's index patient had AML and is not
      a BPDCN clinical observation.
    quote_role: BACKGROUND
diagnosis:
- name: Immunophenotyping by Flow Cytometry or Immunohistochemistry
  description: >-
    Diagnosis integrates tissue morphology with flow cytometry or immunohistochemistry. A pDC marker panel
    and exclusion of competing lineages distinguish BPDCN from AML mimics; expression of the CD4/CD56/CD123
    triad alone is insufficient.
  evidence:
  - reference: PMID:37946878
    reference_title: 'A Case of Acute Myeloid Leukemia Mimicking Blastic Plasmacytoid Dendritic Cell Neoplasm: Utility of the Proposed Upcoming WHO-5 Diagnostic Criteria.'
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      The suggested diagnosis criteria based on immunophenotyping requires expression of CD123 and one other
      pDC marker (e.g., TCF4, TCL1, CD303, or CD304) in addition to CD4 and/or CD56, or, expression of any
      three pDC markers and absent expression of all expected negative markers (e.g., CD3, CD14, CD34, lysozyme,
      and MPO).
    explanation: >-
      This is the discussion's summary of WHO-5 BPDCN criteria. The paper's index patient had AML and is not
      a BPDCN clinical observation.
    quote_role: BACKGROUND
- name: Cerebrospinal Fluid Examination
  description: >-
    Deliberate CSF examination at diagnosis, because CNS involvement is
    frequently present while the patient is neurologically asymptomatic.
  evidence:
  - reference: PMID:38334635
    reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review of the Disease, Central Nervous System Presentations, and Treatment Strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with CNS involvement often overlooked in standard diagnostic workups due to BPDCN's rarity and patients often being neurologically asymptomatic at diagnosis"
    explanation: Justifies CSF examination as a deliberate rather than symptom-triggered step.

    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
  - reference: PMID:26840087
    reference_title: Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      cerebrospinal fluid (CSF) samples positive for tumor plasmacytoid dendritic cells were found in 6/10
      (60%) cases studied at diagnosis
    explanation: >-
      Flow cytometry detected occult CSF disease in six of ten newly diagnosed patients in a small prospective
      cohort; this is not a population prevalence.
    quote_role: PRIMARY_RESULT
- name: Myeloid Next-Generation Sequencing Panel
  description: >-
    Targeted sequencing characterizes the clone and identifies prognostically
    relevant lesions, notably TET2 truncating mutations.
  evidence:
  - reference: PMID:36689729
    reference_title: "TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In multivariate analysis, having at least 1 TET2 truncating mutation was the only risk factor significantly associated with overall survival"
    explanation: Identifies the specific sequencing result that carries prognostic weight.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
- name: Assessment of disease distribution
  description: >-
    Skin examination, marrow evaluation and imaging establish cutaneous, marrow, nodal and other extramedullary
    involvement. CSF assessment is considered separately because imaging and neurologic examination may miss
    occult disease.
  evidence:
  - reference: PMID:38132278
    reference_title: 'Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview.'
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      A Positron Emission Tomography (PET)/CT or CT scan should then be performed to study the lymph nodes
      and extramedullary sites, which may or may not indicate the execution of a lymph node biopsy.
    explanation: >-
      The review summarizes the diagnostic staging approach.
    quote_role: REVIEW_SYNTHESIS
differential_diagnoses:
- name: Acute Myeloid Leukemia with Monocytic Differentiation
  description: >-
    Acute monocytic leukaemia can express CD4, CD56 and CD123 and share the
    blastic morphology. Myeloperoxidase and lysozyme expression, and the
    absence of the full pDC marker set, resolve it.
  evidence:
  - reference: PMID:37946878
    reference_title: "A Case of Acute Myeloid Leukemia Mimicking Blastic Plasmacytoid Dendritic Cell Neoplasm: Utility of the Proposed Upcoming WHO-5 Diagnostic Criteria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tandem flow cytometry showed an atypical population of dim CD45 events with expression of CD4, CD56, CD117, CD123, and monocytic markers such as CD64."
    explanation: A worked case in which AML reproduced the BPDCN marker profile, which is what makes this the key differential.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
- name: Mature Plasmacytoid Dendritic Cell Proliferation Associated with Myeloid Neoplasm
  description: >-
    Mature plasmacytoid dendritic cell proliferation associated with a myeloid neoplasm shares the pDC lineage
    with BPDCN but consists of mature pDCs rather than blasts. Morphology and the associated myeloid neoplasm
    are important alongside immunophenotyping.
  evidence:
  - reference: PMID:38334635
    reference_title: 'Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review of the Disease, Central Nervous System Presentations, and Treatment Strategies.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      While both conditions have origins with proliferation of pDCs, MPDC is characterized by findings of normal
      morphologic and mature pDC proliferation, while BPDCN differs with regard to proliferation of the immature
      pDCs or blasts.
    explanation: >-
      Review-level comparison of the two pDC neoplasm categories.
    quote_role: REVIEW_SYNTHESIS
- name: Leukemia Cutis and Myeloid Sarcoma
  description: >-
    Cutaneous involvement by acute myeloid leukemia. Shares the site and the
    blastic morphology; separated by myeloperoxidase and lysozyme expression
    and the absence of the pDC marker set.
  evidence:
  - reference: PMID:40525728
    reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): 2025 Update on Diagnosis, Pathophysiology, Risk Assessment, and Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diagnosis is based on biopsy of an involved site and is typically based on the identification of blastoid cells displaying the classical immunophenotypes CD123, CD4, and CD56 in addition to specific pDC markers."
    explanation: >-
      States the marker requirement - specific pDC markers on top of the
      CD123/CD4/CD56 triad - that separates BPDCN from myeloid infiltrates
      sharing that triad.

    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
genetic:
- name: TET2
  gene_term:
    preferred_term: TET2
    term:
      id: hgnc:25941
      label: TET2
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  frequency: recurrent; multiple variants in some cases, with biallelic involvement inferred in small cohorts
  evidence:
  - reference: PMID:36689729
    reference_title: "TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In multivariate analysis, having at least 1 TET2 truncating mutation was the only risk factor significantly associated with overall survival"
    explanation: Establishes the prognostic significance of the truncating mutation class.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:36689729
    reference_title: "TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most recurrently mutated gene related to DNA methylation is TET2"
    explanation: Establishes the recurrence claim, which the prognostic sentence above does not carry.

    quote_role: BACKGROUND
    directness: DIRECT
  - reference: PMID:37286599
    reference_title: Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Overall, founder clones contained recurrent alterations in TET2 (5 out of 5 cases, 4 out of 5 cases with
      ≥2 alterations), ASXL1 (3 out of 5 cases) and splicing-factors (3 out of 5 cases), including ZRSR2 (2
      out of 5 cases), suggesting privileged roles in premalignant evolution in BPDCN (Fig. 1e (top)).
    explanation: >-
      Human phylogenies support recurrent founder lesions, without a fixed TET2-before-ASXL1 mutation order.
    quote_role: PRIMARY_RESULT
  notes: >-
    Truncating mutations were associated with poorer survival in a retrospective 57-patient cohort. This prognostic
    association does not establish a validated predictive biomarker for selecting a specific drug.
- name: ASXL1
  gene_term:
    preferred_term: ASXL1
    term:
      id: hgnc:18318
      label: ASXL1
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  frequency: recurrent, including c.1934dupG; may co-occur with TET2
  evidence:
  - reference: PMID:36819168
    reference_title: "Biallelic TET2 mutations and canonical ASXL1 mutations are frequent and cooccur in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): An institutional experience and review of literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "identified a high frequency of biallelic TET2 and canonical ASXL1 (c.1934dupG) mutations"
    explanation: Names the recurrent ASXL1 allele and its co-occurrence with TET2.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:37286599
    reference_title: Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Overall, founder clones contained recurrent alterations in TET2 (5 out of 5 cases, 4 out of 5 cases with
      ≥2 alterations), ASXL1 (3 out of 5 cases) and splicing-factors (3 out of 5 cases), including ZRSR2 (2
      out of 5 cases), suggesting privileged roles in premalignant evolution in BPDCN (Fig. 1e (top)).
    explanation: >-
      Human phylogenies support recurrent founder lesions, without a fixed TET2-before-ASXL1 mutation order.
    quote_role: PRIMARY_RESULT
- name: ZRSR2
  gene_term:
    preferred_term: ZRSR2
    term:
      id: hgnc:23019
      label: ZRSR2
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  frequency: enriched in BPDCN and almost exclusively in males
  evidence:
  - reference: PMID:34615655
    reference_title: "Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Loss-of-function mutations in ZRSR2, an X chromosome gene encoding a splicing factor, are enriched in BPDCN, and nearly all mutations occur in males."
    explanation: Establishes both enrichment and the sex distribution of the lesion.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
- name: IKZF1
  gene_term:
    preferred_term: IKZF1
    term:
      id: hgnc:13176
      label: IKZF1
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  frequency: structural alterations in 13 of 25 patients across discovery and extension cohorts
  evidence:
  - reference: PMID:31846142
    reference_title: "Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "IKZF1, a gene encoding a transcription factor required for the differentiation of plasmacytoid dendritic cell precursors, is focally inactivated through recurrent structural alterations in this neoplasm"
    explanation: Whole-genome evidence for recurrent focal structural inactivation.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
  notes: >-
    The denominator includes one focal duplication whose functional consequence was not directly established.
- name: MYB
  gene_term:
    preferred_term: MYB
    term:
      id: hgnc:7545
      label: MYB
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  frequency: rearranged in about 20% of patients
  evidence:
  - reference: PMID:39499902
    reference_title: "BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Rearrangements of the hematopoietic transcription factor MYB are recurrently found in 20% of patients with blastic plasmacytoid DC neoplasm (BPDCN)"
    explanation: Quantifies MYB rearrangement frequency in BPDCN.

    quote_role: BACKGROUND
    directness: DIRECT
- name: NR3C1
  gene_term:
    preferred_term: NR3C1
    term:
      id: hgnc:7978
      label: NR3C1
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  frequency: monoallelic 5q31 deletion in 13 of 47 cases in the index cohort
  evidence:
  - reference: PMID:27060168
    reference_title: "Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we identify monoallelic deletion of NR3C1 (5q31), encoding the glucocorticoid receptor (GCR), in 13 of 47 (28%) BPDCN patients"
    explanation: Reports the deletion frequency in the defining cohort.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:27060168
    reference_title: "Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Targeted deep sequencing in 36 BPDCN cases, including 10 with NR3C1 deletion, did not reveal NR3C1 point mutations or indels."
    explanation: >-
      No sequence-level NR3C1 alterations were detected in this tested cohort; the negative finding does not
      exclude every possible NR3C1 lesion in BPDCN.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
- name: CDKN2A/CDKN2B
  gene_term:
    preferred_term: CDKN2A
    term:
      id: hgnc:1787
      label: CDKN2A
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  frequency: recurrent 9p21.3 copy-number deletion
  notes: >-
    The chromosome-9p21.3 deletion affects CDKN2A/CDKN2B. CDKN1B on chromosome 12 and RB1 on chromosome 13
    represent separate recurrent deletion targets.
  evidence:
  - reference: PMID:30381297
    reference_title: 'Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Whole-exome sequencing data were also used for cytogenetic CNV analysis, which highlighted extensive
      losses along the chromosome 9 and the associated deletion of the tumor suppressor CDKN2A gene in 8 out
      of 14 BPDCN samples (57%) (Online Supplementary Figure S2), as already reported in the literature.12,15,20
    explanation: >-
      Primary copy-number analysis directly supports chromosome-9 CDKN2A loss; the other tumor suppressors
      are on different chromosomes.
    quote_role: PRIMARY_RESULT
  - reference: PMID:34615655
    reference_title: Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      These included loss of 7p (which harbors IKZF1), 9p (CDKN2A, CDKN2B), 12p (CDKN1B, ETV6), 13q (RB1),
      and 17p (TP53; Supplementary Fig. S2).
    explanation: >-
      Copy-number analysis of purified BPDCN cells places the recurrent losses on separate chromosomes.
    quote_role: PRIMARY_RESULT
- name: MYC
  gene_term:
    preferred_term: MYC
    term:
      id: hgnc:7553
      label: MYC
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  frequency: 8q24 rearrangement in 10-15% of one series and about a third in a cytogenetics review
  notes: >-
    Frequencies differ across cohorts and ascertainment methods; the single-institution and review estimates
    should not be pooled.
  evidence:
  - reference: PMID:29407586
    reference_title: "8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Over an 8-year period in our hospital, 5 of 41 (12%) patients with BPDCN were shown 8q24/MYC rearrangements"
    explanation: The single-institution denominator behind the lower frequency estimate.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:32336417
    reference_title: "Cytogenetics of Blastic Plasmacytoid Dendritic Cell Neoplasm: Chromosomal Rearrangements and DNA Copy-Number Alterations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "One-third of cases of BPDCN harbor the 8q24 rearrangement, most frequently with 6p21 harboring RUNX2"
    explanation: The higher review-level estimate and the characteristic partner locus.

    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
treatments:
- name: Tagraxofusp
  description: >-
    An approved CD123-directed cytotoxin consisting of human interleukin-3 fused to truncated diphtheria toxin.
    Receptor-mediated uptake delivers the toxin to inhibit protein synthesis. In the long-term trial analysis,
    65 treatment-naive patients had a 75% overall response rate and 57% CR/CRc; median response duration was
    24.9 months. Capillary leak syndrome, including fatal events, is an important toxicity. This fusion toxin
    is not protein replacement.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tagraxofusp
      term:
        id: NCIT:C64769
        label: Tagraxofusp-erzs
  target_mechanisms:
  - target: CD123 Overexpression on Malignant pDC Blasts
    description: >-
      The agent's IL-3 moiety uses the node's own overexpressed receptor as
      its address.
    evidence:
    - reference: PMID:31018069
      reference_title: "Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Tagraxofusp (SL-401) is a CD123-directed cytotoxin consisting of human interleukin-3 fused to truncated diphtheria toxin."
      explanation: States the mechanism by which the drug engages the CD123 node.
      quote_role: BACKGROUND
      directness: DIRECT
  evidence:
  - reference: PMID:35820082
    reference_title: "Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For treatment-naive patients, the overall response rate was 75%; 57% achieved CR + CRc."
    explanation: Long-term efficacy result from the largest prospective BPDCN trial.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:35820082
    reference_title: "Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Capillary leak syndrome occurred in 21% of patients (grade ≥ 3: 7%)."
    explanation: Quantifies the characteristic toxicity this treatment's description warns about.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
- name: Venetoclax
  description: >-
    A BCL2 inhibitor used off-label and in investigational combinations for BPDCN. Functional profiling showed
    BCL2 dependence in the studied BPDCN samples, without proving universal clinical sensitivity. Two initially
    reported salvage patients had short-lived or compartment-specific responses; one had no appreciable marrow
    response at four weeks. Combination regimens now have prospective BPDCN data.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: venetoclax
      term:
        id: CHEBI:133021
        label: venetoclax
  target_mechanisms:
  - target: BCL2-Dependent Survival of Malignant pDCs
    description: BCL2 inhibition restores the apoptotic response this node blocks.
    evidence:
    - reference: PMID:27986708
      reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Animals bearing BPDCN patient-derived xenografts had disease responses and improved survival after venetoclax treatment in vivo"
      explanation: In vivo demonstration that inhibiting the node's effector produces disease response.
      quote_role: PRIMARY_RESULT
      directness: DIRECT
  evidence:
  - reference: PMID:27986708
    reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Finally, we report on 2 patients with relapsed/refractory BPDCN who received venetoclax off-label and experienced significant disease responses."
    explanation: First human responses to BCL2 inhibition in BPDCN, from the same study establishing the dependency.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:27986708
    reference_title: Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      He had a decrease in the size of palpable cervical and preauricular lymph nodes, but did not have an
      appreciable response in his bone marrow at that time.
    explanation: >-
      The first salvage patient had a discordant early compartment response.
    quote_role: PRIMARY_RESULT
  - reference: PMID:27986708
    reference_title: Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      He remained on venetoclax 400 mg daily for approximately 12 weeks, at which time he experienced disease
      progression.
    explanation: >-
      The second salvage patient subsequently progressed; early responses do not establish durable monotherapy
      control.
    quote_role: PRIMARY_RESULT
- name: Allogeneic Hematopoietic Cell Transplantation
  description: >-
    The 2026 ASTCT guideline recommends allogeneic HCT for eligible patients in first or second complete remission.
    Myeloablative conditioning, preferably with total-body irradiation, is recommended for younger fit patients;
    reduced-intensity conditioning is recommended for older or frail patients. HCT is not recommended after
    primary induction failure or during active relapsed/refractory BPDCN. These recommendations should not
    be replaced by a causal interpretation of retrospective conditioning comparisons.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: hematopoietic cell transplantation
    term:
      id: NCIT:C15431
      label: Hematopoietic Cell Transplantation
  target_mechanisms:
  - target: Clonal Expansion of pDC-Lineage Blasts
    description: >-
      Consolidation aims to control residual malignant hematopoiesis after remission induction; transplant
      outcomes do not isolate a single mechanistic component.
  - target: Clonal Hematopoiesis of the Mutant Progenitor
    description: >-
      Unlike every pharmacological agent here, an allograft can remove the
      founder clone itself rather than only its malignant descendants.
  evidence:
  - reference: PMID:42612729
    reference_title: 'Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Practice Guidelines From the American Society for Transplantation and Cellular Therapy.'
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      For BPDCN in first complete remission (CR1), the panelists recommended allogeneic HCT and suggested autologous
      HCT for patients who are unfit for allogeneic HCT but without BPDCN marrow involvement.
    explanation: >-
      The 17-expert guideline defines the preferred consolidation and the narrower autologous option.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:42612729
    reference_title: 'Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Practice Guidelines From the American Society for Transplantation and Cellular Therapy.'
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      The panel recommended that conditioning intensity for younger fitter patients be myeloablative, preferentially
      containing total body irradiation, whereas reduced intensity conditioning was recommended for older and/or
      frail ones, in both CR1 or CR2.
    explanation: >-
      Conditioning recommendations depend on fitness and age.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:42612729
    reference_title: 'Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Practice Guidelines From the American Society for Transplantation and Cellular Therapy.'
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      Conversely, the panelists did not recommend allogeneic or autologous HCT in BPDCN after primary induction
      failure or with active relapsed-refractory disease.
    explanation: >-
      The guideline limits transplantation in uncontrolled disease.
    quote_role: REVIEW_SYNTHESIS
- name: Intrathecal CNS-Directed Chemotherapy
  description: >-
    Intrathecal methotrexate and/or cytarabine are used for prophylaxis and treatment of CSF disease alongside
    systemic therapy. In a small prospective series, all six CSF-positive patients assessed at diagnosis cleared
    CSF tumor cells after intrathecal treatment; nonrandomized survival comparisons cannot isolate its effect.
    The 2026 ASTCT guideline also recommends post-HCT intrathecal chemotherapy regardless of prior CNS involvement.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: methotrexate
      term:
        id: CHEBI:44185
        label: methotrexate
    - preferred_term: cytarabine
      term:
        id: CHEBI:28680
        label: cytarabine
  target_mechanisms:
  - target: Central Nervous System Infiltration
    description: Intrathecal delivery treats or prevents disease in the CSF compartment alongside systemic therapy.
  evidence:
  - reference: PMID:38334635
    reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review of the Disease, Central Nervous System Presentations, and Treatment Strategies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Treatment options for CNS involvement include intrathecal (IT) chemotherapies like methotrexate and cytarabine, often in combination with systemic agents."
    explanation: Names the agents and route this treatment describes.
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
  - reference: PMID:38334635
    reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review of the Disease, Central Nervous System Presentations, and Treatment Strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tagraxofusp and traditional regimens for acute myeloid leukemia show limited success at preventing CNS relapse"
    explanation: The negative result that makes a dedicated CNS-directed arm necessary rather than redundant.

    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
  - reference: PMID:26840087
    reference_title: Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      follow-up CSF samples obtained after triple intrathecal therapy (TIT) showed absence of tumor cells in
      6/6 CSF+ cases studied at diagnosis
    explanation: >-
      Direct CSF response in a small cohort; not randomized survival evidence.
    quote_role: PRIMARY_RESULT
  - reference: PMID:42612729
    reference_title: 'Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Practice Guidelines From the American Society for Transplantation and Cellular Therapy.'
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      Post-HCT intrathecal chemotherapy was also recommended regardless of involvement of the central nervous
      system.
    explanation: >-
      Current society guidance adds a post-transplant recommendation.
    quote_role: REVIEW_SYNTHESIS
- name: Intensive Induction Chemotherapy
  description: >-
    ALL-type (hyper-CVAD) and AML- or lymphoma-type multi-agent regimens.
    These are the backbone against which tagraxofusp is positioned, and remain
    an accepted upfront option rather than a historical one.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
  target_mechanisms:
  - target: Clonal Expansion of pDC-Lineage Blasts
    description: >-
      Cytotoxic induction acts on the proliferating blast population rather
      than on any BPDCN-specific dependency.
  evidence:
  - reference: PMID:40525728
    reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): 2025 Update on Diagnosis, Pathophysiology, Risk Assessment, and Management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Either chemotherapy-based regimens or tagraxofusp, a CD123-directed interleukin 3 conjugated with diphtheria toxin, may be used for upfront therapy."
    explanation: Places chemotherapy alongside tagraxofusp as an upfront option.
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
  - reference: PMID:38334635
    reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review of the Disease, Central Nervous System Presentations, and Treatment Strategies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "prompting exploration of combined therapies like hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HyperCVAD) with venetoclax and adding IT chemotherapy to other backbones."
    explanation: Names the hyper-CVAD regimen and the venetoclax and intrathecal additions built onto it.
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
  - reference: PMID:38132278
    reference_title: "Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the main therapeutic schemes used were based on chemotherapy regimens already used in the treatment of lymphomas, acute lymphoblastic leukemia (ALL) and/or acute myeloid leukemia (AML)"
    explanation: >-
      Explains why the regimens here are borrowed ones - there was no
      BPDCN-specific consensus before tagraxofusp.

    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
- name: Hypomethylating Agent Therapy
  description: >-
    Azacitidine and decitabine have preclinical activity in BPDCN, and azacitidine is used in clinical combination
    regimens. In acquired-resistance CAL1 models, azacitidine restores DPH1 expression and tagraxofusp sensitivity.
    This specific rescue mechanism is not established as the explanation for every clinical response to a hypomethylating
    agent.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: azacitidine
      term:
        id: NCIT:C288
        label: Azacitidine
  target_mechanisms:
  - target: Diphthamide Pathway Silencing
    description: >-
      Azacitidine can reverse methylation-associated DPH1 silencing and restore toxin-mediated ADP-ribosylation
      in resistant cell models.
    evidence:
    - reference: url:https://www.jci.org/articles/view/128571
      reference_title: "JCI -\nDNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance"
      supports: SUPPORT
      evidence_source: IN_VITRO
      directness: DIRECT
      snippet: >-
        In agreement with those results, azacitidine treatment also re-sensitized resistant AML and BPDCN cells
        to the cytotoxic activity of tagraxofusp
      explanation: >-
        Azacitidine restored drug sensitivity in acquired-resistance cell models; clinical benefit is evaluated
        separately.
      quote_role: PRIMARY_RESULT
  evidence:
  - reference: url:https://www.jci.org/articles/view/128571
    reference_title: "JCI -\nDNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance"
    supports: SUPPORT
    evidence_source: IN_VITRO
    directness: DIRECT
    snippet: >-
      In agreement with those results, azacitidine treatment also re-sensitized resistant AML and BPDCN cells
      to the cytotoxic activity of tagraxofusp
    explanation: >-
      Azacitidine restored drug sensitivity in acquired-resistance cell models; clinical benefit is evaluated
      separately.
    quote_role: PRIMARY_RESULT
  - reference: PMID:30381297
    reference_title: 'Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    directness: DIRECT
    snippet: >-
      Our experiments revealed that the treatment with 5’-azacytidine in combination with decitabine significantly
      inhibits disease progression and extends survival (P<0.01) in a preclinical mouse model.
    explanation: >-
      The dual-hypomethylating-agent combination was tested in a CAL1 xenograft, not a clinical trial.
    quote_role: PRIMARY_RESULT
- name: All-Trans Retinoic Acid
  description: >-
    Preclinical ATRA treatment causes MYB protein loss, differentiation, cell-cycle arrest and apoptosis in
    BPDCN models. Activity is not restricted to MYB-rearranged disease: CAL1 and primary xenograft-derived
    samples with or without MYB fusions showed sensitivity, and treatment reduced disease burden in mice. Clinical
    efficacy in BPDCN remains unestablished.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: all-trans retinoic acid
      term:
        id: CHEBI:15367
        label: all-trans-retinoic acid
  target_mechanisms:
  - target: Aberrant G2/M Cell Cycle Gene Regulation
    description: >-
      Loss of MYB can disrupt its cell-cycle program whether or not a MYB fusion is present.
    evidence:
    - reference: PMID:39499902
      reference_title: BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia.
      supports: SUPPORT
      evidence_source: IN_VITRO
      directness: DIRECT
      snippet: >-
        These data provide evidence that BPDCN cells, with or without MYB fusions, may show sensitivity to
        ATRA treatment via loss of MYB, as in ACC.
      explanation: >-
        The primary results expressly include BPDCN without MYB fusions.
      quote_role: PRIMARY_RESULT
  evidence:
  - reference: PMID:39499902
    reference_title: BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia.
    supports: SUPPORT
    evidence_source: IN_VITRO
    directness: DIRECT
    snippet: >-
      These data provide evidence that BPDCN cells, with or without MYB fusions, may show sensitivity to ATRA
      treatment via loss of MYB, as in ACC.
    explanation: >-
      The primary results expressly include BPDCN without MYB fusions.
    quote_role: PRIMARY_RESULT
  - reference: PMID:39499902
    reference_title: BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    directness: DIRECT
    snippet: >-
      We also found that ATRA treatment in vivo reduced the leukemic burden in NSG mice transplanted with a
      human BPDCN primary PDX (Figure 6C).
    explanation: >-
      ATRA activity extends to a primary BPDCN xenograft experiment.
    quote_role: PRIMARY_RESULT
- name: BET Inhibition
  description: >-
    Investigational. BET inhibitors disrupt the TCF4-dependent super-enhancer
    network and kill BPDCN cells in vitro and in xenografts. No approved agent
    exists for this indication.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: TCF4-Dependent Super-Enhancer Network Addiction
    description: BET inhibition dismantles the BRD4-bound super-enhancers the node depends on.
    evidence:
    - reference: PMID:27846392
      reference_title: "A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "High-throughput drug screening revealed that bromodomain and extra-terminal domain inhibitors (BETis) induced BPDCN apoptosis, which was attributable to disruption of a BPDCN-specific transcriptional network controlled by TCF4-dependent super-enhancers."
      explanation: Attributes the killing directly to disruption of the targeted network.
      quote_role: PRIMARY_RESULT
      directness: DIRECT
  - target: lincRNA-3q-Dependent Cell-Cycle Program
    description: >-
      BET inhibition reduces the lincRNA-3q program in CAL1 experiments.
    evidence:
    - reference: PMID:27060168
      reference_title: Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms.
      supports: SUPPORT
      evidence_source: IN_VITRO
      directness: DIRECT
      snippet: >-
        In keeping with this, treatment with one such BET inhibitor (JQ1) led to suppression of lincRNA-3q
        levels in a time-dependent manner in MUTZ-3, U937, and CAL-1 BPDCN cells, but not in K562 cells (Figure
        5D).
      explanation: >-
        JQ1 suppresses lincRNA-3q in CAL1 as well as selected AML models; this is not a clinically validated
        drug effect.
      quote_role: PRIMARY_RESULT
  evidence:
  - reference: PMID:27846392
    reference_title: "A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "BETis retarded the growth of BPDCN xenografts, supporting their clinical evaluation in this recalcitrant malignancy."
    explanation: In vivo efficacy supporting the investigational status of this approach.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:27060168
    reference_title: "Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "identifies BET inhibition, acting at least partially via lncRNA blockade, as a novel treatment option in BPDCN"
    explanation: >-
      An independent route to the same conclusion - BET inhibition reached
      through NR3C1-deletion biology and lincRNA-3q blockade rather than
      through the TCF4 super-enhancer screen.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
- name: CD123-Directed CAR-T and CAR-NK Cell Therapy
  description: >-
    CD123-directed CAR-T and CAR-NK products remain investigational. In the phase 1 CAR-T study, two BPDCN
    patients received autologous cells: one achieved CR, but both progressed by days 100 and 29; both subsequently
    underwent allogeneic transplantation. Neither developed CRS and both had grade 1 neurotoxicity. Separate
    reports describe severe toxicity, including a death after allogeneic UCART123 with no definitive cause
    established. A combined ASCT/CAR-T/venetoclax case achieved a 13-month remission but cannot isolate the
    benefit of each component. CAR-NK trial enrollment does not itself establish efficacy.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: CD123-directed chimeric antigen receptor cell therapy
    term:
      id: NCIT:C70601
      label: Cellular Therapy
  target_mechanisms:
  - target: CD123 Overexpression on Malignant pDC Blasts
    description: The engineered receptor addresses the same overexpressed antigen as tagraxofusp.
  evidence:
  - reference: PMID:42681647
    reference_title: A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Of the 2 patients treated on Arm 2, 1 patient achieved CR with complete resolution of an extramedullary
      mass (Fig. 2A). Both patients had disease progression on day 100 and day 29 post infusion, respectively,
      proceeded to an alloHCT at 154 and 99 days post infusion, and received additional treatment.
    explanation: >-
      These are the BPDCN-specific outcomes; the AML response denominator is not imported.
    quote_role: PRIMARY_RESULT
  - reference: PMID:42681647
    reference_title: A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Neither patient with BPDCN developed CRS but both experienced grade 1 neurotoxicity.
    explanation: >-
      Safety results in the two treated BPDCN patients.
    quote_role: PRIMARY_RESULT
  - reference: PMID:35963025
    reference_title: 'CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      No definitive cause of death was determined, but we hypothesized that the patient may have succumbed
      to CAR-T-mediated cardiopulmonary toxicity.
    explanation: >-
      The fatal UCART123 report includes refractory clinical CRS but does not prove a definitive cause of death.
    quote_role: PRIMARY_RESULT
  - reference: PMID:42602092
    reference_title: 'Anti-CD123 CAR-T therapy combined with autologous SCT and venetoclax maintenance in refractory BPDCN ineligible for allogeneic transplantation: a case report and review of the literature.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      the patient underwent high-dose conditioning and autologous stem cell transplantation (ASCT) sequentially
      followed by autologous CD123 CAR T-cell infusion
    explanation: >-
      The initial ASCT preceded CAR-T; a subsequent second stem-cell infusion was needed for prolonged cytopenias.
      Combined treatment and later venetoclax prevent attribution of benefit to CAR-T alone.
    quote_role: PRIMARY_RESULT
- name: Pivekimab Sunirine
  description: >-
    Pivekimab sunirine-pvzy (Decnupaz) is a CD123-directed antibody conjugated to an alkylating payload, FDA-approved
    for adults with BPDCN on May 27, 2026. In the FDA CADENZA analysis, CR/CRc occurred in 23/33 treatment-naive
    patients (69.7%) and 8/51 relapsed/refractory patients (15.7%), with median response durations of 9.7 and
    9.2 months. Active CNS disease was excluded. The label carries a boxed warning for hepatotoxicity including
    hepatic veno-occlusive disease; other risks include infusion reactions, edema, sulfite allergy and embryo-fetal
    toxicity. The single-arm study does not establish superiority over another treatment.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: CD123-directed antibody-based immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: pivekimab sunirine (IMGN632)
      term:
        id: NCIT:C184834
        label: Pivekimab Sunirine
  target_mechanisms:
  - target: CD123 Overexpression on Malignant pDC Blasts
    description: The antibody binds CD123 and delivers an alkylating payload to the malignant cells.
  evidence:
  - reference: url:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pivekimab-sunirine-pvzy-blastic-plasmacytoid-dendritic-cell-neoplasm-ultra-rare
    reference_title: FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy | FDA
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      On May 27, 2026, the Food and Drug Administration approved pivekimab sunirine-pvzy (Decnupaz, AbbVie,
      Inc.), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid
      dendritic cell neoplasm (BPDCN).
    explanation: >-
      The FDA approval supersedes the former investigational-only description.
  - reference: url:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pivekimab-sunirine-pvzy-blastic-plasmacytoid-dendritic-cell-neoplasm-ultra-rare
    reference_title: FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy | FDA
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      In patients with treatment-naïve BPDCN (N = 33), 23 patients (69.7%; 95% CI: 51.3, 84.4) achieved a CR/CRc
      with a median follow-up of 21.5 months.
    explanation: >-
      The regulatory efficacy analysis uses the entire treatment-naive cohort.
  - reference: url:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pivekimab-sunirine-pvzy-blastic-plasmacytoid-dendritic-cell-neoplasm-ultra-rare
    reference_title: FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy | FDA
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      In patients with relapsed or refractory BPDCN (N = 51), 8 patients (15.7%; 95% CI: 7.0, 28.6) achieved
      a CR/CRc with a median follow-up of 24.1 months.
    explanation: >-
      FDA efficacy result for the relapsed/refractory cohort.
  - reference: url:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pivekimab-sunirine-pvzy-blastic-plasmacytoid-dendritic-cell-neoplasm-ultra-rare
    reference_title: FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy | FDA
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      The prescribing information includes a Boxed Warning for hepatotoxicity, including hepatic veno-occlusive
      disease, and warnings and precautions for infusion-related reactions, edema, sulfite allergic reactions,
      and embryo-fetal toxicity.
    explanation: >-
      The approval notice records major safety warnings.
  - reference: PMID:41671533
    reference_title: Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      For all 33 frontline patients, the CR + CRc rate was 70% (95% CI, 51 to 84; n = 23) and the overall response
      rate was 85% (95% CI, 68 to 95; n = 28; Table 2).
    explanation: >-
      The primary report separately analyzes 20 de novo patients (75% CR/CRc) and all 33 frontline patients.
      Its R/R analysis reports 7/51, whereas FDA reports 8/51; these analyses are not pooled.
    quote_role: PRIMARY_RESULT
- name: Autologous Hematopoietic Cell Transplantation
  description: >-
    The 2026 ASTCT guideline suggests autologous HCT for selected patients in CR1 or CR2 who are unfit for
    allogeneic HCT and have no BPDCN marrow involvement. A separate investigational CAR-T/ASCT case with residual
    marrow disease does not establish the safety or efficacy of broader autologous transplantation.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: hematopoietic cell transplantation
    term:
      id: NCIT:C15431
      label: Hematopoietic Cell Transplantation
  evidence:
  - reference: PMID:42612729
    reference_title: 'Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Practice Guidelines From the American Society for Transplantation and Cellular Therapy.'
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      For BPDCN in first complete remission (CR1), the panelists recommended allogeneic HCT and suggested autologous
      HCT for patients who are unfit for allogeneic HCT but without BPDCN marrow involvement.
    explanation: >-
      The 17-expert guideline defines the preferred consolidation and the narrower autologous option.
    quote_role: REVIEW_SYNTHESIS
- name: CD123-Directed Bispecific Antibodies
  description: >-
    Investigational CD123-directed bispecific antibodies recruit T cells to malignant blasts. They are distinct
    from the approved CD123 antibody-drug conjugate pivekimab and from engineered CAR cell products.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
  target_mechanisms:
  - target: CD123 Overexpression on Malignant pDC Blasts
    description: Bispecific binding brings effector T cells into contact with CD123-expressing tumor cells.
  evidence:
  - reference: PMID:38338733
    reference_title: Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123.
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      Ongoing developments with SL-401, IMGN632, CD123 chimeric antigen receptor (CAR) T-cells, and bispecific
      antibodies (BsAb) show promising advancements.
    explanation: >-
      The review identifies bispecific-antibody development; it predates the pivekimab approval.
    quote_role: REVIEW_SYNTHESIS
- name: Tagraxofusp, Azacitidine and Venetoclax Combination
  description: >-
    A 2026 single-arm phase 2 report included 27 BPDCN patients: 16 previously untreated and 11 relapsed/refractory.
    Composite CR/CRi/CRc rates were 88% and 64%, respectively; capillary leak occurred in 15%, mostly grade
    2. Many patients subsequently underwent allogeneic HCT. The endpoint includes incomplete count recovery
    and should not be equated with CADENZA CR/CRc or interpreted as a randomized comparison.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
  evidence:
  - reference: PMID:42413008
    reference_title: Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Twenty-seven patients were enrolled (16 1L, 11 R/R), with median age of 70 years (range 21-81). Composite
      complete remission (CR/CRi/CRc) rates were 88% in 1L and 64% in R/R cohorts.
    explanation: >-
      Prospective BPDCN-specific combination efficacy with explicit denominators and endpoint.
    quote_role: PRIMARY_RESULT
  - reference: PMID:42413008
    reference_title: Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      CLS occurred in 15% of patients; most were grade 2.
    explanation: >-
      Capillary leak remains a safety issue with the combination.
    quote_role: PRIMARY_RESULT
prevalence:
- population: Worldwide
  measure_type: UNKNOWN
  prevalence_class: ULTRA_RARE
  notes: >-
    Reported as accounting for less than 0.5% of all haematologic
    malignancies. That is a proportional-burden figure, not a rate, so it
    does not by itself fix a numeric band - hence measure_type UNKNOWN and a
    qualitative tier rather than a rate_per_100000. No dedicated registry
    prevalence estimate was found.
  evidence:
  - reference: PMID:38334635
    reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review of the Disease, Central Nervous System Presentations, and Treatment Strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the incidence of BPDCN accounting for less than 0.5% of all hematologic malignancies"
    explanation: The proportional-burden figure this record records as a qualitative rarity tier.

    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
epidemiology:
- name: Male Predominance
  description: >-
    BPDCN occurs at least three times more often in men than in women. The
    ZRSR2 finding — X-linked loss-of-function mutations occurring almost
    exclusively in males — is the first mechanistic account of this bias.
  evidence:
  - reference: PMID:34615655
    reference_title: "Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BPDCN occurs at least three times more frequently in men than in women, but the reasons for this sex bias are unknown."
    explanation: Quantifies the male predominance this record describes.
    quote_role: BACKGROUND
    directness: DIRECT
  - reference: PMID:37251924
    reference_title: "Primary blastic plasmacytoid dendritic cell neoplasm: a US population-based study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A total of 340 primary BPDCN patients were included in this study. The average age was 53.7 ± 19.4 years, with 71.5% being male."
    explanation: Independent population-based confirmation of the sex ratio.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
- name: Age Distribution
  description: >-
    The dominant burden falls in older adults, with the median age at
    diagnosis in the seventh decade; a smaller paediatric and young-adult
    group also occurs.
  evidence:
  - reference: PMID:35788129
    reference_title: "Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Median age at diagnosis lies within the seventh decennium and a male predominance is observed"
    explanation: States the median age this record describes.
    quote_role: BACKGROUND
    directness: DIRECT
  - reference: PMID:38334635
    reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review of the Disease, Central Nervous System Presentations, and Treatment Strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BPDCN has also been seen in younger populations, including children in a bimodal distribution pattern."
    explanation: >-
      Supports the paediatric and young-adult half of this record, which the
      seventh-decade sentence above does not carry.

    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
- name: Antecedent or Concurrent Myeloid Neoplasm
  description: >-
    A substantial minority of cases occur alongside or after another myeloid
    neoplasm — CMML, AML or MDS — reflecting a shared clonal-hematopoiesis
    origin rather than coincidence.
  evidence:
  - reference: PMID:35788129
    reference_title: "Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Syn- and metachronous myeloid neoplasms (CMML, AML and MDS) have been reported in up to 20% of cases"
    explanation: Quantifies the association this record describes.
    quote_role: BACKGROUND
    directness: DIRECT
  - reference: PMID:30323983
    reference_title: "Early detection of transformation to BPDCN in a patient with MDS."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The case demonstrates that minimal transformative disease of BPDCN may be detectable in patients with MDS well before fulminant progression."
    explanation: >-
      Serial flow cytometry detected an aberrant pDC population before overt BPDCN in a patient with MDS; this
      case alone does not prove the genetic ancestry of the two neoplasms.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
progression:
- phase: Chemotherapy-Era Outcome
  notes: >-
    Aggressive and rapid. Median overall survival is reported in the range of
    12 to 24 months from diagnosis, with relapse typical after an initial
    chemotherapy response. These are outcomes under conventional
    chemotherapy, not untreated natural history - both sources describe
    patients who responded and then relapsed.
  evidence:
  - reference: PMID:34615655
    reference_title: "Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Outcomes for patients with BPDCN are poor, with a median survival of 12 to 24 months from diagnosis"
    explanation: The survival figure this phase records.
    quote_role: BACKGROUND
    directness: DIRECT
  - reference: PMID:31846142
    reference_title: "Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The median overall survival of patients with BPDCN ranges from 12 to 14 months as the disease typically relapses after initial response to chemotherapy."
    explanation: Independent survival estimate and the relapse pattern after initial chemotherapy response.

    quote_role: BACKGROUND
    directness: DIRECT
- phase: Population-Based Long-Term Survival
  notes: >-
    SEER data on 340 first/only-primary BPDCN cases diagnosed during 2001-2019, restricted to ages 20-89 and
    excluding zero/unknown survival, report 1-, 3-, 5- and 10-year OS of 68.7%, 49.8%, 43.9% and 39.2%. The
    mean age was 53.7 years. Selection, historical coding, missing regimen details and treatment-era differences
    limit comparison with institutional series. Associations with radiotherapy or subsequent malignancies are
    observational and do not establish a treatment effect.
  evidence:
  - reference: PMID:37251924
    reference_title: "Primary blastic plasmacytoid dendritic cell neoplasm: a US population-based study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For all the patients, the 1-year, 3-year, 5-year, and 10-year overall survival (OS) were 68.7%, 49.8%, 43.9%, and 39.2%, respectively"
    explanation: The population-based survival figures this phase records.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:37251924
    reference_title: "Primary blastic plasmacytoid dendritic cell neoplasm: a US population-based study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "multivariate AFT analysis indicated that older age was independently associated with worse survival, while second primary malignancies (SPMs) and radiation therapy were independently associated with extended survival."
    explanation: >-
      The full multivariate result. Three factors survived adjustment, not one:
      age adversely, and second primary malignancies and radiotherapy
      favourably. The latter two are hard to read causally in a registry
      series and are recorded as the source reports them.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
clinical_trials:
- name: NCT02113982
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Pivotal dose-escalation and expansion study of tagraxofusp, including untreated and relapsed/refractory
    BPDCN.
  notes: >-
    Registry phase and recruitment status verified on 2026-10-01. Registered as phase 1/2; the structured phase
    records phase 2.
  evidence:
  - reference: clinicaltrials:NCT02113982
    reference_title: Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      This is a 4-stage, non-randomized, open-label, dose escalation and expansion, multicenter study.
    explanation: >-
      Registry description establishes the intervention and study scope; phase and recruitment status are registry
      metadata.
- name: NCT03386513
  phase: PHASE_II
  status: ACTIVE_NOT_RECRUITING
  description: >-
    Pivekimab sunirine monotherapy study including the CADENZA BPDCN cohorts that supported FDA approval.
  notes: >-
    Registry phase and recruitment status verified on 2026-10-01. Registered as phase 1/2; the structured phase
    records phase 2.
  evidence:
  - reference: clinicaltrials:NCT03386513
    reference_title: A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability,
      PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients
      with CD123+ disease.
    explanation: >-
      Registry description establishes the intervention and study scope; phase and recruitment status are registry
      metadata.
- name: NCT07007052
  phase: PHASE_II
  status: RECRUITING
  description: >-
    Phase 2 tagraxofusp plus venetoclax study in previously untreated adult BPDCN.
  notes: >-
    Registry phase and recruitment status verified on 2026-10-01.
  evidence:
  - reference: clinicaltrials:NCT07007052
    reference_title: Open Label Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      The goal of this clinical trial is to study the efficacy of the tagraxofusp + venetoclax combination
      in treatment-naive blastic plasmacytoid dendritic cell neoplasm adult patients.
    explanation: >-
      Registry description establishes the intervention and study scope; phase and recruitment status are registry
      metadata.
- name: NCT03113643
  phase: PHASE_I
  status: RECRUITING
  description: >-
    Tagraxofusp with azacitidine, with or without venetoclax, in AML, high-risk MDS and BPDCN.
  notes: >-
    Registry verified on 2026-10-01 lists phase 1 and RECRUITING. PMID:42413008 reports a phase 2 BPDCN expansion
    cohort; that publication-specific designation is kept distinct from the registry field.
  evidence:
  - reference: clinicaltrials:NCT03113643
    reference_title: Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk
      MDS.
    explanation: >-
      Registry description establishes the intervention and study scope; phase and recruitment status are registry
      metadata.
  - reference: PMID:42413008
    reference_title: Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Twenty-seven patients were enrolled (16 1L, 11 R/R), with median age of 70 years (range 21-81). Composite
      complete remission (CR/CRi/CRc) rates were 88% in 1L and 64% in R/R cohorts.
    explanation: >-
      Prospective BPDCN-specific combination efficacy with explicit denominators and endpoint.
    quote_role: PRIMARY_RESULT
  - reference: PMID:42413008
    reference_title: Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      CLS occurred in 15% of patients; most were grade 2.
    explanation: >-
      Capillary leak remains a safety issue with the combination.
    quote_role: PRIMARY_RESULT
- name: NCT03485547
  phase: PHASE_I
  status: COMPLETED
  description: >-
    Phase 1 venetoclax study specifically enrolling BPDCN.
  notes: >-
    Registry phase and recruitment status verified on 2026-10-01.
  evidence:
  - reference: clinicaltrials:NCT03485547
    reference_title: Phase 1 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      This research study is studying a drug as a possible treatment for BPDCN.
    explanation: >-
      Registry description establishes the intervention and study scope; phase and recruitment status are registry
      metadata.
- name: NCT02159495
  phase: PHASE_I
  status: ACTIVE_NOT_RECRUITING
  description: >-
    Phase 1 CD123-directed CAR-T study with separate AML and BPDCN arms.
  notes: >-
    Registry phase and recruitment status verified on 2026-10-01.
  evidence:
  - reference: clinicaltrials:NCT02159495
    reference_title: Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      This phase I trial studies the side effects and the best dose of genetically modified T-cells after lymphodepleting
      chemotherapy in treating patients with acute myeloid leukemia or blastic plasmacytoid dendritic cell
      neoplasm that has returned after a period of improvement or has not responded to previous treatment.
    explanation: >-
      Registry description establishes the intervention and study scope; phase and recruitment status are registry
      metadata.
- name: NCT06006403
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Phase 1/2 CD123-directed CAR-NK study in relapsed/refractory AML or BPDCN.
  notes: >-
    Registry phase and recruitment status verified on 2026-10-01. Registered as phase 1/2; the structured phase
    records phase 2.
  evidence:
  - reference: clinicaltrials:NCT06006403
    reference_title: Clinical Study of Targeting CD123 Chimeric Antigen Receptor Natural Killer Cells (CAR-NK) in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate
      the safety and efficacy of targeting CD123 CAR-NK cell preparations in Relapsed/refractory acute myeloid
      leukemia (AML) or blastocytic plasmacytoid dendritic cell neoplasm (BPDCN).
    explanation: >-
      Registry description establishes the intervention and study scope; phase and recruitment status are registry
      metadata.
- name: NCT06690827
  phase: PHASE_I
  status: RECRUITING
  description: >-
    Phase 1 CD123-directed CAR-NK study in relapsed/refractory AML or BPDCN.
  notes: >-
    Registry phase and recruitment status verified on 2026-10-01.
  evidence:
  - reference: clinicaltrials:NCT06690827
    reference_title: Clinical Study of CD123 Targeting Chimeric Antigen Receptor NK Cells (CAR-NK) in the Treatment of Relapse/Refractory Acute Myeloid Leukemia (AML)or Blastic Plasmacytoid Dendritic Cell Neoplasm(BPDCN)
    supports: SUPPORT
    evidence_source: OTHER
    directness: DIRECT
    snippet: >-
      This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD123 CAR-NK
      in the treatment of patients with relapsed/refractory acute myeloid leukemia or blastic plasma cell like
      dendritic cell tumors.
    explanation: >-
      Registry description establishes the intervention and study scope; phase and recruitment status are registry
      metadata.
experimental_models:
- name: CAL-1 and GEN2.2 BPDCN cell lines
  experimental_model_type: CELL_LINE
  description: >-
    The two established human BPDCN cell lines used across the mechanistic
    literature. They were the platform for the RNAi and drug screens that
    identified the TCF4-BRD4 dependency.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  publication: PMID:27846392
  modeled_mechanisms:
  - target: TCF4-Dependent Super-Enhancer Network Addiction
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: MOLECULAR
    description: >-
      The lines reproduce the BPDCN-specific TCF4-driven transcriptional
      program and die when it is disrupted genetically or pharmacologically.
    limitations: >-
      Established lines carry the transcriptional dependency but not the
      clonal-evolution history (founder TET2/ASXL1 lesions, transformation
      from an antecedent myeloid neoplasm) or the immune microenvironment,
      so they cannot report on the initiating steps of the chain.
    evidence:
    - reference: PMID:27846392
      reference_title: "A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "its downregulation caused the loss of the BPDCN-specific gene expression program and apoptosis"
      explanation: Establishes the lines as informative for the TCF4 dependency node.

      quote_role: PRIMARY_RESULT
      directness: DIRECT
- name: Tet2-edited HOXB8 dendritic differentiation culture
  experimental_model_type: CELL_LINE
  organism:
    preferred_term: Mus musculus
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  description: >-
    Mouse marrow progenitors immortalized with estrogen-responsive HOXB8 are gene-edited and differentiated
    into pDCs and cDCs after estrogen withdrawal. UV exposure is applied ex vivo during differentiation.
  publication: PMID:37286599
  modeled_mechanisms:
  - target: UV-Selected Survival of TET2-Mutant pDC Precursors in Sun-Exposed Skin
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Tet2 knockout preferentially increases pDC survival after UV exposure.
    limitations: >-
      The experiment tests lineage-specific UV survival in culture. It does not reproduce skin homing, complete
      malignant transformation or systemic dissemination.
    evidence:
    - reference: PMID:37286599
      reference_title: Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin.
      supports: SUPPORT
      evidence_source: IN_VITRO
      directness: DIRECT
      snippet: >-
        After UV exposure (100, 500 μJ cm−2), Tet2 knockout caused a further increase in the proportion of
        surviving
        pDCs, but had no protective effect on cDCs (Fig. 5e).
      explanation: >-
        Tet2 knockout was tested in differentiated mouse HOXB8 cultures ex vivo, not by inducing skin tumors
        with UV in living mice.
      quote_role: PRIMARY_RESULT
animal_models:
- name: BPDCN patient-derived xenograft
  species: Mouse
  genotype: Immunodeficient host engrafted with primary patient BPDCN cells
  description: >-
    Xenografts of primary patient BPDCN cells in immunodeficient mice, used to
    test BCL2 inhibition in vivo before the first off-label human use.
  publication: PMID:27986708
  modeled_mechanisms:
  - target: BCL2-Dependent Survival of Malignant pDCs
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Patient-derived xenografts retain the BCL2 dependence measured in
      primary cells and respond to venetoclax in vivo.
    limitations: >-
      Immunodeficient hosts cannot reproduce the T-cell exhaustion and
      interferon-skewed microenvironment described in patient marrow, so the
      model is silent on the immune component of the disease.
    evidence:
    - reference: PMID:27986708
      reference_title: "Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Animals bearing BPDCN patient-derived xenografts had disease responses and improved survival after venetoclax treatment in vivo"
      explanation: Establishes the xenograft as informative for the BCL2-dependent survival node.

      quote_role: PRIMARY_RESULT
      directness: DIRECT
- name: MYB fusion-driven myeloid-dendritic acute leukemia mouse
  species: Mouse
  genotype: MYB::PLEKHO1 or truncated MYB in Hoxb8-FL hematopoietic progenitors, with genotype-specific Cdkn2a status
  description: >-
    Transplanted Hoxb8-FL-derived cells expressing MYB::PLEKHO1 induced myeloid-dendritic leukemia with intact
    or deleted Cdkn2a. Truncated MYB required Cdkn2a knockout in this system.
  publication: PMID:39499902
  modeled_mechanisms:
  - target: Plasmacytoid Dendritic Cell Differentiation Block
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: ORGANISM
    description: >-
      The model reproduces the differentiation block and transformation caused
      by a MYB fusion.
    limitations: >-
      The leukemia is myeloid-dendritic rather than a complete phenocopy of human BPDCN. Hoxb8 immortalization
      creates a nonphysiological progenitor state, and the cooperating-lesion requirement differs between MYB
      constructs.
    evidence:
    - reference: PMID:39499902
      reference_title: "BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "expression of MYB fusions in vivo impaired DC differentiation and induced transformation to generate a mouse model of myeloid-dendritic acute leukemia."
      explanation: Establishes the model and the differentiation-block phenotype it reproduces.

      quote_role: PRIMARY_RESULT
      directness: DIRECT
    - reference: PMID:39499902
      reference_title: BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      directness: DIRECT
      snippet: >-
        In contrast to MYB-TR, MYB::PLEKHO1 did not require Cdkn2a KO to initiate leukemia in Hoxb8-FL cells.
      explanation: >-
        The two MYB constructs have different requirements for a cooperating cell-cycle lesion.
      quote_role: PRIMARY_RESULT
- name: Zrsr2 and Tet2 edited marrow chimera
  species: Mouse
  genotype: Cas9 marrow progenitors edited for Zrsr2, Tet2 or both, transplanted into irradiated wild-type recipients
  description: >-
    Eight-week marrow-chimera experiments test the effects of BPDCN-associated founder lesions on hematopoiesis,
    pDC abundance, RNA splicing and activation.
  publication: PMID:34615655
  modeled_mechanisms:
  - target: Blunted TLR-Induced pDC Activation
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Mutant pDCs show altered splicing and reduced activation after a TLR agonist.
    limitations: >-
      No BPDCN or overt clonal evolution was observed in these short-term experiments. The model supports premalignant
      phenotypes, not sufficiency for malignant transformation.
    evidence:
    - reference: PMID:34615655
      reference_title: Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      directness: DIRECT
      snippet: >-
        In vivo, Zrsr2/Tet2-mutant pDCs had impaired activation after systemic exposure to R848 (Fig. 7F).
      explanation: >-
        Edited marrow chimeras reproduce reduced pDC activation in vivo.
      quote_role: PRIMARY_RESULT
environmental:
- name: Cutaneous ultraviolet radiation exposure
  description: >-
    UV-associated mutational signatures in BPDCN skin tumors and human clonal reconstructions implicate exposure
    during a cutaneous route to disease. Tet2-edited cultures support lineage-specific survival selection.
    These data do not estimate population-level risk per UV dose or establish UV as necessary for every BPDCN.
  exposure_term:
    preferred_term: exposure to ultraviolet radiation
    term:
      id: ECTO:0000006
      label: exposure to ultraviolet radiation
  influences_mechanisms:
  - target: UV-Selected Survival of TET2-Mutant pDC Precursors in Sun-Exposed Skin
    environmental_effect: PREDISPOSES
    causal_link_type: DIRECT
    description: >-
      UV exposure imposes the selective pressure under which Tet2-deficient pDCs preferentially survive in
      the ex vivo differentiation assay.
    evidence:
    - reference: PMID:37286599
      reference_title: Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin.
      supports: SUPPORT
      evidence_source: IN_VITRO
      directness: DIRECT
      snippet: >-
        After UV exposure (100, 500 μJ cm−2), Tet2 knockout caused a further increase in the proportion of
        surviving
        pDCs, but had no protective effect on cDCs (Fig. 5e).
      explanation: >-
        Tet2 knockout was tested in differentiated mouse HOXB8 cultures ex vivo, not by inducing skin tumors
        with UV in living mice.
      quote_role: PRIMARY_RESULT
  evidence:
  - reference: PMID:37286599
    reference_title: "Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BPDCN skin tumours first develop at sun-exposed anatomical sites and are distinguished by clonally expanded mutations induced by ultraviolet (UV) radiation"
    explanation: >-
      Establishes the exposure's fingerprint in the tumours themselves rather
      than by epidemiologic inference.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
datasets:
- accession: geo:GSE227690
  title: Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin
  data_type: SINGLE_CELL_RNA_SEQ
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  publication: PMID:37286599
  description: >-
    Single-cell transcriptomics with genotyping plus tumour phylogenomics on
    BPDCN patient material, the primary data behind the UV-selection and
    marrow-origin findings curated in this entry.
- accession: geo:GSE278318
  title: Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis [PDX]
  data_type: BULK_RNA_SEQ
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  publication: PMID:34615655
  description: >-
    RNA-seq of BPDCN patient-derived xenografts from the study linking
    X-linked ZRSR2 loss to the disease's male predominance.
- accession: geo:GSE261534
  title: BPDCN MYB Fusions Regulate Cell Cycle Genes, Impair Differentiation and Induce Myeloid-Dendritic Cell Leukemia [BPDCNCutRun]
  data_type: CHIP_SEQ
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  publication: PMID:39499902
  description: >-
    CUT&RUN chromatin profiling in BPDCN cells showing MYB fusion binding
    redirected onto G2/M cell-cycle loci.
  notes: >-
    CUT&RUN data are represented under the closest available chromatin-profiling data type. The companion series
    GSE261411 profiles K562 rather than BPDCN material.
- accession: geo:GSE164939
  title: 'Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target'
  data_type: BULK_RNA_SEQ
  publication: PMID:30381297
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  description: >-
    RNA sequencing associated with the original epigenetic-regulation study: five discovery BPDCN samples,
    four extension BPDCN samples and four normal pDC controls. The dataset was subsequently reused in the neural-program
    study PMID:34572907.

  notes: >-
    The broader publication also includes whole-exome and histone-mark profiling; these modalities should not
    all be inferred from the BULK_RNA_SEQ label.
discussions:
- discussion_id: bpdcn_cutaneous_tropism_mechanism
  kind: KNOWLEDGE_GAP
  prompt: >-
    How do UV selection and adhesion-gene dysregulation contribute to cutaneous disease?
  rationale: >-
    Human phylogenies and Tet2-edited cultures support UV-associated selection during a cutaneous route in
    some BPDCN cases. IKZF1-associated adhesion signatures suggest a separate possible contribution to homing
    or retention. Neither establishes a universal explanation for skin involvement, and the two processes have
    not been directly tested together.
  attaches_to:
  - pathophysiology#UV-Selected Survival of TET2-Mutant pDC Precursors in Sun-Exposed Skin
  - pathophysiology#Aberrant Cell Adhesion Program
  - pathophysiology#Cutaneous Infiltration by Malignant pDC Blasts
- discussion_id: bpdcn_models_omit_founder_lesion
  kind: HUMAN_MODEL_MISMATCH
  prompt: >-
    Which additional events convert a premalignant pDC-lineage clone into BPDCN?
  rationale: >-
    Tet2-edited HOXB8 cultures model UV survival before transformation, and Zrsr2/Tet2 marrow chimeras model
    pDC expansion and impaired activation without developing BPDCN in the reported experiment. Thus founder-lesion
    models exist, but a complete model connecting clonal hematopoiesis, tissue exposure, additional lesions
    and human BPDCN remains missing.
  attaches_to:
  - pathophysiology#TET2 Loss in a Hematopoietic Precursor
  - experimental_models#Tet2-edited HOXB8 dendritic differentiation culture
  - animal_models#Zrsr2 and Tet2 edited marrow chimera
- discussion_id: bpdcn_txnrd1_resistance
  kind: KNOWLEDGE_GAP
  prompt: Does reduced TXNRD1 cause tagraxofusp resistance in patients?
  rationale: >-
    A 12-patient study found low TXNRD1 expression in residual tumor clusters and increased CAL1 viability
    after TXNRD1 inhibition. The proposed impairment of toxin processing or translocation was not directly
    measured; inhibitor-associated survival effects also occurred without tagraxofusp. TXNRD1 is a candidate
    biomarker and resistance mechanism requiring functional rescue and prospective validation.
  attaches_to:
  - pathophysiology#Diphthamide Pathway Silencing
  evidence:
  - reference: PMID:42410207
    reference_title: Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Unlike that study, we found reduced expression of TXNRD1, a key enzyme in the cytosolic release of diphtheria
      toxin, in cluster 22.
    explanation: >-
      The primary observation concerns expression in residual tumor cells; the proposed toxin-processing consequence
      remains to be tested.
    quote_role: PRIMARY_RESULT
  - reference: PMID:42410207
    reference_title: Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Here, we have identified TXNRD1 as a potential biomarker of response for further investigation.
    explanation: >-
      The authors explicitly treat the marker as a candidate rather than a validated predictor.
    quote_role: PRIMARY_RESULT
- discussion_id: bpdcn_pivek_resistance
  kind: KNOWLEDGE_GAP
  prompt: Which resistance changes in pivekimab-exposed GEN2.2 cells operate in patients?
  rationale: >-
    Serial pivekimab exposure generated resistant GEN2.2 cells with reduced CD123 protein but preserved RNA
    levels and increased ABCB1 expression. The study did not establish a functional ABCB1 rescue or validate
    these routes in patients. These observations show why CD123 retention in earlier tagraxofusp models should
    not be generalized to every CD123-directed therapy.
  attaches_to:
  - pathophysiology#CD123 Overexpression on Malignant pDC Blasts
  - treatments#Pivekimab Sunirine
  evidence:
  - reference: PMID:41641634
    reference_title: 'Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm: assessing spatial response and unraveling resistance mechanisms.'
    supports: SUPPORT
    evidence_source: IN_VITRO
    directness: DIRECT
    snippet: >-
      Our results showed an antigen loss (CD123) at protein levels but not RNA levels.
    explanation: >-
      Protein and transcript findings diverged in the selected GEN2.2 resistance model.
    quote_role: PRIMARY_RESULT
- discussion_id: bpdcn_neural_program
  kind: KNOWLEDGE_GAP
  prompt: Do neural-associated expression programs promote BPDCN dissemination?
  rationale: >-
    miRNA/transcriptome analysis and immunohistochemistry found neural-associated gene expression in BPDCN
    cells, including DCX, UCHL1 and cholinergic machinery. The 15-biopsy validation set lacked tumor-associated
    nerve fibers or neural cells. Marker expression does not demonstrate neurotransmitter exchange, CNS migration
    or a clinically effective neural target; functional experiments are needed.
  attaches_to:
  - pathophysiology#Central Nervous System Infiltration
  evidence:
  - reference: PMID:34572907
    reference_title: Newly-Discovered Neural Features Expand the Pathobiological Knowledge of Blastic Plasmacytoid Dendritic Cell Neoplasm.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      Future studies are needed to assess their mechanistic role in BPDCN metastasis and evaluate their prognostic
      and or therapeutic relevance in the BPDCN clinical setting.
    explanation: >-
      The authors identify mechanistic and clinical validation as future work, despite suggestive expression
      and staining results.
notes: >-
  BPDCN is a distinct plasmacytoid dendritic cell neoplasm in WHO-HAEM5. The older MONDO label CD4+/CD56+ hematodermic
  neoplasm refers to the same disease concept. Molecular heterogeneity includes founder clonal hematopoiesis,
  lineage-regulatory abnormalities and several routes to treatment resistance; no single sequence of lesions
  accounts for every case.
biochemical:
- name: PLD4 expression in BPDCN tissue
  notes: >-
    An emerging tissue biomarker, not a stand-alone diagnostic criterion or validated therapeutic target. A
    single-patient multi-organ transcriptomic analysis nominated PLD4, with immunostaining assessed in two
    six-patient BPDCN cohorts and control tissues. Some controls stained positive; the small study does not
    establish universal specificity.
  evidence:
  - reference: PMID:41219867
    reference_title: Multi-organ single-cell analysis reveals PLD4 as a biomarker and potential therapeutic target of blastic plasmacytoid dendritic cell neoplasm.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      The specificity was 77.08% (37/48) for CD123 and 83.33% (40/48) for PLD4.
    explanation: >-
      The measured specificity is limited to this study's control panel, despite broader specificity language
      in the abstract.
    quote_role: PRIMARY_RESULT
  - reference: PMID:41219867
    reference_title: Multi-organ single-cell analysis reveals PLD4 as a biomarker and potential therapeutic target of blastic plasmacytoid dendritic cell neoplasm.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      To further assess the diagnostic accuracy, we performed IHC analysis on skin biopsies from the second
      validation cohort of six BPDCN patients, and the results showed that PLD4 was positive in the dermis
      of all patients (Fig. S3A).
    explanation: >-
      Independent small-cohort immunostaining supports further biomarker evaluation.
    quote_role: PRIMARY_RESULT
references:
- reference: PMID:26840087
  title: Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy.
- reference: PMID:27060168
  title: "Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms."
- reference: PMID:27846392
  title: "A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm."
- reference: PMID:27986708
  title: "Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax."
- reference: PMID:29407586
  title: "8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms."
- reference: PMID:30323983
  title: "Early detection of transformation to BPDCN in a patient with MDS."
- reference: PMID:30381297
  title: 'Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target.'
- reference: PMID:31018069
  title: "Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm."
- reference: PMID:31437130
  title: DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.
- reference: PMID:31846142
  title: "Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm."
- reference: PMID:32336417
  title: "Cytogenetics of Blastic Plasmacytoid Dendritic Cell Neoplasm: Chromosomal Rearrangements and DNA Copy-Number Alterations."
- reference: PMID:34572907
  title: Newly-Discovered Neural Features Expand the Pathobiological Knowledge of Blastic Plasmacytoid Dendritic Cell Neoplasm.
- reference: PMID:34615655
  title: Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.
- reference: PMID:35359938
  title: Single-Cell Multiomics Reveals Clonal T-Cell Expansions and Exhaustion in Blastic Plasmacytoid Dendritic Cell Neoplasm.
- reference: PMID:35788129
  title: "Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm."
- reference: PMID:35820082
  title: "Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm."
- reference: PMID:35963025
  title: 'CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights.'
- reference: PMID:36689729
  title: "TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm."
- reference: PMID:36819168
  title: "Biallelic TET2 mutations and canonical ASXL1 mutations are frequent and cooccur in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): An institutional experience and review of literature."
- reference: PMID:37251924
  title: "Primary blastic plasmacytoid dendritic cell neoplasm: a US population-based study."
- reference: PMID:37286599
  title: "Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin."
- reference: PMID:37407876
  title: '[Blastic plasmacytoid dendritic cell neoplasm (BPDCN) : A rare hematologic neoplasm with frequent cutaneous involvement].'
- reference: PMID:37946878
  title: "A Case of Acute Myeloid Leukemia Mimicking Blastic Plasmacytoid Dendritic Cell Neoplasm: Utility of the Proposed Upcoming WHO-5 Diagnostic Criteria."
- reference: PMID:38132278
  title: "Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview."
- reference: PMID:38334635
  title: "Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review of the Disease, Central Nervous System Presentations, and Treatment Strategies."
- reference: PMID:38338733
  title: Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123.
- reference: PMID:39499902
  title: BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia.
- reference: PMID:40525728
  title: "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): 2025 Update on Diagnosis, Pathophysiology, Risk Assessment, and Management."
- reference: PMID:41219867
  title: Multi-organ single-cell analysis reveals PLD4 as a biomarker and potential therapeutic target of blastic plasmacytoid dendritic cell neoplasm.
- reference: PMID:41641634
  title: 'Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm: assessing spatial response and unraveling resistance mechanisms.'
- reference: PMID:41671533
  title: Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.
- reference: PMID:42410207
  title: Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.
- reference: PMID:42413008
  title: Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.
- reference: PMID:42602092
  title: 'Anti-CD123 CAR-T therapy combined with autologous SCT and venetoclax maintenance in refractory BPDCN ineligible for allogeneic transplantation: a case report and review of the literature.'
- reference: PMID:42612729
  title: 'Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Practice Guidelines From the American Society for Transplantation and Cellular Therapy.'
- reference: PMID:42681647
  title: A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm.
- reference: clinicaltrials:NCT02113982
  title: Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- reference: clinicaltrials:NCT02159495
  title: Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
- reference: clinicaltrials:NCT03113643
  title: Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)
- reference: clinicaltrials:NCT03386513
  title: A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
- reference: clinicaltrials:NCT03485547
  title: Phase 1 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- reference: clinicaltrials:NCT06006403
  title: Clinical Study of Targeting CD123 Chimeric Antigen Receptor Natural Killer Cells (CAR-NK) in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
- reference: clinicaltrials:NCT06690827
  title: Clinical Study of CD123 Targeting Chimeric Antigen Receptor NK Cells (CAR-NK) in the Treatment of Relapse/Refractory Acute Myeloid Leukemia (AML)or Blastic Plasmacytoid Dendritic Cell Neoplasm(BPDCN)
- reference: clinicaltrials:NCT07007052
  title: Open Label Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients
- reference: url:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pivekimab-sunirine-pvzy-blastic-plasmacytoid-dendritic-cell-neoplasm-ultra-rare
  title: FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy | FDA
- reference: url:https://www.jci.org/articles/view/128571
  title: "JCI -\nDNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance"
mechanistic_hypotheses:
- hypothesis_group_id: UV_ASSOCIATED_TRANSFORMATION
  hypothesis_label: UV selection during a cutaneous route to BPDCN
  status: EMERGING
  description: >-
    Human phylogenies and ex vivo Tet2 experiments support UV selection in a subset of BPDCN. The intervening
    transformation steps and applicability to noncutaneous disease remain unresolved.
  evidence:
  - reference: PMID:37286599
    reference_title: "Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A reconstruction of tumour phylogenies reveals that UV damage can precede the acquisition of alterations associated with malignant transformation"
    explanation: >-
      Supports the ordering claim - UV damage before transformation - that
      makes this a selective step rather than a consequence of the tumour.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
- hypothesis_group_id: ADHESION_SKIN_TROPISM
  hypothesis_label: Adhesion-gene dysregulation contributes to skin homing
  status: EMERGING
  description: >-
    IKZF1-associated expression changes may promote tissue retention or homing. Functional BPDCN migration
    and tissue-homing studies are needed.
  evidence:
  - reference: PMID:31846142
    reference_title: "Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "up-regulation of cellular processes responsible for cell-cell and cell-ECM interactions, which is a hallmark of IKZF1 deficiency, was prominent in BPDCN"
    explanation: Reports the adhesion-program upregulation and attributes it to IKZF1 deficiency.

    quote_role: PRIMARY_RESULT
    directness: DIRECT
- hypothesis_group_id: CHRONIC_IFN_TCELL_EXHAUSTION
  hypothesis_label: Accumulated blasts sustain interferon-associated T-cell exhaustion
  status: EMERGING
  description: >-
    The small single-cell study supports expression and clonotype associations; tumor-derived chronic interferon
    as their cause requires direct perturbation.
  evidence:
  - reference: PMID:35359938
    reference_title: Single-Cell Multiomics Reveals Clonal T-Cell Expansions and Exhaustion in Blastic Plasmacytoid Dendritic Cell Neoplasm.
    supports: SUPPORT
    evidence_source: OTHER
    directness: INDIRECT
    snippet: >-
      We hypothesize that, despite the tumor cells exhibiting lower IFNA production at the individual cell
      level, abnormal accumulation of pDC-like tumor cells in BPDCN may lead to increased IFNA production and
      chronic T-cell activation, eventually leading to T-cell exhaustion and consequent TNFA downregulation.
    explanation: >-
      The authors propose this sequence; cytokine production and its causal contribution were not experimentally
      demonstrated.

📚

References & Deep Research

References

PMID:26840087

Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy.